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Abstract 
 Thyroid cancer is the most frequent endocrine malignancy, with an incidence 
constantly increasing. Despite well-differentiated thyroid tumors are generally cured by 
conventional therapy, a fraction of them relapses and progresses towards 
undifferentiated forms, characterized by a poor prognosis. Target therapies introduced in 
clinical testing are often unsuccessful; therefore, novel therapeutic strategies are needed. 
To identify critical nodal points for therapeutic intervention, our laboratory faced the 
“non-oncogene addiction” (NOA) paradigm, which asserts that the tumorigenic state 
relies on the activity of genes that are essential to support the phenotype of cancer cells 
but not required to the same degree for normal cell viability. By screening a siRNA library 
on normal and tumor thyroid cell lines, we identified 15 genes whose silencing interfered 
with the growth of tumor but not normal thyroid cells.  
 The overall aim of this project was to validate NOA genes to identify thyroid tumor cell 
vulnerabilities and to explore their role in the regulation of thyroid tumor cell biology. 
Among the 15 hit genes, we selected MASTL, Cyclin D1 and COPZ1 for validation studies. 
We confirmed the growth inhibitory effect of their silencing in tumor but not normal 
thyroid cells and observed that these effects were common to a panel of thyroid tumor 
cell lines, irrespective of the histotype or genetic lesion. Functional studies on MASTL 
demonstrated that its depletion in thyroid tumor cells inhibited cell growth, led to mitotic 
catastrophe and induced DNA damage and cell death. COPZ1 depletion induced abortive 
autophagy, endoplasmic reticulum stress and apoptotic cell death in thyroid tumor cells, 
as well as tumor growth inhibition in vivo. Together, our studies identified MASTL and 
8 
 
COPZ1 as vulnerability genes for thyroid tumor cells and provided the rationale for future 
studies aimed to explore their targeting for potential therapeutic intervention.  
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1. Introduction 
 
1.1.  Thyroid cancer 
 Thyroid cancer (TC) is the most frequent malignancy of the endocrine system, and 
notably it is characterized by a global incidence increasing during the last decades. In the 
United States of America, TC is the fifth most common cancer in women, and accounts for 
more than 62000 cases occurred in men and women in 2015 (1). Thyroid is a butterfly-
shaped organ located on the anterior surface of trachea, at the base of the neck, and it is 
formed by aggregates of lobules of spherical follicles filled with colloid (2). Epithelial 
follicular cells mark follicles and are responsible for the production and secretion of 
thyroid hormones thyroxine (T4) and triiodothyronine (T3), while parafollicular “C” cells, 
located within follicles, are the neuroendocrine cells responsible for calcitonin secretion 
(Figure 1.1). Thyroid tumors can originate from both follicular epithelial cells and 
parafollicular “C” cells. Tumors originating from the follicular cells are distinguished into 
different subtypes: papillary thyroid carcinoma (PTC, accounting for 80-85% of cases), 
follicular thyroid carcinoma (FTC, 10-15% of cases), poorly differentiated thyroid 
carcinoma (PDTC, about 5% of cases) and anaplastic thyroid carcinoma (ATC, 2-3% of 
cases) (3). Tumors originating from parafollicular C cells are known as medullary thyroid 
carcinoma (MTC) and account for a small proportion of thyroid malignancies (2-3% of 
cases).  
10 
 
 
Figure 1.1 Structure of thyroid gland 
Schematic representation of the thyroid; the structure of follicles, together with follicular and 
parafollicular thyroid cells, are indicated. Image adapted from (2). 
 
Explanations for the worldwide increase of thyroid tumor incidence are controversial. 
Fine-needle aspiration biopsy (FNAB) and histopathological assessment are the 
cornerstone of diagnostic management of thyroid nodules; however, in the last years a 
progressive increase in the use of more sensitive techniques, that are high-resolution 
ultrasonography, computerized tomography, magnetic resonance or positron emission 
tomography, as diagnostic tools, was observed (4). According to some experts, the 
increased diagnosis of thyroid tumors is related to the increase in diagnostic sensitivity. 
Conversely, others attribute the increase of incidence rate to a major exposure to risk 
factors, like radiation exposure during medical procedures (5), obesity (6), chronic 
autoimmune thyroiditis (7), or environmental factors (8). 
However, in contrast to incidence rates, mortality rates are stable or decreasing both in 
the United States (9) and in Europe (10), supporting the evidence that probably the 
increased incidence is mainly related to improvement of surveillance (11). On the other 
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hand, the problem of probable overdiagnosis of thyroid tumors has emerged as a growing 
public health concern (12). 
 
1.1.1. Follicular cell-derived thyroid tumors 
 The majority of thyroid malignancies originates from follicular cells and is 
distinguished in different subgroups, according to their differentiation status, as well as to 
some histological and clinical features (Figure 1.2 and Table 1.1). PTC and FTC are 
classified together as well-differentiated thyroid carcinomas (WDTC) and are generally 
characterized by a good prognosis, with over 98% five-year survival rate in Europe and 
North America (13). By contrast, patients with ATC have a poor prognosis, with median 
survival of 5 months, and less than 20% are alive 1 year after diagnosis (14). 
1.1.1.1. Papillary thyroid carcinoma (PTC) 
 PTC is the most common tumor histotype, occurring more frequently in women than 
in men, and is also the most common pediatric malignancy. PTC presents as an enlarged 
solid nodule in more than half of patients and often forms multifocal tumors that can be 
either unilateral or extended to both thyroid lobes (15). Lymphatic vessels are the main 
system for PTC diffusion; indeed, cervical lymph node metastases are clinically detectable 
on initial presentation.  
 “Classical” PTC is microscopically characterized by a papillary architecture and 
epithelial cells with “ground glass” nuclei, which include irregularities as grooves and 
nuclear pseudoinclusions (16). Psammoma bodies, which represent a typical PTC feature, 
are found in at least 50% of cases, are formed by focal areas of infarction of the tips of 
papillae and can be found also in tumor stroma and lymphatic spaces. Even if regional 
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lymph node metastases are common at initial presentation of usual PTC, this feature 
apparently does not affect long-term prognosis that is generally good for PTC patients. 
 In addition to classical PTC, which is the most frequent, several histological variants 
differing in morphological pattern as well as in prognosis, have been described. The most 
common are papillary thyroid microcarcinoma, follicular, oncocytic, clear cells, diffuse 
sclerosing, tall cell, columnar cell, solid and cribriform variants (17). These variants have 
good prognosis, similar to that of classical PTC, with the exception of tall cell, columnar 
cell, and solid variants, characterized by aggressive behavior, vascular invasion and worse 
outcome. 
1.1.1.2. Follicular thyroid carcinoma (FTC) 
 FTC is characterized by evidence of follicular cell differentiation lacking the diagnostic 
nuclear features of PTC. It is more frequent in women over 50 years of age (18) and in 
iodine-deficient areas (19). FTC is an encapsulated tumor and generally presents as 
unifocal. Unlike PTC, it spreads hematogenously rather than by lymphatic vessels, and 
distant metastases, primarily to the lung and bone, can be found at the diagnosis (20). 
FTC can originate from follicular thyroid adenoma (FTA), which is a benign tumor of 
thyroid gland surrounded by a thin fibrous capsule (21). Indeed, FTAs can acquire 
oncogenic mutations and progress towards the malignant FTC form. 
 Hürtle cell carcinoma (HCC), or “oncocytic or oxyphilic”, is considered a rare variant of 
FTC (and less frequently of PTC) (22). The tumor is composed of at least 75% Hürtle cells, 
that are large polygonal cells characterized by an abundant eosinophilic granular 
cytoplasm, due to a high content of mitochondria. As FTCs, HCCs can spread 
hematogenously to metastasize to bone and lungs, but can also present regional lymph 
node involvement.  
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 FTC is generally considered a more aggressive disease than PTC, with a prognosis 
depending on several factors, among which the degree of invasiveness of the tumor: 
patients with minimally invasive FTC have a survival expectance similar to that of normal 
population matched for age and sex, while 50% of patients with widely invasive 
carcinoma die of the disease (18). 
1.1.1.3. Poorly Differentiated Thyroid Carcinoma (PDTC) 
 PDTCs comprise thyroid tumors showing histological and prognostic features that are 
intermediate between those of differentiated (PTC and FTC) on one hand and anaplastic 
(ATC) carcinomas on the other. A consensus meeting held in Turin established the 
diagnostic criteria for PDTC assessment, which include solid/trabecular/insular 
microscopic growth pattern, lack of well-developed nuclear features of PTCs, convoluted 
nuclei, tumor necrosis and high mitotic index (23). PDTC can either be the terminal stage 
of dedifferentiation process of PTC and FTC (Figure 1.2) or grow ex novo (19). It often 
presents as a unique thyroid mass rapidly growing, and has high rate of metastatic spread 
to lymph nodes and distant organs, such as lung and bone. Prognosis of PDTC patients is 
worse than that of PTC, with a 5 year survival rate from 20 to 60% (24). 
1.1.1.4. Anaplastic Thyroid Carcinoma (ATC) 
 ATC is one of the most aggressive and deadly cancers among humans (25). Like PDTCs, 
it can develop from a pre-existing DTC or can arise ex novo (Figure 1.2). ATC is composed 
of undifferentiated cells (spindle, epithelioid and pleomorphic giant cells) retaining 
markers of an epithelial lineage. Histological features include invasiveness, extensive 
tumor necrosis, pleomorphic nuclei with irregular contours and high mitotic activity with 
atypical mitotic figures. ATC presents as a large rapidly growing thyroid mass infiltrating 
surrounding tissues that causes compressive symptoms in patients including dysphagia, 
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dysphonia, and dyspnea. The peak incidence is in the sixth and seventh decades of life, 
and the median survival is 6 months from the diagnosis (26). About 50% of patients 
present distant metastatic disease at the diagnosis, primarily in the lungs but also in 
bones and brain, and approximately 25% of patients will develop metastases during the 
clinical course of the disease: it can be so rapid that surgery procedures are often useless. 
 
Figure 1.2 Multistep process of thyroid carcinogenesis 
Scheme of the development and dedifferentiation of follicular-cell derived thyroid tumors. Tumor 
frequencies and molecular alterations that drive the multistep process are indicated. Image 
adapted from (27). 
 
 
RET rearrangement
TRK rearrangement
BRAF mutations
RAS mutation
PPARγ rearrangement
RAS mutation
PIK3CA mutation
CTNNB1 mutation
TP53 mutation
10-15%
80-85%
< 5% <2%
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Table 1.1 Characteristics of thyroid tumors 
FTA, follicular thyroid adenoma; PTC, papillary thyroid carcinoma; FTC, follicular thyroid 
carcinoma; PDTC, poorly differentiated thyroid carcinoma; ATC, anaplastic thyroid carcinoma; 
*PTC and FTC are usually referred together as well-differentiated carcinomas (WDTC). Table 
adapted from (3). 
 
1.1.2. Genetic alterations in thyroid cancer 
 In the last decades much effort has been made in studies aimed to identify molecular 
alterations at the basis of thyroid tumorigenesis (3). Nowadays, it is well known that 
thyroid cancer originates from various genetic and epigenetic alterations that include: 
activating/inactivating somatic mutations, alterations in gene expression patterns, 
microRNA deregulation, aberrant gene methylation; these lesions gradually accumulate 
to promote tumor progression. The main genetic lesions found in TC consist of point 
mutation, which is the result of a single nucleotide change within DNA chain, and 
chromosomal rearrangement, that is a genetic abnormality with breakage and fusion of 
parts of the same or different chromosomes. Among the different TC histotypes, PTCs 
have one of the lowest mutation densities of cancers that have been studied by means of 
whole-exome sequencing (28), while undifferentiated ATCs are characterized by a high 
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mutation burden (29). To date, it is well known that the main genetic alterations in TC are 
found in members of the mitogen-activated protein kinase (MAPK) and 
phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathways (Figure 1.3). 
 
 
Figure 1.3 Main signaling pathways involved in thyroid carcinogenesis 
The main genetic alterations that drive thyroid tumor formation and progression are found in 
members of the MAPK and PI3K/AKT signaling pathways. These signaling cascades have the 
important role of propagating signals from external stimuli, via cell membrane receptor tyrosine 
kinases, into the nucleus, to regulate cell proliferation, differentiation and survival processes. 
Image adapted from (27). 
 
1.1.2.1. Next-generation sequencing (NGS) revolution  
 The introduction of next-generation sequencing (NGS) technologies improved, in the 
recent years, the understanding of alterations of genes and pathways involved in human 
carcinogenesis and tumor maintenance (30). NGS is a high-throughput method that 
allows a massive parallel sequencing of multiple targeted genomic regions, thus being 
more advantageous than the earlier genome-sequencing methods. It has been recently 
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applied also on thyroid cancer, with the aim of shedding light on the molecular alterations 
that drive thyroid tumorigenesis (31,32). In 2014, a study by the TCGA consortium had 
revolutionized the understanding of PTC genomic landscape (33). A comprehensive 
multiplatform analysis on a cohort of 496 PTC specimens, which was the largest cohort 
ever analyzed to date, was performed through next-generation DNA and RNA sequencing, 
copy-number analysis, DNA methylation and proteomic assays; as result, driving 
oncogenic lesions already known were confirmed, and novel driver mutations and gene 
fusions were detected, thus reducing from 25% to 3.5% the so-called “dark matter”, that 
is the fraction of PTC cases with unknown genetic drivers. The study also proposed a 
reclassification of PTC into molecular subtypes, as tool for better management of the 
disease.  
These findings paved the way for following NGS studies performed on FTC (34), PDTC (29) 
and ATC (29,35), with the aim of improving the knowledge of the genetic landscape 
thyroid tumors. 
1.1.2.2. MAPK signaling pathway 
 The MAPK signaling pathway plays an important role in the regulation of cell growth 
and survival and also in human tumorigenic processes. In TC, the importance of this 
pathway has been well established, as many mutations in members belonging to this 
signaling cascade were identified (3). 
 BRAF  
 BRAF (v-Raf murine sarcoma viral oncogene homolog B1) is a proto-oncogene, located 
on human chromosome 7p24, that encodes a cytosolic serine/threonine protein kinase 
expressed in most human cells, including thyroid follicular cells (2). BRAF plays a role in 
the MAPK pathway signal transduction, that is a crucial axis in the regulation of gene 
expression, cell proliferation and differentiation. Upon RAS activation, wild-type (wt) 
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BRAF is recruited to the plasma membrane and activated. Activated BRAF triggers 
sequential phosphorylation of its downstream target, that is mitogen-activated protein 
kinase kinase (MEK), which, in turn, activates the extracellular signal-regulated kinase 
(ERK), thus stimulating consequent effectors of the MAPK cascade. 
In TC, BRAF can be activated by point mutations, small in-frame deletions or insertions, or 
chromosomal rearrangements, eventually leading to chronic stimulation of MAPK 
pathway. The most common mechanism of BRAF activation is a thymidine to adenine 
substitution at nucleotide position 1799 in exon 15. This nucleotide transversion results in 
a valine-to-glutamate replacement (V600E), producing the constitutively active 
BRAFV600E mutant protein by the disruption of hydrophobic interactions between 
residues in the ATP binding site (36). Other BRAF mutations include adenine to guanine 
substitution at nucleotide position 1801, which results in a lysine-to-glutamate 
replacement (K601E), and small in-frame insertions or deletions surrounding codon 600 
(37). BRAF rearrangement AKAP9/BRAF was also described and it is the result of 
paracentric inversion of chromosome 7q that leads to the fusion of BRAF-kinase domain 
with a portion of AKAP9 gene (38). 
Activating BRAF mutations are not specific for TC. On the contrary, BRAF mutations were 
found in many types of cancer (39), with the highest prevalence (50%) in melanoma (40). 
BRAF mutations in TC are commonly found in nearly 60% of PTC (33), and are also present 
in nearly 30% of PDTC and 45% of ATC (29). It was demonstrated that transgenic mice 
with thyroid-specific expression of BRAFV600E developed PTC closely recapitulating those 
seen in human tumors (41), thus supporting the role of mutant BRAF in tumor initiation 
and differentiation. A multicentre study showed that BRAFV600E mutation was 
associated with aggressive behavior of PTC, including aggressive clinicopathological 
features, tumor recurrence and treatment failure (42).  
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 RAS  
 RAS (rat sarcoma) gene family encodes small-GTPases involved in signal transduction 
from the membrane to the nucleus (43), leading to protein synthesis and regulation of 
cell survival, proliferation and differentiation. In humans, RAS family consists of three 
genes: NRAS, KRAS and HRAS. 
RAS is a monomeric guanosine-nucleotide binding protein which resides in the inner 
surface of cell membrane and cycles between an inactive form, when bound to guanosine 
diphosphate (GDP), and an active form, when bound to guanosine triphosphate (GTP). 
After binding of the ligand to tyrosine kinase and G-protein coupled receptors, RAS 
switches to the GTP-bound active conformation and transmits signals on downstream 
pathways, including MAPK and PI3K/AKT cascades. RAS mutations were found in many 
tumor types and are usually limited to a small number of amino acids (12, 13, 59 and 61) 
(44). These single point mutations cause the loss of the GTPase activity of RAS, which is 
blocked in the constitutively active GTP-bound form and continuously stimulates signal 
transduction. 
NRAS and HRAS mutations at codon 61 are the most common in TC. In PTC, RAS mutation 
is the second most frequent genetic alteration identified (13-20%) and is commonly 
observed in the follicular variant (27,33). Mutations of RAS are found in benign FTAs (3), 
are common in FTC (49%) (45), and also present in PDTC (45%) and ATC (23%) (46). It is 
worth to note that, in TC, BRAF and RAS mutations are mutually exclusive (33,46). Even 
though activated mutant RAS is not sufficient to induce tumor formation per se, it may 
predispose normal cells to acquire further genetic or epigenetic alterations leading to a 
fully transformed phenotype (47).  
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 RET  
 RET (rearranged during transfection) encodes a transmembrane receptor tyrosine 
kinase (RTK) that binds, together with its co-receptors of the GDNF family receptor-α 
(GFRα1-4) family, members of the glial cell line-derived neurotrophic factor (GDNF) family 
of extracellular signaling molecules (48). Upon ligand binding to the co-receptor, RET 
dimerizes and autophosphorylates its intracellular tyrosine residues, which serve as 
docking sites for adaptor proteins that stimulate multiple downstream pathways such as 
MAPK and PI3K/AKT (49). RET is located in the pericentromeric region of chromosome 
10q11.2, and is required for the normal development, maturation and maintenance of 
several tissues and cell types, such as nervous system, kidney and male germ cells (50). 
Germline loss-of-function mutations of RET cause impaired formation of the enteric 
nervous system and congenital aganglionosis of the colon (Hirschsprung’s disease), while 
germline activating point mutations are causally related to the hereditary forms of MTC: 
multiple endocrine neoplasia type 2A and 2B (MEN2A, MEN2B) and familial MTC. 
In follicular cell-derived TC, several fusions of RET with partner genes, as result of 
chromosomal rearrangements, were identified (48). RET rearrangements, which generate 
the so-called RET/PTC oncoprotein, occur in 7-20% of PTCs (27,33) and generally result in 
a juxtaposition of the RET 3’ sequences, encoding the intracellular tyrosine kinase (TK) 
domain, with 5’ sequences of other partner genes (51). To date, up to 20 different RET 
rearrangements were identified in TC, and all partner genes share the peculiarity of 
constitutive expression in thyroid follicular cells. The resulting chimeric fusion protein 
RET/PTC is located in the cytosol, instead of membrane, and is able to form dimers in a 
ligand-independent manner, leading to chronic stimulation of downstream signaling 
pathway and tumorigenesis in thyroid cells. The two most common RET/PTC 
rearrangements thus far identified in PTC are RET/PTC1 and RET/PTC3, in which RET is 
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fused to CCDC6 (also known as H4) and NCOA4 (also known as ELE1 or RFG), respectively. 
Both rearrangements are intrachromosomal inversions of the long arm of chromosome 
10.  
Several studies reported an increase in the prevalence of RET/PTC rearrangements in PTC 
patients with a radiation history (52,53). Indeed, ionizing radiations produce double-
stranded breaks that can cause the misjoining of chromosome 10 loci, predisposing to 
intrachromosomal inversion and RET/PTC formation (51). 
Apart from PTC, even if rare, RET/PTC rearrangements were also found in PDTC and ATC, 
mainly in tumors associated with a differentiated component (54). 
The association of RET/PTC rearrangement with clinicopathological features of increased 
mortality in PTC is still controversial; however, a positive correlation with a more 
aggressive phenotype and tumor advanced stage was demonstrated in sporadic PTCs with 
RET/PTC3 rearrangements, which had both large tumor size and an advanced disease 
stage at the time of diagnosis; other studies highlighted a role of RET/PTC3 in metastatic 
spread (51).  
Interestingly, RET rearrangements are not limited to TC, but were identified also other 
solid tumors such as lung, breast and colon carcinomas (55). 
 TRK  
 TRK oncogenes are the product of rearrangements of NTRK1 (neurotrophic receptor 
tyrosin kinase A, or TRKA) gene on chromosome 1q21-22 (56). NTRK1 encodes the 
transmembrane high affinity receptor for the nerve growth factor (NGF), which exerts a 
critical role in the regulation of development and differentiation of peripheral and central 
nervous system. Following NGF binding, NTRK1 undergoes dimerization and 
autophosphorylation on intracellular tyrosine residues; these phosphorylated residues 
recruit adaptor proteins that activate multiple downstream pathways, such as MAPK and 
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PI3K/AKT (57). These signals, similar to those triggered by RET, culminate in the induction 
of genes that regulate cell proliferation and survival. 
Deregulation of NTRK1 signaling was found associated with different human diseases: 
NTRK1 mutations were found in CIPA (Congenital Insensitivity to Pain with Anhidrosis 
(58), acute myeloid leukemia (59), and deregulated NGF/NTRK1 activity was found 
associated with prostate (60) and breast (61) cancer development. 
Several TRK oncogenes originating from NTRK1 rearrangements were found in TC, 
particularly in the PTC histotype (56). The most frequent is TRK, that results from the 
fusion of the NTRK1 sequence, encoding the TK domain, to sequences from of the non-
muscle tropomyosin (TMP3) gene on chromosome 1q22-23. Other rearrangements 
include TRK-T1 and TRK-T2, which derive both from the rearrangement of NTRK1 with 
translocated promoter region (TPR) gene located on chromosome 1q25, but each 
displaying a different structure. TRK-T3 oncogene derives from the fusion of portions of 
NTRK1 and the ubiquitously expressed TRK-fused gene (TFG), located on chromosome 
3q11-12 and first identified in this rearranged version (62). 
Somatic rearrangements of NTRK1 account for about 1-2% of genetic alterations in PTC. 
Although occurring less frequently than RET rearrangements, experimental evidence 
indicate that TRK oncogenes represent an early event in the thyroid carcinogenesis, as 
transgenic mice carrying TRK-T1 under control of thyroglobulin promoter (Tg-TRK-T1 
mice) develop hyperplasia and PTC (63). 
As for RET, also NTRK1 rearrangements were identified in solid tumors besides PTC: these 
consist in colorectal cancer, lung cancer, pediatric brain tumors and glioblastoma, 
cholangiocarcinoma and sarcoma (55). 
23 
 
1.1.2.3. PI3K/AKT signaling pathway 
 PI3K/AKT signaling pathways plays an important role in the regulation of several 
cellular functions such as growth, motility and survival (64). The relevance of this pathway 
in human tumorigenesis and its targeting as therapeutic approach have been widely 
investigated in the last decade (65,66), also in thyroid tumors (67).  
 PIK3CA 
 Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit α (PIK3CA) encodes 
the 110 kDa catalytic subunit of the class I PI3 kinase complex that is activated by RTKs 
and, when active, phosphorylates phosphatidylinositol-4,5-bisphosphate to produce 
phosphatidylinositol-3,4,5-trisphosphate (PIP3), the activator of AKT. 
PIK3CA involvement in human cancer development is well documented, as somatic 
activating mutations of this gene were identified in a variety of tumors, such as colorectal, 
breast and ovarian carcinomas (68). In the context of thyroid, mutations of PIK3CA were 
identified in FTC and ATC histotypes, with a frequency of 10-15%, and in PDTC and ATC 
either recurrent or with metastatic disease (64). Also PIK3CA copy-number gain is 
reported in TC, mainly in FTC and ATC and uncommonly in PTC. This alteration results in 
PIK3CA amplification and is associated with overexpression of the protein and hyper-
phosphorylation of AKT.  
 PTEN 
 Phosphatase and tensin homolog (PTEN) encodes the protein phosphatase responsible 
for the degradation of PIP3, thus antagonizing and terminating the PI3K/AKT signaling. 
PTEN has a crucial role as tumor suppressor gene and different mechanisms inhibiting its 
activity were described for human cancers, including TC (64). These mechanisms include 
somatic mutations (although with low frequency), loss of heterozygosity or deletion, and 
promoter hypermethylation. Germline inactivating mutations of PTEN cause Cowden’s 
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syndrome and predispose patients to develop tumors, including FTC. PTEN alterations are 
found in FTC and, more commonly, in ATC (15%) where, together with other genetic 
alterations of members of the PI3K/AKT pathway, can ideally cooperate and contribute to 
the aggressiveness of this thyroid tumor (29). 
1.1.2.4. Other mutations 
 PAX8/PPARγ  
 The paired box 8/peroxisome proliferator-activated receptor-γ fusion gene 
(PAX8/PPARγ) is another recombinant oncogene in TC, originating from translocation 
between chromosomal regions 2q13 (PAX8) and 3p25 (PPARγ) (69). PAX8 is a member of 
the paired box family of transcription factors required for normal thyroid development; it 
also induces the expression of thyroid-specific genes in the mature thyroid. PPARγ is a 
member of the nuclear receptor family of transcription factors and is the master regulator 
of adipogenesis; it is expressed at very low levels and has no known function in the 
normal thyroid. The fusion product PAX8/PPARγ encodes a nearly full length PPARγ, 
whose expression is under transcriptional control of PAX8 promoter which is highly active 
in thyroid follicular cells. Several in vitro experiments provided evidence that 
PAX8/PPARG acts as oncogene in TC (70-72), although the specific mechanism is yet to be 
defined. PAX8/PPARγ rearrangements are prevalent in FTC (30-35%), follicular variant of 
PTC (13%), and follicular adenomas, while they are absent in undifferentiated PDTC and 
ATC (73). 
 TP53 
 TP53 encodes a transcription factor that acts as tumor suppressor, playing a pivotal 
role in regulation of cell proliferation, DNA damage response and apoptosis (74). In 
physiological conditions, p53 forms a complex with MDM2, an E3 ubiquitin protein ligase 
that promotes its degradation by the proteasome. Upon DNA damage or other cellular 
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stresses, various pathways activate and culminate in p53 activation by promoting its 
dissociation from MDM2. Once activated, p53 binds to DNA and drives the expression of 
several genes that lead to cell cycle arrest, apoptosis and/or senescence, contributing to 
the maintenance of genome stability. TP53 mutations are found in up to 50% of human 
cancers and are generally loss-of-function missense mutations (75). TP53 mutations are 
rare in well-differentiated PTC and FTC (76) and also in PDTC (about 8% of frequency), 
while they are a common genetic event in the undifferentiated ATCs (up to 73% of cases) 
(29). It was demonstrated that TP53 mutations have a role in the progression from well-
differentiated TC to the most aggressive ATC (77), thus supporting the notion that TC 
initiation and progression occurs through gradual accumulation of multiple genetic 
lesions. 
 
1.1.3. Treatment of thyroid cancer 
1.1.3.1. Conventional therapy 
 The treatment of choice for well-differentiated primary thyroid tumors is surgery, that 
consists of partial lobectomy or total thyroidectomy, based on the dimensions and the 
clinicopathological features of the thyroid nodule detected (78). Controversy still exists on 
the extent of the surgery: partial lobectomy was shown to have the same effects on 
patient overall free survival as total thyroidectomy did, but with less frequent adverse 
events (such as hypocalcemia and laryngeal nerve paralysis) (79). Nevertheless, with the 
exception of unifocal low-risk PTCs smaller than 1 cm, the American Thyroid Association 
(ATA) guidelines recommend the complete removal of the thyroid to minimize the risks of 
malignancy relapse (80). Together with the thyroid, patients diagnosed with primary PTC 
undergo lymph node removal even in the absence of clear nodal metastases, since from 
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22% to 90% of PTCs spread locally to lymphoid glands. Following surgery, patients are 
usually treated with radioactive iodine (RAI, 131I), in order to remove potential occult 
WDTC foci and decrease the long-term risk of tumor recurrence. In addition to surgery 
and RAI, thyroid-stimulating hormone (TSH) suppressive treatment is practiced to prevent 
major adverse clinical events, since WDTCs are usually responsive to TSH stimulation in 
terms of cell growth. WDTC are generally cured by standard therapy; nevertheless, tumor 
recurrence can happen, as in up to 20% of patients the tumor relapses and in 10% of 
patients distant metastases occur (81). 
 Management of the undifferentiated ATCs is more challenging: surgical removal of the 
thyroid remains the first choice of therapeutic intervention, but many patients often 
present at diagnosis with extended local disease invading the surrounding structures 
(such as trachea and larynx) that makes the tumor mass unresectable (25). Moreover, 
ATCs are usually refractory to RAI therapy. When surgery is feasible, thyroidectomy is 
combined with locoregional radiation therapy and chemotherapy with agents such as 
taxanes or platinum-based antineoplastic drugs, like carboplatin. For patients with 
unresectable disease, palliative therapy to preserve the airway is mandatory, and a 
combination of radiations and chemotherapy is applied with the aim of achieving local 
tumor regression and/or durable local tumor control. However, even if multimodality 
therapy has shown to prolong patient survival, a successful standardized protocol has not 
been defined yet and the optimal sequence of multimodality therapy still remains to be 
determined. 
1.1.3.2. Novel therapies 
 In the last decades, the increased knowledge on the molecular events that drive 
tumorigenesis allowed the development of the so-called precision medicine (82): in 
cancer, including TC, the improved understanding of the pathogenesis and genetics of 
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tumors prompted the development of new therapeutic opportunities for patient 
treatment (Figure 1.4) (83). 
 
 
Figure 1.4 Signaling pathways involved in TC pathogenesis and their relevant inhibitors  
Kinase receptors are shown with their corresponding ligands and downstream signaling pathways. 
Pharmacological inhibitors, which operate at different levels in signaling pathways, are indicated. 
Image from (83). 
 
 A variety of molecular-targeted agents able to inhibit RTKs or downstream effectors is 
nowadays available. These small molecules are competitive inhibitors of the ATP-binding 
domains of multiple kinases and acquired great interest as most of their targets belong to 
the main pathways involved in TC pathogenesis and progression. The potential of this 
relatively new class of drugs is that their activity may not be restricted to only one target, 
but that can act on multiple signaling pathways. WDTCs are characterized by increased 
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peritumoral angiogenesis and high secretion of the vascular endothelial growth factor 
(VEGF), and the blockade of its receptor (VEGFR) has shown promising results in 
attenuating tumor cell growth in vivo. Small-molecule tyrosine kinase inhibitors (TKI) 
often inhibit, in addition to the target kinase, VEGFR and other angiokinase receptors 
(such as PDGFR, FGFR), thus hindering multiple signaling pathways of potential 
therapeutic relevance (Table 1.2). 
 
 
Table 1.2 Small-molecule TKIs and their targets tested in clinical trials for TC 
Adapted from (84) 
 
Among the several TKIs tested in phase I, II and III trials for TC treatment, only 4 of them 
were approved for clinical treatment: sorafenib and lenvatinib for progressive DTC, 
vandetanib and cabozantinib for MTC (84). Despite the longer patient-free survival 
duration relative to placebo in randomized clinical trials, these drugs produced several 
side verse effects in patients (Table 1.3) and, to date, few data are available about the 
prolongation of patient overall survival. Of note, treatment of ATC with TKIs has still to be 
rigorously studied and defined: among the variety of molecules previously listed, only 
lenvatinib showed promising antitumor activity in ATC patients (85). 
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Table 1.3 TKIs approved for the treatment of TC and details of phase III trials 
Adapted from (84) 
 
 As mortality is increased for patients with WDTCs that become refractory to RAI 
therapy, another strategy that has been developed in the last decades is the development 
of agents that promote tumor re-differentiation, which can make tumors radioiodine-avid 
again and therefore treatable with 131I. Several agents, among which retinoic acid, were 
tested in RAI-refractory patients but gave no significant benefits (86). A promising 
candidate for RAI-resensitization is the MEK inhibitor selumetinib, which has been able to 
increase the uptake of RAI and gave a partial response and decrease in tumor size, 
especially in patients with NRAS-mutant tumors (87).  
 Another therapeutic approach for TC cell re-differentiation is the use of epigenetic 
drugs, specifically histone deacetylase (HDAC) inhibitors. Epigenetic alterations in tumor 
cells often result in the silencing of genes involved in cell differentiation, given by the 
hypermethylation of cytosines of the promoter and the subsequent recruitment of HDACs 
to repress expression of the genes (88). There are various classes of HDACs in cells, thus 
different compounds were developed to specifically target one class or another. 
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Suberoylanilide hydroxamic acid (SAHA, Vorinostat®) is a pan-HDAC inhibitor that was 
able to increase Na+/I- symporter (NIS) expression and reduce WDTC and ATC cell growth 
in vitro. Romidepsin (IstodaxTM) is a class I-HDAC inhibitor able to restore RAI avidity in 
some TC patients and therefore could potentially increase the response to RAI therapy. 
Panobinostat (Fraydak®) induced re-expression of NIS and increased response to RAI 
treatment in vitro, while valproic acid (Depakene®) was able to increase NIS mRNA 
expression. Nevertheless, none of these compounds produced significant responses in the 
clinics to date. 
1.1.3.3. Conclusions 
 Despite the improvement of TC therapy, some areas of uncertainty persist (84). 
Limitations of targeted therapy are mainly made by the toxicity profiles that usually lead 
to the reduction of therapy doses, the onset of escape mechanisms of resistance to 
treatment, and notably no data about the long-term effects on patient quality of life is 
available. ATC still remains one of the deadliest diseases worldwide, as no effective 
therapy has been identified to date and targeted therapies are now tested in phase II 
clinical trials. 
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1.2. Non-Oncogene Addiction 
1.2.1. Oncogene and non-oncogene addiction principles 
 Nowadays it is well known that cancer arises from a mutagenic multistep process 
during which transforming cells acquire several properties, such as uncontrolled 
proliferation, resistance to antiproliferative signals and resistance to apoptotic stimuli 
(89). These properties are shared by all tumor cells and are achieved through random 
mutations and epigenetic changes in oncogenes and tumor suppressor genes, which 
eventually lead to the modification of already existing cellular programs normally used 
during development. The concept of “oncogene addiction” indicates the dependency of 
tumor cells on the activity of oncogenes and oncogenic pathways that are essential for 
tumor cell survival (90). This concept put the rationale for therapeutic intervention by 
targeting the mutated components of key cellular pathways on which tumor cells became 
dependent. A variety of drugs targeting specific oncogenes in different tumors were 
developed and tested, such as HER2 in breast cancer (91), BRAF in melanoma (92), EGFR 
in non-small cell lung cancer (93) and BCR-ABL in chronic myeloid leukemia (94). 
However, even though remissions were observed in some cases, these were often 
followed by the recurrence of drug-resistant tumor cells. Moreover, the targeting of 
oncogenes like RAS or MYC is complex, as the identification of compounds specifically 
targeting them is difficult. Based on these observations, the “synthetic lethality” concept 
was exploited. It indicates a phenomenon of lethal combination of 
mutations/perturbations in two genes, where mutations in only one of those genes have 
no effect on cell viability (95). The targeting of a synthetic lethal partner of a mutated 
driver gene in tumor cells may provide two main advantages: the overcoming of the lack 
of inhibitors for certain oncogenes and the sparing of normal cells during therapeutic 
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intervention. An example of promising synthetic lethality application in the clinics is the 
use of poly ADP-ribose polymerase (PARP) inhibitors in advanced ovarian cancer patients 
with mutations in BRCA1/2, which exhibit specific DNA repair defect and result sensitive 
to this class of drugs (96).  
 Beyond the concept of oncogene addiction, it was observed that tumor cells often 
face increased levels of cellular stresses, caused by the sustained activation of oncogenic 
pathways, compared to normal cells (97). This phenomenon was referred to as “stress 
phenotype” of cancer cells (Figure 1.5). 
 
 
Figure 1.5 The hallmarks of cancer revisited 
In addition to the six hallmarks of cancer initially proposed by Hanahan and Weinberg (89), 
additional hallmarks were proposed, in order to highlight the “stress phenotype” of cancer cells. 
These new hallmarks include DNA damage, metabolic, oxidative, mitotic and proteotoxic stresses 
and, together with the other cancer hallmarks, promote the tumorigenic state of cancer cells. 
Image from (98) 
 
Increased cellular stresses associated with the oncogenic activity are tolerated by cancer 
cells through the activation of stress support pathways, on which they become therefore 
33 
 
addicted. These genes act in oncogenic pathways but are not classical oncogenes 
themselves, as they are not mutated, aberrantly expressed or responsible for 
tumorigenesis initiation (98). This phenomenon has been termed “non-oncogene 
addiction” (NOA) and highlights the potential of non-oncogenes as point of intervention 
for cancer therapy, since the impairment of their functions would ideally be lethal for 
tumor cells while sparing normal ones (Figure 1.6). 
 
 
Figure 1.6 Schematic representation of cellular non-oncogene addiction effects 
Cancer cells, according to NOA paradigm, face elevated cellular stresses produced by collateral 
events of the tumorigenic process. Interfering with the stress support pathways in tumor cells will 
lead to their killing, while normal cells are able to tolerate these perturbations. Image adapted 
from (99). 
 
Tumor cell dependencies on NOA genes provide an attractive target for therapeutic 
intervention, which could be achieved through two different approaches: stress 
sensitization, that consists in diminishing the activity of stress support pathways in order 
to promote cell growth inhibition and cell death, and stress overload, that aims to 
intensify oncogenic stress to overload the stress support pathways in tumor cells and 
eventually lead to growth arrest or cell death. Stresses faced by tumor cells are DNA 
damage, mitotic, proteotoxic, metabolic and oxidative stress (Figure 1.7). 
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Figure 1.7 Non-oncogene addiction examples in tumor cells 
The tumorigenic state of cancer cells results in several alterations of cellular homeostasis related 
to the hallmarks of cancer, described in Figure 1.5. These alterations represent potential tumor 
vulnerabilities, and interfering with regulators of these support pathways could display synthetic 
lethality with the tumor phenotype. Image from (98) 
 
Because of the high degree of replication and the activity of oncogenes themselves, the 
rate of spontaneous DNA damage in tumor cells is increased, compared to the normal 
ones. Indeed, several studies demonstrated that inhibition of members of DNA damage 
response pathway, such as ATM and CHK1, exerted selective toxicity on tumor cells, as 
they increased DNA damage stress. Linked to the high degree of replication of tumor 
cells, there is also mitotic stress, which is the result of increased rates of chromosome 
segregation errors caused by mutations altering mitosis fidelity. The inhibition of proteins 
regulating mitosis was found effective in sensitizing tumor cells to stress overload, as it is 
commonly observed upon treatment with taxol or mitotic kinase inhibitors. 
Transcriptional alterations and copy-number variations normally happening in tumor cells 
also result in proteotoxic stress: these changes often produce alterations of protein 
dosage balance, thus resulting in steady activation of chaperone pathways to maintain 
normal proteome homeostasis and, in case of unfolded proteins, of the ubiquitin-
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proteasome pathway. Indeed, inhibition of the proteasome with bortezomib has proven 
to be deleterious for tumor cells, and provides an example of proteotoxic stress overload. 
All these lines of evidence support the concept that NOA genes are attractive targets for 
therapeutic intervention, since they represent key functional nodes in the oncogenic 
network and their inhibition would result in system failure. According to the NOA 
paradigm, several groups already provided promising results in “targeting of non-
oncogene addiction”: PARP inhibition in glioblastoma (100), silencing of heat shock factor 
1 (HSF1) in multiple cancer cells (101), and HDAC6 inhibition in breast cancer (102) 
resulted in inhibition of tumor cell growth. 
 
1.2.2. Tools for the identification of cancer cell vulnerabilities 
 The traditional approach used to identify potential targets for cancer treatment, in the 
last decades, consisted in the identification of the specific genetic lesions at the basis of 
tumorigenic process, such as copy-number variations, gene mutations, transcriptional 
changes and epigenetic modifications (103). Despite being a powerful approach for 
identifying genetic changes in oncogenes or tumor suppressor genes, some limitations 
persist: sequencing techniques nowadays mostly limit to coding regions and therefore 
NOA genes and pathways are not detected, since they are not directly mutated albeit 
supportive in the tumorigenic process. However, the revolution of RNA interference 
(RNAi) technologies allowed the development of a functional approach to identify such 
critical nodal points for cancer therapeutic intervention (104). Functional RNAi screenings 
are indeed able to identify cancer vulnerabilities, as the investigation is not limited to 
mutated genes, such as oncogenes, but also includes genes and pathways important for 
tumor sustainment, that is NOA genes. This strategy is also powerful in terms of target 
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discovery, as either partial or complete loss of protein function strictly mimics the effects 
of a pharmacological inhibitor. The wide development of commercially available large-
scale RNAi libraries, that can be constructed with different strategies (Figure 1.8), 
contributed to the improvement of the use of large-scale RNAi-based screenings with the 
aim of dissecting complex biological processes (105). Such large scale RNAi-based 
functional screenings performed both in vitro (106-108) and also in vivo (109,110) were 
successful in identifying genes essential for the regulation of different types of cancer. 
 
 
 
37 
 
 
Figure 1.8 RNAi library screening approaches 
RNAi screenings can be performed using different strategies. Arrayed library screening, using 
synthetic small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs), target each gene 
separately in a multiwell format and various readouts can be used to determine the silencing 
effect on the phenotype of interest (a). Arrayed screening using cell microarrays allow to plate 
cells directly onto microarrays containing the siRNAs/shRNAs, and the target gene is identifiable 
by the position on the array (b). Pooled library screens target many genes pools of shRNA 
expressing vectors are introduced into cells by transfection or infection for pooled library 
screening; cells are exposed to a selective agent and the shRNA-plasmids present in surviving cells 
are identified by DNA sequencing or barcode microarray analysis (c). Image from (111). 
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Aim of the study 
 The non-oncogene addiction paradigm highlighted novel tumor cell vulnerabilities that 
could represent potential points for therapeutic intervention in cancer. Moreover, the 
improvement of RNAi technologies allowed the development of new tools, that are large-
scale RNAi screening libraries, for the investigation of these critical nodal points in the 
complex cancer network. While NOA was approached for tumors such as myeloma and 
breast cancer, in the context of thyroid cancer the NOA paradigm is a completely novel 
concept. Given that current therapies for thyroid tumors are not always effective, 
particularly for the most aggressive and advanced cases, the identification of TC cell 
vulnerabilities would be useful for the development of new therapeutic approaches. 
 Using a siRNA library targeting the whole “druggable” genome, our laboratory has 
previously performed a loss-of-function based screening on a tumor and a normal thyroid 
cell lines, in order to identify genes whose silencing interfered with the growth of tumor 
but not normal cells. This screening allowed us to identify 15 differentially active hits in 
the tumor versus the normal cell lines. 
 The overall aim of the project was the identification of thyroid tumor cell vulnerability 
genes, according to the NOA paradigm, and the dissection of their role in thyroid tumor 
cell biology, in order to unveil potential novel targets for thyroid cancer treatment. Most 
of the work was devoted to hit gene validation studies and to studies on MASTL, a 
vulnerability gene we identified in TC cells. These two sections have been well developed 
and hereafter presented in two distinct chapters. The thesis includes a third chapter that 
summarized the studies regarding COPZ1, which is another vulnerability gene identified in 
TC cells, to which I collaborated. 
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2. Materials and methods 
 
2.1. Cell Biology 
2.1.1. Cell culture 
 Nthy-ori 3-1 cell line (SV-40 immortalized normal human thyroid follicular cells) was 
purchased from European Collection of Cell Cultures (ECACC) (Salisbury, UK); tumor 
BCPAP, TPC-1, WRO82-1, 8505C and KAT-18 cell lines were obtained from Prof. A. Fusco 
(University of Federico II, Naples, Italy); HTC/C3 cell line was purchased from Riken Cell 
Bank (Tsukuba, Japan). Information regarding the histotype derivation of cell lines and the 
mutational status are provided in Table 2.1. HEK 293T cell line was purchased from 
American Type Culture Collection (ATCC). 
Nthy-ori 3-1 cells were cultured in RPMI 1640 medium (Gibco Life Technologies, Carlsbad, 
CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (EuroClone, 
Pero, Italy). The other cell lines were maintained in DMEM medium (Gibco Life 
Technologies, Carlsbad, CA, USA) containing 10% FBS and 2mM glutamine. All cell lines 
were cultured as monolayer at 37°C in a 5% CO2 humidified atmosphere. 
Cell lines were authenticated by short tandem repeat (STR) profiles using Stem Elite ID 
System (Promega Corporation, Madison, USA) by the Fragment Analysis Facility of 
Fondazione IRCCS Istituto Nazionale dei Tumori. The profiles obtained matched to their 
original profiles (112,113). WRO82-1 profile matched to that reported by Xu and 
colleagues (114) and HTC/C3 to that reported by JCRB Cell Bank 
(http://cellbank.nibio.go.jp/legacy/celldata/jcrb0164.htm). 
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Mycoplasma contamination was tested periodically and found negative in all cell lines 
(PCR Mycoplasma Detection Set, TAKARA Bio Inc). 
 
Table 2.1 List of thyroid cell lines with histological derivation and mutational status 
Cell lines Hystological type Mutational status 
Nthy-ori 3-1 normal human thyrocytes 
 BCPAP PTC BRAF V600E 
TPC-1 PTC RET/PTC1 
WRO82-1 FTC 
 8505C ATC BRAF V600E; TP53 R248L 
HTC/C3 ATC BRAF V600E; TP53 P152L 
KAT-18 ATC 
  
 
2.1.2. Cell transfection and gene silencing 
 Transient gene silencing of the hit genes was obtained in thyroid cell lines by the 
transfection of specific siRNAs, detailed in Table 2.2, using Lipofectamine RNAiMAX 
reagent (Invitrogen Life Technologies, Carlsbad, CA, USA), according to manufacturer’s 
protocol. Briefly, cells were seeded at the optimal density and transfected the following 
day by adding a mixture of Opti-MEM (Reduced Serum Media) (Gibco Life Technologies, 
Carlsbad, CA, USA) containing 20 nM siRNA and 3 µl/ml Lipofectamine RNAiMAX.  
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Table 2.2 List of siRNAs used for gene silencing 
siRNA Sequence/catalog number Source 
siNT 
ON-TARGET plus Non-targeting Pool 
siRNA D-0018-10-05 
ThermoScientific, Dharmacon 
Inc., Chicago, IL, USA 
siPSMC3 MISSION esiRNA EHU107331 
Sigma-Aldrich, St. Louis, MO, 
USA 
siMASTL #1 
ON-TARGET plus set of 4 siRNAs 
J-004020-12 
5’-CCAUUGAGACGAAAGGUUU-3’ 
ThermoScientific, Dharmacon 
Inc., Chicago, IL, USA 
siMASTL #2 
ON-TARGET plus set of 4 siRNAs 
J-004020-11 
5’-GCAAAUUGUAUGCAGUAAA -3’ 
ThermoScientific, Dharmacon 
Inc., Chicago, IL, USA 
siMASTL #3 
ON-TARGET plus set of 4 siRNAs 
J-004020-10 
5’-ACUGGACGCUCUUGUGUAA-3’ 
ThermoScientific, Dharmacon 
Inc., Chicago, IL, USA 
siMASTL #4 
ON-TARGET plus set of 4 siRNAs 
J-004020-09 
5’-GGACAAGUGUUAUCGCUUA-3’ 
ThermoScientific, Dharmacon 
Inc., Chicago, IL, USA 
siMASTL#5 
5'-UGUGGAUUCUGGUGGGAUAdTdT 
3' 
in house 
siCCND1 MISSION esiRNA EHU153321 
Sigma-Aldrich, St. Louis, MO, 
USA 
siCOPZ1 MISSION esiRNA EHU1040461 
Sigma-Aldrich, St. Louis, MO, 
USA 
siMAP4K5 MISSION esiRNA EHU120861 
Sigma-Aldrich, St. Louis, MO, 
USA 
siCOPE MISSION esiRNA EHU069701 
Sigma-Aldrich, St. Louis, MO, 
USA 
siPLA2G15 #1 
ON-TARGET plus set of 4 siRNAs 
J-009622-08 
5’-GAAGAUGGCUGGCUCAUGC-3’ 
ThermoScientific, Dharmacon 
Inc., Chicago, IL, USA 
siPLA2G15 #2 
ON-TARGET plus set of 4 siRNAs 
J-009622-07 
5’-GCGAUGGUACUGUGAACUU -3’ 
ThermoScientific, Dharmacon 
Inc., Chicago, IL, USA 
siPLA2G15 #3 
ON-TARGET plus set of 4 siRNAs 
J-009622-06 
5’-GGAGAUGUACCAGCUGUAU -3’ 
ThermoScientific, Dharmacon 
Inc., Chicago, IL, USA 
siPLA2G15 #4 
ON-TARGET plus set of 4 siRNAs 
J-009622-05 
5’-CAGCGUGGGUUCCUAUUUC-3’ 
ThermoScientific, Dharmacon 
Inc., Chicago, IL, USA 
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2.1.3. Cell proliferation assays 
2.1.3.1. CellTiter-Glo assay 
 For hit validation studies described in chapter 3, cells (500 cells/well) were reverse 
transfected in 96-well plate with 20 nM specific siRNAs using the Lipofectamine RNAiMAX 
reagent and, ten days later, cell viability was assessed by CellTiter-Glo® Luminescent Cell 
Viability Assay (Promega Corporation, Madison, USA), performed as recommended by the 
supplier. Luminescence signals were acquired using a microplate reader (TecanUltra, 
Tecan Trading AG, Switzerland).  
 For MASTL studies described in chapter 4, HTC/C3 and 8505C cells (1.9 x 105) were 
seeded in 60mm dishes transfected the day later with 20 nM of specific siRNAs using 
Lipofectamine RNAiMAX. 24 hours after transfection, cells were harvested and plated 
(2x103 cells/well) in 96-well plates; 8505C-TRIPZ-shMASTL #2 (2x103) cells were plated in 
96-well plates in absence or presence of 2 µg/ml doxycycline. Growth rates were 
evaluated at the time points indicated in the growth curves after plating by CellTiter-Glo® 
Luminescent Cell Viability Assay as described above. 
2.1.3.2. Trypan Blue exclusion test 
 BCPAP and 8505C (1x105), TPC-1 (6 x 104), WRO82-1, HTC-C3 and KAT-18 (8 x 104) cells 
were transfected the day after the seeding in 6-well plate with 20 nM of specific siRNAs 
using Lipofectamine RNAiMAX, following manufacturer’s protocol. At different days after 
transfection (4 days for TPC-1, 8505C and HTC/C3 cells; 5 days for KAT-18 cells, 6 days for 
BCPAP cells, 7 days for WRO82-1 cells) the fraction of viable and dead cells was analyzed. 
2.1.3.3. Growth inhibition Assay 
 For experiments with palbociclib, which is a CDK4 and CDK6 inhibitor (115), cells 
(8x104 cells/well) were seeded in black/clear bottom 96-well plates and, the following 
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day, treated with increasing doses of the palbociclib (PD 0332991) (Selleck Chemicals, 
Houston, TX, USA, cat. S2768). After 72 hours, cells were fixed with 3.7% 
paraformaldehyde solution for 30 minutes at room temperature, washed and stained 
with 1 mg/ml Hoechst 33342. The plates were analyzed with an ArrayScan VTI high-
content screening reader (Thermo-Fisher Scientific, Pittsburgh, PA): at least 800 cells 
were acquired in each well with a 10X objective in one fluorescence channel (XF93 optical 
filter set). Cell nuclei were automatically recognized and counted in ten fields to estimate 
the cell number per well as proliferation readout. IC50 values were calculated by sigmoid 
curve fitting of experimental points. 
 For MASTL studies, HTC/C3 and 8505C (1.2 X 104) cells were plated in 24 well-plates 
and transfected the following day with 20 nM of siRNAs using the Lipofectamine 
RNAiMAX reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). Seven days after 
transfection, cells were fixed with 3.7% formaldehyde solution (v/v) at room temperature 
for 15 minutes, washed with PBS and stained for 20 minutes with 0.1% crystal violet 
(w/v). Crystal violet was then dissolved in 10% acetic acid (v/v) for 30 minutes on a rocker 
and then diluted 1:4 in ddH2O. Optical density at λ=590 nm was measured by using 
Ultrospec 2100 Pro spectrophotometer (GE Healthcare Bio-Sciences, Pittsburgh, PA). 
2.1.4. Immunofluorescence analysis 
 For hit validation studies described in chapter 3, 8505C cells growing on glass 
coverslips were transfected with 20 nM control (NT) or MASTL siRNAs and fixed 48 hours 
later for 10 minutes with 4% paraformaldehyde (Sigma Aldrich, St Louis, Mo, USA). After 
permeabilization for 10 minutes with 1% BSA and 0.1% Triton X-100 in PBS, and 
incubation for 30 minutes with 1X blocking solution (2% BSA in PBS), cells were incubated 
with anti-β-tubulin (clone TUB 2.1: T4026, 1:400, Sigma Aldrich, St. Louis, MO, USA) or 
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anti-histone H3 (phospho S10) (E173: ab32107, 1:1000, Abcam, Cambridge, UK) primary 
antibodies for 1 hour. After washing with PBS, cells were incubated with Alexa Fluor® 546 
rabbit (1:500, Invitrogen/Molecular Probes®) and Alexa Fluor 488® mouse (1:500, 
Invitrogen/Molecular Probes®) secondary antibodies for 1 hour. Slides were then 
prepared using ProLong Diamond Antifade mountant with DAPI (P36966, Molecular 
Probes®) and imaged with immunofluorescence microscopy (Eclipse E1000; Nikon 
Instruments, Inc. NY, USA). 
 For MASTL studies described in chapter 4, HTC/C3 and 8505C cells growing on glass 
coverslips were transfected with 20 nM NT or MASTL siRNAs and fixed 120 (for HTC/C3) 
and 76 (for 8505C) hours later for 10 minutes with 4% paraformaldehyde. After 
permeabilization performed as described above, slides were prepared using ProLong 
Diamond Antifade mountant with DAPI (P36966, Molecular Probes®) and imaged with 
immunofluorescence microscopy. A minimum of 1900-2000 (for HTC/C3) and 3000 (for 
8505C) cells was counted for each siRNA treatment, and the number of cells with 
abnormal nuclei was expressed as percentage of the total count.  
2.1.5. Annexin V assay 
 HTC/C3 (1.9 x 105) cells were seeded in 60mm dishes and transfected the following 
day with 20 nM NT and MASTL #5 siRNAs using Lipofectamine RNAiMAX. At 48, 72, 96 
and 120 hours after transfection, both adherent and floating cells were harvested and 
processed for flow cytometry analysis using FITC Annexin V Apoptosis Detection Kit 
(Becton Dickinson, San Jose, CA, USA): after washing with PBS, cells were resuspended in 
Annexin V Binding Buffer and incubated with FITC-conjugated Annexin V for 15 minutes, 
at room temperature in the dark. TO-PRO-3 iodide (1:2000; Invitrogen/Molecular 
Probes®), instead of propidium iodide, was then added to each sample. Samples were 
45 
 
acquired using BD FACSCanto (Becton Dickinson, San Jose, CA, USA) instrument and 
analyzed with FlowJo v7.6 software (TreeStar). 
2.1.6. Lentiviral-mediated stable MASTL silencing 
2.1.6.1. Generation of lentiviral particles 
 For lentiviral particles generation, TRIPZ-shMASTL #1 (V2THS_177827, 
ThermoScientific, Dharmacon Inc., Chicago, IL, USA) or TRIPZ-shMASTL #2 
(V2THS_261809, ThermoScientific, Dharmacon Inc., Chicago, IL, USA) plasmids were 
transfected in 293T cells by using the Trans-Lentiviral shRNA Packaging Kit 
(ThermoScientific, Dharmacon Inc., Chicago, IL, USA) according to manufacturer’s 
instruction. In details, 293T (5.5x106) cells were plated in 100mm dishes and transfected 
the following day with a mixture of  42 µg of TRIPZ-shMASTL #1 or TRIPZ-shMASTL #2 
plasmids, together with 30 µl of Trans-lentiviral packaging mix, by calcium phosphate 
protocol. After 16 hours, cells were washed and incubated with DMEM, supplemented 
with 5% FBS, for 48 hours. Supernatant containing lentiviral particles was then collected, 
centrifuged at 1600 x g at 4°C for 10 minutes, filtered through a sterile 0.45 µM filter 
(Millipore, Billerica, MA, USA), aliquoted and stored at -80°C. Lentiviral particles were 
titered according to manufacturer’s instructions. 
2.1.6.2. Lentiviral transduction  
 8505C (6x104) cells were seeded in 6-well plates and, the day after, growth medium 
was replaced with lentiviral particles-containing supernatant (multiplicity of infection, 
MOI=1), in presence of 6 µl/ml polybrene (Sigma-Aldrich, St. Louis, MO, USA), for 4 hours. 
After 4 hours incubation, supernatant was replaced with fresh lentiviral supernatant in 
presence of 6 µl/ml polybrene; 4 hours later supernatant was replaced with complete 
growth medium. After 48 hours of culture, 1 µg/ml puromycin (Sigma-Aldrich, St. Louis, 
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MO, USA) was added to medium, in order to select transduced cells. After one-week 
selection, cells were tested for shRNA production by 1 µg/ml and 2 µg/ml doxycycline 
(Sigma-Aldrich, St. Louis, MO, USA) administration. 
2.2. Biochemical analysis 
2.2.1. Protein extraction and sample preparation 
 Both adherent and floating cells were collected and centrifuged. Proteins were 
extracted in RIPA modified buffer (20mM Tris-HCl, pH 7.4, 150mM NaCl, 5mM EDTA, 1% 
NonidetP-40) supplemented with Complete Mini EDTA-free protease Inhibitor Cocktail 
(Roche, Manheim, Germany), 1mM Na3VO4 and 1mM PMSF. After incubation at 4°C for 
20 minutes, samples were centrifuged at 13200 rpm for 30 minutes at 4°C and 
supernatant with proteins was then recovered. Total amount of protein for each sample 
was determined by Bradford protein assay (Bio-rad, Hercules, CA, USA) and a total 
amount of 30-40 µg protein extracts were boiled in NuPAGE LDS sample buffer 
(Invitrogen, Carlsbad, CA, USA) and then subjected to western blot analysis. Of note, for 
siCOPZ1-BCPAP and siCOPZ1-TPC-1 cells assayed for trypan blue exclusion test in chapter 
3, the entire protein extract was subjected to western blot, as the amount of proteins 
recovered was less than 20 µg. 
2.2.2. Western blot analysis 
 Protein samples were separated on 4-12% or 10% NuPAGE Novex Gel (Invitrogen, 
Carlsbad, CA, USA) in MOPS running buffer, under reducing conditions, and resolved 
proteins were then transferred onto nitrocellulose membranes (GE Healthcare Bio-
Sciences, Pittsburgh, PA) using XCell II Blot Module (Invitrogen, Carlsbad, CA, USA). After 
blocking with 2% bovine serum albumin (BSA) (Sigma-Aldrich, St. Louis, MO, USA) in Tris-
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Buffered Saline and Tween 20 (TBS-T [50mM Tris, 150mM NaCl, 0.1% Tween 20]), 
membranes were incubated overnight at 4°C with primary antibodies, listed in Table 2.3. 
Antibody binding was assessed by horseradish peroxidase (HRP)-conjugated secondary 
antibodies (1:5000, GE Healthcare Bio-Sciences, Pittsburgh, PA). Immunoreactive bands 
were visualized by enhanced chemiluminescence (GE Healthcare Bio-Sciences, Pittsburgh, 
PA). Densitometric analysis of the bands was performed by using Quantitative One 
software (Bio-rad, Hercules, CA, USA). 
 
Table 2.3 List of antibodies used for western blot analysis 
Actin A2066 Sigma-Aldrich, St Louis, MO, USA 
Cdc2 p34 17: sc-54 Santa Cruz, CA, USA 
cleaved PARP (Asp214) 9541 
Cell Signaling Technology, Danvers, 
MA, USA 
cleaved-caspase 3 (Asp175) 9664 
Cell Signaling Technology, Danvers, 
MA, USA 
COPE E-20: sc-12104 Santa Cruz, CA, USA 
COPZ1 D-20: sc-13349 Santa Cruz, CA, USA 
Cyclin D1 DCS-6: sc-20044 Santa Cruz, CA, USA 
gamma-H2AX A300-081A-M 
Bethyl Laboratories, Montgomery, 
TX, USA 
GAPDH 6C5: sc-3223 Santa Cruz, CA, USA 
MAP4K5 N-19: sc-6429 Santa Cruz, CA, USA 
MASTL ab86387 Abcam, Cambridge, UK 
NUDT9 V-22: sc-133857 Santa Cruz, CA, USA 
phospho-cdc2 (Tyr15) 9111 
Cell Signaling Technology, Danvers, 
MA, USA 
PLA2G15 H-167: sc-135297 Santa Cruz, CA, USA 
RASD1 4229 
Cell Signaling Technology, Danvers, 
MA, USA 
RGS3 C-20: sc-9304 Santa Cruz, CA, USA 
Vinculin V9131 Sigma-Aldrich, St Louis, MO, USA 
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2.3. Molecular biology 
2.3.1. RNA extraction, RT-PCR and real time PCR 
 RNA extraction was performed using NucleoSpin® RNA II extraction kit (Macherey-
Nagel GmbH, Düren, Germany). 1 µg of RNA was retro-transcribed using SuperscriptIII 
(Invitrogen, Carlsbad, CA, USA) with random examers. PCR products were separated on 
2% agarose gels, stained with ethidium bromide and visualized under UV 
transillumination. Primers used for the detection of RGS3, NUDT9, RASD1 and OXTR are 
listed in Table 2.4. GAPDH was used as housekeeping gene. For Real Time PCR analysis, 20 
ng of retrotranscribed RNA were amplified in PCR reactions carried out in triplicate on an 
ABI PRISM 7900 using TaqMan gene expression assays (Applied Biosystem, Foster City, 
CA). Hs00212698_m1 was used for COPZ2 expression; human HPRT1 (HPRT-
Hs99999909_A1) was used as housekeeping gene for the normalization among samples. 
Data analysis was performed using the SDS (Sequence Detection System) 2.4 software. 
 
Table 2.4 List of primers used for RGS3, NUDT9, RASD1, OXTR and GAPDH detection by RT-PCR 
Gene Primers Sequence 
RGS3 
forward 5′-ATGAGAGGCCTGTGGAGCACT-3′ 
reverse 5′-TCATGTGTCGACTTGCAGGAG-3′ 
NUDT9 
forward 5′-GCAGATCCTCAGATCAGTGAA-3′ 
reverse 5′-TATAATGGGATCTGCAGCGTG-3′ 
RASD1 
forward 5′-CGAGGTCTACCAGCTCGACAT-3′ 
reverse 5′-CACGTCCACGTTCTCCTTGGT-3′ 
OXTR 
forward 5′-ATGTGGAGCGTCTGGGATGC-3' 
reverse 5′-GCTCAGGACAAAGGAGGACG-3′ 
GAPDH 
forward 5′-ACCATCTTCCCAGGAGCGAGAT-3′  
reverse 5′-GGCAGAGATGATGACCCTTT-3′ 
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2.4. Gene expression analysis 
 The thyroid TCGA data set, which contains the molecular data of 496 PTC samples, is 
the largest data collection so far available 
(https://tcgadata.nci.nih.gov/tcga/tcgaCancerDetails.jsp?diseaseType=THCA&diseaseNam
e=Thyroid). Illumina HiSeq Level 3 data were downloaded from TCGA Data Portal and 
RSEM (116) gene normalized expression values of selected genes were derived for 58 PTC 
patients, in tumor and adjacent normal samples, respectively. The statistical significance 
of gene expression difference between PTC and normal groups was assessed using 
Wilcoxon test. 
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3. Results: siRNA library screening hit validation 
 
3.1. Introduction 
 The NOA paradigm (section 1.2.1) states that the uncontrolled growth of tumor cells 
relies on the activity of genes and pathways, not oncogenic themselves but whose activity 
is essential for tumor cell viability and not for normal ones (98). Genes presenting these 
features can be identified by loss-of-function RNAi-based genetic approaches that allow 
the generation of either “synthetic lethal signature”, against specific oncogenes and 
tumor suppressors, or “cancer lethal signature”, if using both normal and tumor cells for 
the screening. Several reports suggested that this approach was likely to shed new light 
on the mechanisms of tumor maintenance: myelomas were found to be addicted to an 
abnormal regulatory network controlled by IRF4 regardless the oncogenic lesion (117), 
while genes synthetic lethal with mutant KRAS were identified in several tumors 
harboring this mutation (118). In order to identify a “cancer lethal signature” in thyroid 
tumors, our laboratory performed a loss of function siRNA library screening on tumor 
(BCPAP, PTC-derived, carrying the BRAFV600E oncogene) and normal immortalized (Nthy-
ori 3-1) thyroid cell lines (119). Thyroid cell lines were transfected with a siRNA library 
containing oligos targeting about 9000 potentially druggable genes and colony forming 
assay (CFA) was performed after 7 (for Nthy-ori 3-1 cells) and 8 (for BCPAP cells) days 
(Figure 3.1A and 3.1B). Non-targeting siRNA (siNT) and a siRNA targeting the proteasomal 
subunit PSMC3 (siPSMC3) were transfected as negative and positive controls, 
respectively. The screening identified genes whose silencing was capable of inhibiting the 
growth of both cell lines, referred to as “lethal hits”, but also genes whose silencing 
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selectively inhibited the growth of tumor cells, referred to as “differential hits” (Figure 
3.1C and 3.1D). 
 
Figure 3.1 siRNA library screening on normal and tumor thyroid cell lines 
A) Schematic representation of siRNA library screening automated procedure; 309 mother 96-
well-plates, containing 25139 siRNA oligos targeting 9031 genes (three deconvoluted siRNAs for 
each gene), have been screened in duplicates in BCPAP and NThy-ori 3-1 cell lines. The effect of 
each siRNAs on the cell viability was analyzed at seven/eight days after transfection by a medium-
high throughput CFA. B) Representative colony plates generated from transfection described in 
A); a indicates siRNA oligos lethal for both cell lines; b indicates siRNA oligos selectively lethal for 
BCPAP cells; siNT and siPSMC3 represent negative and positive controls, respectively. C) Scatter 
plot of Colony Formation (CF) values obtained from the screening, reported as % of growth 
respect to non targeting (siNT) for inter-plate data normalization (dots are the averages of two 
technical replicates performed in both cell lines). D) Scatter plot of normalized CF values showing 
the negative controls (siNT, blue), the lethal hits (green) and the differentially active hits (red); 
insert: distribution of normalized d values after sigma binning). Image adapted from (119). 
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Technical confirmation of differential hits was then performed by manual transfection of 
siRNAs on Nthy-ori 3-1 and BCPAP cells, with the same experimental conditions employed 
in the primary screening. A list of 15 confirmed hit genes, whose inhibition was able to 
inhibit the growth of tumor but not normal cell lines, was then generated (Table 3.1). 
Functional annotation analysis revealed that hit genes identified were involved in several 
biological processes, such as cell cycle and DNA damage checkpoint regulation, vesicular 
transport and intracellular signal transduction. The relevance and reliability of this 
screening in identifying TC cell vulnerabilities was given by two lines of evidence. First, 
among the confirmed hits we found BRAF; this was expected, as BCPAP cells are known to 
be addicted to BRAFV600E oncogene (120). Second, we identified genes whose silencing 
was lethal for both normal and tumor cell viability, and most of them were already 
identified to be essential survival genes by other RNAi screenings (121-123).  
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Table 3.1 List of confirmed hits from the screening 
The 15 hit genes, whose inhibition resulted to inhibit the growth of thyroid tumor cells, are listed. 
Representative Gene Ontology-Biological Process (GO-BP) terms are indicated for each of them, 
by means of DAVID6.7 functional annotation analysis. 
  
Gene Symbol Full Gene Name Accession GO-BP Term
MASTL
microtubule associated serine/threonine 
kinase-like
NM_032844
GO:0006468
protein amino acid phosphorylation
GO:0006793
phosphorus metabolic process
PLA2G15 phospholipase A2, group XV NM_012320
GO:0006575
cellular amino acid derivative metabolic process
GO:0006643
membrane lipid metabolic process
COPE coatomer protein complex, subunit epsilon NM_007263
GO:0006890
retrograde vesicle-mediated transport, Golgi to ER transport
GO:0051640
organelle localization
RGS3 regulator of G-protein signaling 3 NM_017790
GO:0000165
MAPKKK cascade
GO:0008277
regulation of G-protein coupled receptor protein
signaling pathway
CCND1 Cyclin D1 NM_053056
GO:0000075
cell cycle checkpoint
GO:0000077
DNA damage checkpoint
RASD1 RAS, dexamethasone-induced 1 NM_016084
GO:0007264
small GTPase mediated signal transduction
GO:0016481
negative regulation of transcription
NUDT9
nudix (nucleoside diphosphate linked 
moiety X)-type motif 9
NM_024047
GO:0006163
purine nucleotide metabolic process
GO:0006811
ion transport
OXTR oxytocin receptor NM_000916
GO:0000165
MAPKKK cascade
GO:0003012
muscle system process
BRAF
v-raf murine sarcoma viral oncogene 
homolog B1
NM_004333
GO:0000165~MAPKKK cascade
GO:0010941
regulation of cell death
COPZ1 coatomer protein complex, subunit zeta 1 NM_016057
GO:0006886
intracellular protein transport
GO:0006890
retrograde vesicle-mediated transport, Golgi to ER
MAP4K5
mitogen-activated protein kinase kinase 
kinase kinase 5
NM_006575
GO:0000165
MAPKKK cascade
GO:0001932
regulation of protein amino acid phosphorylation
EPHB4 EPH receptor B4 NM_004444
GO:0007169
transmembrane receptor protein tyrosine kinase signaling 
pathway
GO:0045765
regulation of angiogenesis
DNM3 dynamin 3 NM_015569
GO:0006897
endocytosis
GO:0010324
membrane invagination
REM2 RAS (RAD and GEM)-like GTP binding 2 NM_173527
GO:0006355
regulation of transcription, DNA-dependent
GO:0007264
small GTPase mediated signal transduction
SRPK1 SFRS protein kinase 1 NM_003137
GO:0006396
RNA processing
GO:0007243
protein kinase cascade
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3.2. Aims of the chapter 
 Functional siRNA library screening identified a number of genes whose silencing 
interfered selectively with tumor cell viability and, among those, 15 hit genes were 
confirmed by technical validation. The aims of this chapter are: to identify the molecular 
profile of selected hits in thyroid cancer; to validate the growth inhibitory effect of these 
genes by using different siRNA sequences in the two cell models used for the screening; 
to correlate the growth inhibitory effect with the extent of target gene knockdown; to 
extend the analysis of the growth inhibitory effect of their silencing on a large panel of 
thyroid tumor cell lines, representative of the different histotypes. 
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3.3. Results 
3.3.1. Analysis of expression levels of hit genes in normal and PTC samples 
 In 2014, the TCGA consortium published an important study that improved our 
understanding of the genomic landscape of PTC (33) (section 1.1.2.1). The study reported 
analysis of the largest PTC cohort ever analyzed to date, with 58 out of 496 PTC 
specimens paired with the corresponding normal counterpart. We interrogated the 
thyroid TCGA dataset with the aim of assessing the expression level and the mutational 
status of the 15 genes identified by our functional screening. Expression analysis was 
investigated on both the whole dataset and on the 58 matched tumor and normal 
samples, and the results obtained were identical. By comparing normal and PTC samples, 
we classified hit genes in three groups, according to their expression levels (Figure 3.2): i) 
genes with significant high overexpression in PTC vs normal thyroid, which are CCND1, 
RGS3, OXTR, RASD1, DNM3 (panel A); ii) genes with equal or slightly different expression 
in PTC compared to normal thyroid, that are COPE, COPZ1, PLA2G15, SRPK1, REM2, 
EPHB4, BRAF (panel B); iii) genes that are significantly downregulated in PTC compared to 
normal thyroid, which are MASTL, MAP4K5, NUDT9 (panel C). 
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Figure 3.2 Hit gene expression levels in PTC vs normal thyroid specimens 
Box plot distribution of RNAseq normalized expression values of the 15 hit genes from the thyroid 
TCGA dataset analysis in 58 matched normal (N) and PTC samples. A) Genes overexpressed in PTC 
vs N samples. B) Genes equally expressed in PTC and N samples. C) Genes downregulated in PTC 
vs N sample. Statistical significance of differences among the two groups of samples was assessed 
by Wilcoxon test. 
 
For mutational status, we detected BRAF mutations with high frequency, as present in 
248 out of 496 samples. With the exception of a silent mutation for COPZ1 in one sample, 
no mutations affecting the other genes were detected in the whole dataset. 
We also retrieved data from the Cancer Cell Line Encyclopedia (CCLE, 
http://www.broadinstitute.org/ccle/home), which provides public access to genomic 
data, analysis and visualization for about 1000 cell lines, among which the BCPAP cell line. 
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We found that all the hit genes are expressed by BCPAP cells, at variable level, ranging 
from “low expression” to “very high expression” (Table 3.2). CCND1, MASTL, MAP4K5, 
SRPK1 and EPHB4 were found to be at the wild type status, while no data for the 
mutational status of the other hit genes were available. 
 
Table 3.2 Expression level of hit genes in BCPAP cells from CCLE 
 
 
3.3.2. Analysis of hit gene expression levels in TC cell lines 
 In order to assess whether these putative “non-oncogenes” are expressed by TC cell 
lines, we first searched for and purchased commercially available antibodies for western 
blot analysis for the first 11 hit genes except for BRAF. Of note, for some of these genes 
(PLA2G15, RGS3, RASD1, NUDT9, OXTR, COPZ1), no published working antibodies were 
available at the time of the analysis. We first tested the optimal working conditions for 
the antibodies purchased by western blot analysis of control cell lines indicated by the 
antibody datasheets. As reported in Figure 3.3A-F, we were successful in detecting the 
Gene Value Expression level 
MASTL 5,2564 low 
PLA2G15 6,7379 moderate 
COPE 10,841 very high 
RGS3 6,5896 moderate 
CCND1 9,7431 high 
RASD1 6,843 moderate 
NUDT9 8,7534 high 
OXTR 4,5271 low 
BRAF 6,8071 moderate 
COPZ1 10,779 very high 
MAP4K5 8,6024 high 
EPHB4 5,9189 low 
DNM3 4,2194 low 
REM2 6,0285 moderate 
SRPK1 8,5579 high 
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expression of MASTL, PLA2G15, COPE, MAP4K5, Cyclin D1 and COPZ1. For RGS3, NUDT9 
and RASD1 (Figure 3.3G-I), the antibodies tested did not allow the detection of the 
corresponding protein.  
 
Figure 3.3 Analysis of working efficiency of antibodies for hit gene detection 
Western blot analysis of control cell lines for the setup of working conditions of antibodies for: A) 
MASTL; B) PLA2G15; C) COPE; D) MAP4K5; E) Cyclin D1; F) COPZ1; G) RGS3; H) NUDT9; I) RASD1. 
 
We investigated the expression of the hit genes in the normal (Nthy-ori 3-1) and tumor 
(BCPAP) cell lines used for the screening and in a panel of thyroid tumor cell lines, 
representative of the different histotypes and/or carrying different oncogenes: PTC-
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derived (TPC-1, carrying the RET/PTC1 oncogene), FTC-derived (WRO82-1), ATC-derived 
(8505C and HTC/C3, which carry BRAFV600E oncogene, KAT-18). MASTL, Cyclin D1, 
COPZ1, MAP4K5, PLA2G15 and COPE expression was investigated by western blot (Figure 
3.4A). In comparison with Nthy-ori 3-1, MASTL was found to be less expressed in thyroid 
tumor cell lines; Cyclin D1 expression, except for KAT-18, was higher in the tumor cell 
lines compared to the normal one; also COPZ1 expression was higher in TC cell lines, 
compared to Nthy-ori 3-1; PLA2G15 expression was slightly reduced in all the tumor cell 
lines, except for BCPAP, and strongly reduced in KAT-18; MAP4K5 was found to be 
expressed at variable levels, with a slight increase in BCPAP, WRO82-1 and 8505C, and a 
decrease in the remaining; COPE expression in tumor cells was higher compared to 
normal Nthy-ori 3-1, with the exception of KAT-18. The expression of RGS3, NUDT9, 
RASD1 and OXTR was investigated by RT-PCR. All the genes are expressed in the cell lines 
tested with no appreciable differences (Figure 3.4B).  
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Figure 3.4 Hit gene expression levels in thyroid tumor cell lines 
A) MASTL, Cyclin D1, COPZ1, MAP4K5, PLA2G15 and COPE expression level analyzed by western 
blot in a panel of normal (N) and tumor thyroid cell lines representative of the different histotypes 
(PTC, FTC, ATC); values represent band intensity assessed by densitometry analysis and reported 
as ratio to Nthy-ori 3-1; GAPDH and Actin were used as loading controls. B) RGS3, RASD1, NUDT9 
and OXTR mRNA expression tested by RT-PCR on cell lines tested for A); GAPDH represents the 
housekeeping control. 
 
3.3.3. Analysis of siRNA silencing efficiency for hit validation 
 Among the list of candidate “non-oncogenes” described above, we selected for 
validation studies only those genes for which western blot analysis was feasible. We 
purchased commercially available siRNAs, with oligonucleotide sequences different from 
those of the library, for MASTL, PLA2G15, COPZ1, CCND1, COPE and MAP4K5. Four 
different oligos for MASTL and PLA2G15, and a smart pool of oligos for CCND1, COPZ1, 
MAP4K5 and COPE, were used. Nthy-ori 3-1 cells were transiently transfected with the 
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specific siRNAs and with non-targeting control (siNT) oligos and then subjected to 
western blot analysis, in order to evaluate silencing efficiency (Figure 3.5). For MASTL, we 
obtained the highest silencing efficiency with oligos #1 and #4 72 hours after transfection; 
oligos targeting Cyclin D1, COPZ1 and MAP4K5 completely abrogated protein expression 
at 72 hours. For PLA2G15 and COPE, siRNA oligos were inefficient or slightly efficient in 
abrogating protein expression, respectively. Notably, oligos with good silencing efficiency 
gave no macroscopic effects on the growth and survival of Nthy-ori 3-1 cells, in keeping 
with what obtained from siRNA library screening. 
 
 
Figure 3.5 Evaluation of siRNA silencing efficiency for validation studies 
Western blot analysis of MASTL, COPZ1, PLA2G15, MAP4K5, Cyclin D1 and COPE expression in 
Nthy-ori 3-1 cells, transiently transfected with the indicated siRNAs and collected at the indicated 
timepoints. Actin and vinculin represent loading controls. 
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3.3.4. Effects of MASTL, COPZ1 and Cyclin D1 depletion on BCPAP cell growth 
 Based on the silencing efficiency of siRNAs previously tested and on background 
literature data about the hit genes, we selected MASTL, COPZ1 and Cyclin D1 for the 
validation studies. We transfected siRNAs in the two cell lines used for the screening, 
Nthy-ori 3-1 and BCPAP. We used the same protocol as for the screening: cells were 
transfected in 96-well plates with the oligos described in section 3.3.3 and siNT and 
siPSMC3 controls, and cell growth was evaluated 10 days later by CellTiter-Glo® assay. 
The luminescence signal, indicative of viable cells, is reported in the scatter plot in Figure 
3.6A, normalized with respect to siNT. We observed that siMASTL #1, siMASTL #4, 
siCOPZ1 and siCCND1 reduced BCPAP cell growth by 60%, 93%, 94% and 86%, 
respectively; this efficiency is comparable to that of positive control siPSMC3, that is 93% 
reduction. We did not observe any significant reduction of the growth of BCPAP cells 
transfected with siMASTL #2 and siMASTL #3; this result is in keeping with the low siRNA 
silencing efficiency we previously observed in Nthy-ori 3-1 (Figure 3.5). Of note, no 
significant reduction of Nthy-ori 3-1 cell growth was observed with MASTL-, COPZ1- and 
CCND1-targeting oligos, while the positive control siPSMC3 was able to reduce cell growth 
as for BCPAP. We further confirmed the effect of MASTL, COPZ1 and CCND1 silencing with 
a different experimental approach. BCPAP cells were transfected in 6-well plates with the 
oligos that previously resulted to be efficient in gene silencing: siMASTL #1 and #4, 
siCOPZ1 and siCCND1. We also used an additional in-house synthesized siRNA targeting 
MASTL, that was found to be efficient in MASTL silencing when transfected in Nthy-ori 3-1 
(Figure 3.6B). At 6 days after transfection, we noticed an evident effect of MASTL, COPZ1 
and CCND1 silencing by microscopy observation: BCPAP cells were less confluent 
compared to negative control (siNT), with a large number of floating cells (Figure 3.6C). By 
trypan blue exclusion test, we found a reduction of cell growth, in comparison with 
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control (siNT), of: 69.5%, 59.7% and 71% for siMASTL #1, #4 and #5, respectively; by 
99.6% for siCOPZ1; by 91.5% for siCCND1 (Figure 3.6D). The same cells were tested by 
western blot at the end of the experiment and complete abrogation of MASTL and Cyclin 
D1 expression was observed; an insufficient amount of protein extract was recovered 
from siCOPZ1-transfected cells, due to the massive lethal effect on this cell line, so 
western blot analysis was not informative (Figure 3.6E). 
On the whole, our results confirmed the growth inhibitory effect of MASTL, COPZ1 and 
Cyclin D1 knockdown on BCPAP cells, thus validating them as vulnerability genes of 
BCPAP. 
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Figure 3.6 Effects of MASTL, COPZ1 and Cyclin D1 depletion on BCPAP cell line 
A) Scatter plot representing the percentage of cell growth (luminescence values of CellTiter-Glo® 
assay), normalized to control (siNT), of Nthy-ori 3-1 and BCPAP cells, 10 days after transfection 
with the indicated siRNAs. One representative out of three experiments is shown. B) Western blot 
analysis of MASTL expression in Nthy-ori 3-1 cells, transiently transfected with the control (siNT) 
and the new MASTL (siMASTL #5) siRNAs, and collected at the indicated time points. Actin 
represents loading control. C) Representative pictures of BCPAP cells 6 days after transfection 
with the indicated siRNAs. D) BCPAP cell growth evaluated by trypan blue exclusion test 6 days 
after transfection; cell count of viable cells was normalized to that of control (100% of siNT); data 
represent the mean +/- sd of two independent experiments; asterisks indicate statistical 
significant differences by unpaired Student’s t-test (***p<0.001); E) Western blot analysis of 
MASTL, Cyclin D1 and COPZ1 expression in BCPAP cells, assayed in panel D; actin was used as 
loading control.  
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3.3.5. Effects of MASTL, COPZ1 and Cyclin D1 depletion on the growth of several 
TC cell lines 
 According to NOA paradigm, tumor cells may share common vulnerabilities based on 
the stress support pathways needed for sustaining the tumorigenic phenotype, regardless 
the main oncogenic drivers. We decided to assess whether the survival genes previously 
confirmed in BCPAP may be involved in such common pathways and therefore represent 
common vulnerabilities for thyroid tumors. To this aim, we evaluated the functional 
effects of MASTL, COPZ1 and Cyclin D1 silencing on the panel of TC cell lines in which we 
have previously determined their expression levels (see Figure 3.4). TC cell lines were 
transfected in 96-well plates with control (siNT and siPSMC3) siRNAs and siRNAs targeting 
MASTL, COPZ1 and CCND1, and cell viability was evaluated by CellTiter-Glo® assay 10 
days later. We found that silencing of the three genes induced variable extents, ranging 
from 15% to 95%, of cell growth inhibition (Figure 3.7A) in the majority of cell lines tested, 
compared to control. Only for CCND1 in 8505C and KAT-18, and for MASTL in KAT-18 cell 
lines, we did not observe any effect of gene silencing on cell viability. We additionally 
assessed the effects on cell growth by performing trypan blue exclusion test from 4 to 7 
days after cell transfection in 6-well plates, as already performed on BCPAP (detailed 
previously in 3.3.4). A reduction in the growth of cells upon transfection of siRNAs 
targeting MASTL, COPZ1 and CCND1, compared to control (siNT) transfected cells, was 
appreciable by microscopy observation (Figure 3.7B). Cell count revealed that, with the 
exception of KAT-18 cell lines, silencing of MASTL, COPZ1 and CCND1 significantly reduced 
the growth of all cell lines tested (Figure 3.7C). Compared to control, inhibition of cell 
viability was observed by: 30-63% for siMASTL #1, 35-75% for siMASTL #4, 40-75% for 
siMASTL #5, 75-99% for siCOPZ1 and 70-94% for siCCND1. In KAT-18, we found a decrease 
of cell growth by 31% for siMASTL #1, 53% for siCOPZ1 and 43% for CCND1; siMASTL #4 
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and #5 had no significant effect on cell viability; PSMC3 silencing in KAT-18 had a growth 
inhibitory effect of 53%. We performed western blot analysis on the same samples at the 
end point of the experiment and observed a high efficiency of gene silencing in all of 
them (Figure 3.7D). As for BCPAP cells, also in TPC-1 cells we were not able to recover 
enough protein extract to assess COPZ1 knockdown in siCOPZ1-transfected samples, due 
to the massive lethal effect of gene silencing on this cell line. Of note, by this alternative 
approach we were able to notice a growth inhibitory effect of CCND1 silencing in 8505C 
and KAT-18, and of MASTL silencing in KAT-18 cells, which was not previously observed; 
this could be related to the variability of silencing efficiency and/or experimental 
conditions. 
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Figure 3.7 Effects of MASTL, COPZ1 and Cyclin D1 depletion on a panel of TC cell lines 
A) Scatter plot representing the percentage of cell growth (luminescence values of CellTiter-Glo® 
assay), normalized to control (siNT), of the indicated TC cell lines 10 days after transfection with 
the indicated siRNAs. One representative out of three experiments is shown. B) Representative 
images of TPC-1, WRO82-1, 8505C, HTC/C3 and KAT-18 cells, transfected with the indicated 
siRNAs, before the trypan blue exclusion test. D) Cell proliferation assayed by trypan blue 
exclusion test 4 days (for TPC-1, 8505C and HTC/C3 cells), 5 days (for KAT-18 cells), 6 days (for 
BCPAP cells) and 7 days (for WRO82-1 cells) after siRNA transfection; cell count was normalized to 
that of siNT (100% growth) and expressed as mean +/- sd of two independent experiments; 
statistically significant differences are indicated by asterisks (ns: not significant; *p<0.05; 
**p<0.01;, ***p<0.001; according to unpaired Student’s t-test). E) Western blot analysis of 
MASTL, COPZ1 and Cyclin D1 expression in TC cells assayed in panel D; actin was used as loading 
control. 
 
3.3.6. Characterization of TC cell dependency on CCND1, MASTL and COPZ1 
 In order to explore the potential of MASTL, Cyclin D1 and COPZ1 targeting in TC we 
performed additional experiments. 
 Given that Cyclin D1 acts as activator of its dependent kinases CDK4 and CDK6, we 
tested whether TC cell lines may be susceptible to palbociclib (PD-0332991), a specific 
inhibitor of CDK4 and 6 (115). The panel of TC cell lines previously tested was treated with 
palbociclib for 72 hours. The effects of palbociclib administration were appreciable by 
microscopy observation: after 72 hours, all TC cells treated with palbociclib were less 
confluent compared to the control (CTRL) (Figure 3.8A). The treatment with increasing 
doses of palbociclib showed a consistent growth inhibitory effect on all TC cell lines tested 
(Figure 3.8B).  The IC50 values were variable, ranging from <0.003 µM for BCPAP cells to 
0.20 µM for HTC/C3 cells (Figure 3.8C). 
 Since it was reported that MASTL depletion induced multiple mitotic defects (124), we 
tested whether MASTL-depleted 8505C cells could present the same defects. 48 hours 
after MASTL silencing in 8505C, immunofluorescence analysis for β-tubulin, 
phosphorylated histone H3 (Ser10) and DAPI revealed the presence of aberrant mitotic 
figures (Figure 3.8D): while no anomalies were observed in control siNT (i), MASTL 
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knockdown was associated with formation of multinuclear cells (ii), lagging chromosomes 
not aligned to metaphase plate (iii) and chromatin bridges connecting daughter cells (iv). 
 COPZ1 vulnerability of tumor cells was found to be associated with the 
downregulation of its paralogous COPZ2 (125). We performed real time PCR in normal 
(Nthy-ori 3-1) and TC cell lines to assess COPZ2 expression level (Figure 3.8E): we found 
that all tumor cells, except for WRO82-1, showed a downregulation of COPZ2 mRNA, 
compared to normal thyrocytes. 
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Figure 3.8 Characterization of Cyclin D1, MASTL and COPZ1 vulnerabilities of TC cells 
A) Representative ArrayScan fields of TC cell lines untreated (CTRL) or treated with 2.2 µM 
palbociclib for 72 hours and stained with Hoechst (scalebar: 50µm). B) Dose-response curve of TC 
cell growth treated with palbociclib for 72 hours; nuclei were stained with Hoechst and counted in 
each well by an ArrayScan high-content screening reader; cell count values derived from nuclear 
staining (reported as growth parameter normalized with respect to untreated controls) are 
presented as mean +/- sd of two replicates. C) IC50 values (µM) obtained using a sigmoid function 
of nonlinear interpolation of experimental points; for KAT-18, IC50 value was derived from 
graphical analysis. D) Immunofluorescence analysis for β-tubulin (microtubules, green), 
phosphorylated histone H3 Ser10 (red) and DAPI (nuclei, blue) on 8505C cells 48 hours after 
transfection with control (siNT) and MASTL (siMASTL) siRNAs; arrows indicate normal mitosis (i), 
multinuclear cell (ii), lagging chromosomes (iii) and DNA bridge (iv). E) Real time PCR analysis of 
COPZ2 expression; results are presented as log10-transformed relative quantity (RQ) of COPZ2 
mRNA normalized for HPRT housekeeping expression and presented as mean +/- sd of three 
independent experiments. 
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3.4. Discussion 
 Our laboratory performed a loss of function siRNA-based screening on normal and 
tumor thyroid cell lines, with the aim of identifying potential “non-oncogenes” in thyroid 
tumor cells. A list of 15 genes, whose silencing was detrimental for tumor but not normal 
cell viability, was generated. We analyzed their molecular profiles in normal and PTC 
samples by TCGA dataset interrogation and found, with the exception of BRAF, no 
mutations of hit genes in PTC samples, while their expression level was equal or 
differential (both upregulation and downregulation) between normal and tumor 
specimens. We documented their expression in a panel of thyroid tumor cell lines and 
selected MASTL, COPZ1 and CCND1 for validation studies. We confirmed their inhibitory 
effect on BCPAP cell growth, by using siRNA oligos different from those of the library, and 
verified the abrogation of their expression at protein level in BCPAP cells. Importantly, we 
observed that their depletion resulted to be detrimental for the growth and survival of 
several thyroid tumor cell lines, representative of the different histotypes and carrying 
different oncogenic lesions. 
 Molecular studies performed in the last years extensively characterized the genomic 
landscape of PTCs and ATCs. These findings were translated into the use of small-
molecule inhibitors, specifically TKIs, in the clinics for the treatment of advanced TC 
patients who do not respond to conventional therapy (126); even though TKIs showed 
promising therapeutic strategies, their efficacy gave contrasting evidence in clinical trials, 
since mechanisms of resistance to TKIs often develop and severe side verse effects 
present (127). This evidence underlines the need for alternative approaches aimed to 
identify novel targets for TC treatment. Large scale RNAi-based functional screenings are 
a tool nowadays widely used to identify tumor cell vulnerabilities for potential 
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therapeutic goals (106,107,110). Indeed, these high-throughput screening approaches 
permit to discover potential target genes to which cancer cells are addicted and that are 
not necessarily oncogenic themselves. In this chapter, we presented the results of a high-
throughput siRNA phenotypic screening on normal and tumor thyroid cells, aimed to 
identify thyroid tumor cell vulnerabilities (119). For the first time, we identified a panel of 
genes whose silencing preferentially inhibited the growth of the tumor cell line as 
compared to that of normal thyrocytes. TCGA dataset analysis revealed no mutations of 
hit genes (besides BRAF); this suggests that alterations of their function in thyroid tumor 
cell biology may be excluded, and that they represent “non-oncogenes” in TC. We verified 
that these genes were actually expressed in the cell models used for the screening and 
also extended the analysis to a panel of thyroid tumor cell lines; this first approach 
allowed us to select some of them for validation studies, according to the availability of 
reagents such as commercial antibodies efficiently working. For hit genes whose 
expression was not ascertainable by western blot analysis, due to antibodies not 
efficiently working, we assessed their mRNA expression in TC cell lines by RT-PCR; since 
western blot was not feasible for them, they were excluded from validation studies. To 
validate the remaining hits, we first tested siRNA oligos different from those of the library 
and found that some of them were actually not efficient, thus making further 
investigation not feasible. We selected MASTL, COPZ1 and CCND1 for the confirmation 
studies in BCPAP. 
 Cyclin D1 is a cell cycle regulator that forms a complex with cyclin-dependent kinases 
(CDK) 4 and 6 to activate them and promote the transition from G1 to S phase of the cell 
cycle (128). CCND1 is frequently found deregulated in tumors: gene mutations and 
amplifications, as well as protein overexpression, are events frequently reported. For this 
reason, Cyclin D1 has been proposed as therapeutic target for cancer treatment. Its 
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targeting may result difficult since it lacks enzymatic activity; a more feasible approach 
would be the inhibition of its associated kinases CDK4 and CDK6. Indeed, several CDK4/6 
inhibitors are currently under clinical evaluation in different tumors (129). Cyclin D1 was 
frequently found overexpressed at both protein (130) and mRNA (131,132) levels in TC, 
but no functional data about its role in thyroid tumorigenesis were reported. We 
demonstrated that Cyclin D1 inhibition impaired the growth of all TC cell lines tested. 
Interestingly, the expression level of Cyclin D1 was heterogeneous among them; this 
finding suggests that TC cell dependency on CCND1 may not require the aberrant 
expression of the protein. Moreover, we observed that TC cell lines are sensitive to the 
CDK4/6 inhibitor palbociclib, that is already used for the treatment of ER+/HER2- breast 
cancer in combination with letrozole (133). Our results prompt the evidence that Cyclin 
D1 represents a TC cell vulnerability and provide a rationale for further preclinical and 
clinical studies aimed to develop a therapeutic strategy to inhibit it, directly or indirectly 
by using CDK4/6 inhibitors, for TC treatment. 
 MASTL (microtubule associated serine/threonine kinase-like) is a regulator of mitosis 
as its activity is required for the inhibition of PP2A/B55δ, the main protein phosphatase 
complex responsible for dephosphorylation of CDK1 substrates. MASTL activity was 
shown to be necessary to prevent defects in chromosome segregation and avoid 
prometaphase arrest and mitotic failure (134). Little was known about the role of MASTL 
in cancer. In lung cancer, it was reported that MASTL inhibition was able to sensitize 
tumor cells to radiations and to promote cytokinesis defects (135). Another study (136) 
reported that MASTL has a role in head and neck tumor recurrence and resistance to 
chemotherapy with cisplatin, thus proposing it as possible therapeutic target. They also 
found MASTL to be overexpressed in prostate, breast and recurrent head and neck 
tumors, compared to normal counterpart. In this chapter, we identified MASTL as a 
74 
 
vulnerability gene for thyroid tumors. We observed that its inhibition interfered with the 
growth of TC cell lines, with variable extents. We also found that MASTL-depleted 8505C 
exhibited errors in the mitotic process. Moreover, we found no mutations in PTC samples 
and observed that MASTL is not associated with overexpression in PTC compared to 
normal samples. Together, these findings highlighted that further investigations about 
the role of MASTL in TC cell biology were needed, in order to assess whether it could 
represent a therapeutic target for TC. These studies are presented in the next chapter of 
the thesis together with a more deepened discussion. 
 COPZ1 (coatomer protein complex ζ1) is the zeta-subunit of the secretory coatomer 
protein complex I (COPI), which is involved in vesicular trafficking from Golgi apparatus to 
endoplasmic reticulum, endosome maturation, autophagy (137,138) and lipid 
homeostasis (139). Shtutman and colleagues (125) proposed COPZ1 as therapeutic target 
as they observed that tumor cells become dependent on COPZ1 because of 
downregulation of COPZ2 and COPZ1 silencing dramatically induced apoptotic cell death. 
In this chapter, we showed that COPZ1 is a TC vulnerability gene as its silencing led to 
growth inhibition of all TC cell lines tested. We also found COPZ2 downregulation in the 
majority of TC cell lines, apart from WRO82-1: even if COPZ2 mRNA level was higher than 
control, this cell line resulted to be sensitive to COPZ1 depletion; this finding suggests that 
other mechanisms may be involved in determining COPZ1 sensitivity in TC cells. Further 
experiments were needed to better understand the mechanisms by which COPZ1 affects 
TC cell viability, and are presented in an independent chapter of the thesis. 
 In conclusion, in this chapter we described the identification of a “cancer lethal 
signature” for thyroid carcinoma, as result of a siRNA-based functional screening on 
normal and tumor thyroid cell lines. Among the novel potential therapeutic targets that 
emerged, we functionally characterized Cyclin D1, MASTL and COPZ1 and demonstrated 
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that their depletion was deleterious for TC cell growth irrespective of tumor histotype 
and/or genetic lesion. These findings indicate that they represent common examples of 
“non-oncogene addiction” in thyroid cancer, highlighting them as attractive targets for 
new therapeutic approaches for thyroid tumors which would spare normal cells, thus 
having limited side effects. 
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4. Results: MASTL studies 
 
4.1. Introduction 
 Microtubule associated serine/threonine kinase-like (MASTL) is the human orthologue 
of greatwall (GWL), a gene first discovered in Drosophila in 2004, which encodes a kinase 
involved in the regulation of mitosis (140). The name “greatwall” came from the evidence 
that mutations in this gene caused defects in chromosome condensation and delay in 
mitotic progression, thus suggesting that it had a role in protecting chromosome 
structure. A following study in Xenopus egg extracts revealed that GWL was involved in 
the complex regulatory feedback loop that drives the phosphorylation of proteins in 
mitosis progression (141). Central to this complex regulatory loop is cell division cycle 
protein 2 homolog (cdc2), also known as cyclin-dependent kinase 1 (CDK1): it encodes a 
serine/threonine kinase that has the essential role of promoting G2/M transition and 
mitosis entry, once bound to Cyclin B1, thus forming the maturation promoting factor 
(MPF) complex (142). CDK1 activation is tightly controlled during cell cycle, in order to 
ensure correct progression through mitosis: during G1, S and G2 phases, MYT1 and WEE1 
kinases phosphorylate CDK1 on Thr14 and Tyr15 inhibitory residues, in order to maintain 
it in an inactive state; at the onset of mitosis, CDC25 phosphatase removes these 
inhibitory modifications, allowing the activation of CDK1 and, consecutively, of MPF 
complex (Figure 4.1). Active CDK1 is able to further activate CDC25, as well as to 
inactivate its inhibitor WEE1. Furthermore, it also phosphorylates polo-like kinase 1 
(PLK1), which contributes to a further activation of CDC25. Yu and colleagues showed 
that, during mitosis, GWL was phosphorylated and activated by CDK1, and GWL depletion 
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led to accumulation of inhibitory phosphorylations on CDK1 that prevented mitosis 
progression. It was later demonstrated that GWL contributed to mitosis progression by 
inhibiting the protein phosphatase 2A (PP2A) associated with the B55δ regulatory subunit 
(PP2A/B55δ), which is the main phosphatase complex responsible for the 
dephosphorylation of mitotic substrates of the MPF complex (143). This inhibition was 
shown to be mediated by two proteins identified as GWL substrates, namely cyclic 
adenosine monophosphate–regulated phosphoprotein 19 (ARPP19) and α-Endosulfine 
(ENSA); once activated by GWL, they associated with PP2A/B55δ and inhibited it, thus 
promoting mitotic entry (144,145). Until recently, no specific regulators of GWL were 
identified; only the work from Ma and colleagues (146) suggested that protein 
phosphatase 1 (PP1) could be responsible for GWL inactivation. 
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Figure 4.1 Regulatory network model of GWL during mitosis entry and exit 
At G2/M transition, CDK1/Cyclin B1 complex and GWL are activated. CDK1/CycB1 phosphorylates 
mitotic substrates and GWL, which contributes to maintenance of mitotic substrate activation by 
inhibiting PP2A/B55δ complex through ARPP19/ENSA activation. PP2A/B55δ inhibition fully 
activates mitotic substrates and promotes entry in mitosis. At mitotic exit, Cyclin B1 is 
ubiquitinated by APC-CDC20 ubiquitin ligase and degraded; GWL is therefore inactivated and 
PP2A/B55δ consequent activation removes activating phosphorylations from mitotic substrates. 
Image from (147). 
 
 The functional orthologue of GWL in humans is MASTL, a gene that shares 50.2% and 
65.7% of sequence homology to Drosophila and Xenopus GWL, respectively, and whose 
function is well-conserved (148). MASTL is located on chromosome 10 and encodes a 
protein kinase composed of 879 amino acids and with a molecular mass of about 97 kDa 
(Figure 4.2). To date, no crystal structures of full-length MASTL are available. 
Bioinformatic analysis revealed that MASTL has an unusual kinase structure: it contains 
the DFG and APE motifs, which are commonly shared by protein kinases and delimitate 
the activation segment (149) but, in between these two motifs, there is a large non-
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conserved middle region (NCMR) of about 500 amino acids (150). The structure and the 
function of NCMR are still ambiguous, but it was demonstrated that this domain 
prevented MASTL to be expressed in a soluble form in Escherichia coli. 
 
 
Figure 4.2 MASTL protein structure 
Schematic representation of MASTL kinase structure: between the conserved DFG and APE 
motifs, it contains a ~500 amino acid region (non-conserved middle region, NCMR) whose 
function is still not clear; amino acid boundaries of the N- and C-terminals are indicated, as well as 
the Ser875 phosphorylation site known to be essential for MASTL function. Image from (150). 
 
MASTL has a nuclear localization pattern throughout interphase but, during mitosis, it is 
exported to the cytoplasm before nuclear envelop breakdown (151). As for Drosophila 
and Xenopus GWL, MASTL has the crucial role of inhibiting the phosphatase activity of 
PP2A/B55δ complex during mitosis, in order to sustain the phosphorylation of CDK1 
substrates (124); moreover, its inhibition caused multiple mitotic defects, such as lagging 
chromosomes, DNA bridges and cytokinesis failure. Also in human cells, MASTL was 
shown to be inactivated by PP1 phosphatase activity (152). 
 In addition to the regulation of mitotic progression, GWL was shown to function also 
as regulator of the DNA damage response (DDR); its depletion was associated with the 
delay of both checkpoint recovery and progression into cell cycle upon DNA damage 
induction (153). Human MASTL maintained this function and was also shown to be an 
essential player for the maintenance of genome integrity: its downregulation delayed the 
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entry in mitosis of damaged cells, caused a premature activation of the APC/C complex 
and induced genomic instability associated with genome endoreduplication (154). 
 In the recent years, evidence of both MASTL involvement in cancer progression and its 
targeting as promising approach for cancer therapy were provided. MASTL inhibition 
sensitized recurrent head and neck tumor cells to cisplatin treament (136) and lung 
cancer cells to radiation therapy (135). In breast cancer, MASTL upregulation was 
associated with a more advanced clinical stage (136) and also proposed as indicator of 
metastatic and disease relapse risk within the ER+ breast tumor subtype (155). Moreover, 
in both breast and colon cancer cell lines, it was demonstrated that upregulation of 
MASTL promoted tumor cell growth through the degradation of the phosphatase PHLPP, 
which usually inhibits AKT activity, thus leading to AKT hyperactivation (156). Based on 
these recent findings that characterized MASTL as a highly valuable drug target for cancer 
treatment, a preliminary small-molecule MASTL inhibitor was developed (150); of note, it 
was created starting from the structure of the GWL minimal kinase domain, since the 
crystallization of full-length human GWL was not feasible.  
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4.2. Aims of the chapter 
 We have previously demonstrated, as described in chapter 3, that MASTL is a 
vulnerability gene for thyroid tumor cells, since its inhibition interfered with the growth of 
tumor but not of normal thyroid cells. In this chapter we aimed to dissect the molecular 
mechanisms that are at the basis of TC cell dependency on MASTL function. In particular, 
we depleted MASTL in TC cells by using RNAi, and investigated the effects of its silencing 
on cell proliferation, cell division, cell viability and accumulation of DNA damage. 
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4.3. Results 
4.3.1. Effects of MASTL depletion on TC cell growth 
 We have previously observed that MASTL depletion led to inhibition of the growth of 
a panel of TC cell lines (section 3.3.5). For the studies hereafter presented, we selected 
two ATC-derived cell lines, namely HTC/C3 and 8505C; the results obtained would ideally 
contribute to the design of alternative strategies to ATC treatment, as they currently lack 
effective therapies (already described in section 1.1.1.4). HTC/C3 and 8505C cells were 
transfected with control (siNT) and three MASTL (siMASTL #1, #4 and #5) siRNAs and 
plated 24 hours later for both silencing efficiency and proliferation analyses (Figure 4.3A). 
By western blot we confirmed the effective silencing of MASTL in both HTC/C3 (Figure 
4.3B) and 8505C (Figure 4.3C) cells. Cell proliferation was investigated by CellTiter-Glo 
assay and we found that MASTL siRNAs reduced the growth of both HTC/C3 (Figure 4.3D) 
and 8505C cells (Figure 4.3E), although with different extents. The effect of MASTL 
depletion on cell growth was also tested by colony forming assay as alternative approach: 
HTC/C3 and 8505C cells were transfected with control and MASTL siRNAs and stained 7 
days later with crystal violet (Figure 4.3F-G); even if with different extents, cell growth 
inhibition was observed for all three MASTL siRNAs used, compared to control. Overall, 
these results suggest that MASTL is required for the proliferation of TC cells. 
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Figure 4.3 Effects of MASTL knockdown on TC cell proliferation 
A-E) HTC/C3 and 8505C cells were transfected with control (siNT) and MASTL (siMASTL #1, #4 and 
#5) siRNAs and the following day were plated for silencing efficiency and proliferation ability 
testing as outlined in (A). Western blot analysis of MASTL expression in HTC/C3 (B) and 8505C (C); 
actin represents loading control. Growth curves of HTC/C3 (D) and 8505C (E) transfected and 
analyzed as indicated in A); cell growth was evaluated by CellTiter-Glo assay at the indicated time 
points after plating, plotted as mean +/- sd and normalized on day 1 values. E-F) Colony forming 
assay of HTC/C3 (E) and 8505C (F) cells 7 days after transfection with the indicated siRNAs; values 
represent optical density of Crystal Violet and are indicated as mean +/- sd of two (for HTC/C3) or 
three (for 8505C) independent experiments. Unpaired Student’s t-test was used to compare 
control vs MASTL siRNAs (*p<0.05; **p<0.01; ***p<0.001). 
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4.3.2. Effects of MASTL knockdown on mitosis 
 MASTL plays a crucial role in the regulation of mitosis progression (124) and we have 
previously observed the presence of aberrant mitotic figures in TC cells upon its depletion 
(section 3.3.6). Since it is well established that aberrant mitoses can generate cells with 
abnormal nuclei (157), such as multiple/lobate nuclei, nuclear blebs and micronuclei, we 
investigated whether such nuclear aberrations could be produced by MASTL depletion. 
HTC/C3 cells transfected with control (siNT) and MASTL (siMASTL #1, #4 and #5) siRNAs 
were scored for the presence of aberrant nuclear structures 120 hours later by 
immunofluorescence (Figure 4.4A). The nuclear anomalies previously listed were 
observed in 16.9% of siMASTL #1-cells, 19.3% of siMASTL #4-cells and 21.1% of siMASTL 
#5-cells, but only 6.1% of control siNT-cells (Figure 4.4B). We performed the same 
analysis on 8505C cells 76 hours after siRNA transfection (Figure 4.4C). Also in this case, 
we observed a significant increase of cells displaying aberrant nuclei (Figure 4.4D): 28.1% 
for siMASTL #1, 36.8% for siMASTL #4 and 41.1% for siMASTL #5, in comparison with 14% 
for siNT. On the whole, these results suggest that MASTL depletion interferes with TC cell 
division process originating cells with abnormal nuclei. 
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Figure 4.4 Analysis of the effects of MASTL knockdown on the structure of TC cell nuclei 
A and C) Representative images of HTC/C3 and 8505C cells transfected with control (siNT) and 
three MASTL siRNAs and stained for nuclei (blue, DAPI) 120 (A) and 76 (C) hours later;  cells with 
aberrant nuclei are indicated by arrows. B and D) Quantification of HTC/C3 and 8505C cells with 
abnormal nuclei analyzed in A and C); for each set, the percentage of abnormal nuclei 
(represented as mean +/- sd) was determined by counting a total number of 1900-2000 cells (B) 
and 3000 cells (D) from 8 and 6 independent experiments, respectively. Unpaired two-tailed 
Student’s t-test was used to compare control (siNT) vs MASTL (siMASTL #1, #4, #5) depleted cells; 
asterisks indicate statistical significance (***p<0.001) 
 
4.3.3. Effects of MASTL depletion on TC cell viability 
 Mitotic aberrations and formation of cells with abnormal nuclei (such as multiple 
nuclei and micronuclei) are generally described as “mitotic catastrophe”, an event that 
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reduction of TC cell growth (section 4.3.1) and an increase of TC cells displaying nuclear 
aberrations upon MASTL depletion (section 4.3.2), we investigated whether MASTL 
silencing might be associated with occurrence of TC cell death. For the studies hereafter 
presented, we used siMASTL #5 oligo to deplete MASTL, as we previously observed that it 
gave the maximum effects on growth inhibition and aberrant nuclei formation. HTC/C3 
and 8505C were transfected with siNT and siMASTL #5 and analyzed at different time 
points. Starting from 72 hours after transfection, we observed morphological changes in 
HTC/C3 depleted cells, as some appeared to be enlarged in size, together with the 
presence of floating cells (Figure 4.5A). Western blot analysis showed efficient MASTL 
silencing, as early as 48 hours after transfection, and an increase of apoptotic markers 
cleaved Caspase 3 and cleaved PARP, starting from 72 hours after transfection (Figure 
4.5B). Moreover, we observed an increase of phosphorylated-CDK1 levels on Tyrosine 15 
at the latest time points, thus supporting impairment in cell cycle progression. For 8505C 
cells, although morphological changes were not marked as for HTC/C3, we observed the 
presence of floating cells starting from 96 hours after transfection of MASTL siRNA (Figure 
4.5C). Similarly to HTC/C3, western blot analysis showed efficient MASTL silencing and 
increased expression of cleaved Caspase 3, cleaved PARP and phosphorylated-CDK1 in 
MASTL-depleted cells, compared to control (Figure 4.5D). These findings suggest that 
MASTL depletion is associated with apoptotic cell death. 
 
   
88 
 
 
 
48h 72h 96h 120h
s
iN
T
s
iM
A
S
T
L
#
5
A
B
siNT + -
+-
120 h
GAPDH
MASTL
CleavedCaspase3
CleavedPARP
GAPDH
siMASTL #5
+ -
+-
96 h
+ -
+-
48 h
+ -
+-
72 h
HTC/C3
97
19
17
14
MW 
(KDa)
36
89
116
36
P-CDK1 (Y15)
CDK1
34
34
48h 72h 96h 120h
s
iN
T
s
iM
A
S
T
L
#
5
siNT + -
+-siMASTL #5
+ -
+-
+ -
+-
+ -
+-
120 h96 h48 h 72 h
C
D
GAPDH
MASTL
CleavedCaspase 3
CleavedPARP
GAPDH
8505C
97
19
17
14
MW 
(KDa)
36
89
116
36
P-CDK1 (Y15)
CDK1
34
34
89 
 
Figure 4.5 Effects of MASTL knockdown on TC cell viability 
A and C) Representative images of HTC/C3 (A) and 8505C (C) at the indicated time points after 
transfection with control (siNT) and MASTL (siMASTL #5) siRNAs. B and D) Western blot analysis 
of HTC/C3 (B) and 8505C (D) cells for MASTL, phosphorylated CDK1 (Tyr15), total CDK1, cleaved 
Caspase 3 and cleaved PARP expression; GAPDH was used as loading control. One representative 
out of two independent experiments is shown for each cell line. 
 
 To further corroborate the occurrence of TC cell death upon MASTL depletion, we 
performed Annexin V assay on MASTL-depleted and control HTC/C3 cells followed by flow 
cytometry analysis (Figure 4.6A). We observed that MASTL depletion reduced the number 
of viable cells in comparison with control (Figure 4.6B): siNT-HTC/C3 viable cells (TO-PRO-
3-/Annexin V-) were 92.7% at 48 hours, 80.2% at 72 hours, 62.2% at 96 hours and 71.0% 
at 120 hours after transfection; siMASTL-HTC/C3 viable cells were 91.4% at 48 hours, 
65.5% at 72 hours, 27.6% at 96 hours and 30.6% at 120 hours after transfection. The 
percentage of early apoptotic cells (TO-PRO-3-/Annexin V-) of siNT and siMASTL 
transfected cells respectively were: 0.9% and 0.6% at 48 hours, 1.9% and 4.5% at 72 
hours, 3.4% and 4.0% at 96 hours, 3.6% and 1.3% at 120 hours. Dead cells in apoptosis 
(TO-PRO-3+/Annexin V+) for control and MASTL-depleted groups respectively were: 4.1% 
and 3.5% at 48 hours, 13.0% and 22.7% at 72 hours, 28.6% and 42.5% at 96 hours, 18.1% 
and 31.4% at 120 hours. Cells considered either necrotic or which already ended cell 
death through apoptosis (TO-PRO-3+/Annexin V-) were respectively for siNT and siMASTL: 
2.3% and 4.5% at 48 hours, 5.0% and 7.3% at 72 hours, 5.8% and 26.0% at 96 hours, 7.1% 
and 36.6% at 120 hours after transfection. The same analysis is currently in progress on 
8505C cells. Overall, our findings indicate that MASTL depletion is associated with 
decreased TC cell viability and increased cell death. This was associated with apoptosis 
but, given that we also observed an increase of MASTL-depleted cells that are considered 
either necrotic or apoptotic cells having already lost membrane integrity and Annexin V 
staining, we could not exclude that also necrotic cell death may occur. 
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Figure 4.6 Characterization of MASTL knockdown effects on HTC/C3 viability 
Representative dot plot (A) and relative histogram representation (B) of FACS analysis of HTC/C3 
cells, transfected with control (siNT) and MASTL (siMASTL #5) siRNAs, at the indicated time points 
after transfection; cells were stained with FITC Annexin V Apoptosis Detection Kit (BD 
PharmingenTM), in which TO-PRO-3 iodide replaced propidium iodide; TO-PRO-3-/Annexin V- 
staining represent viable cells, TO-PRO-3-/Annexin V+ represents early apoptotic cells, TO-PRO-
3+/Annexin V+ indicates apoptotic cells; TO-PRO-3+/Annexin V- indicates necrotic cells and dead 
cells that have already ended apoptosis and have lost membrane integrity and Annexin V staining. 
One representative out of two independent experiments is shown. 
 
4.3.4. Effects of MASTL depletion on DNA damage 
 It is well established that chromosome segregation errors are often associated with 
occurrence of structural chromosomal aberrations and DNA double strand breaks (DSB) 
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evidence of MASTL involvement in response to DNA damage (136), we investigated 
whether its depletion may induce DNA DSBs in TC cells. To this aim, we analyzed by 
western blot the expression of phosphorylated histone H2AX on Serine 139 (referred to 
as γH2AX), an established marker of DNA DSBs (160), in control (siNT) and MASTL 
depleted (siMASTL #5) cells. Together with efficient MASTL silencing as early as 48 hours 
after siRNA transfection, we observed a gradual increase of γH2AX expression levels in 
both HTC/C3 (Figure 4.7A) and 8505C (Figure 4.7B) MASTL-depleted cells starting from 72 
hours after transfection. These results suggest that MASTL depletion may lead to 
accumulation of DNA damage in TC cells. 
 
 
 
Figure 4.7 Effects of MASTL depletion on occurrence of DNA damage 
Western blot analysis of MASTL and γH2AX expression in HTC/C3 (A) and 8505C (B) cells at the 
indicated time points after transfection with control (siNT) and MASTL (siMASTL #5) siRNAs. 
GAPDH was used as loading control. One representative out of two independent experiments is 
shown. Protein extracts used in panel A for HTC/C3 are the same used in figure 4.4. 
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4.3.5. Lentiviral-mediated stable MASTL silencing in TC cells 
 We searched for a system to stably inhibit MASTL expression for future studies, in 
order to obtain a more controlled MASTL knockdown and to explore the long-term effects 
of its depletion in TC cells. To this aim we purchased an inducible lentiviral shRNA system, 
namely TRIPZ (Figure 4.8A): the lentiviral vector carried a specific shRNA together with 
red fluorescent protein (RFP) under the control of a tetracycline-inducible promoter, thus 
allowing the expression of the shRNA only upon doxycycline administration. The plasmid 
also contained a puromycin-resistance cassette to allow the selection of stably 
transduced cells. TRIPZ system was already demonstrated to produced efficient gene 
silencing in other cell models (161,162). We purchased TRIPZ vectors containing two 
different shRNA sequences targeting MASTL, namely TRIPZ-shMASTL #1 and TRIPZ-
shMASTL #2. We transduced 8505C cells with the two vectors and selected transduced 
cells with puromycin. Cells were then treated with 1 µg/ml and 2 µg/ml doxycycline and 
RFP expression was monitored: as early as 24 hours after treatment, both 8505C-TRIPZ-
shMASTL #1 and 8505C-TRIPZ-shMASTL #2 cells were positive for RFP at fluorescent 
microscope observation (Figure 4.8B). Western blot analysis of 8505C-TRIPZ-shMASTL #1 
and 8505C-TRIPZ-shMASTL #2 cells showed a gradual decrease of MASTL expression upon 
doxycycline administration, in comparison with untreated cells (Figure 4.8C), thus 
indicating that the shRNAs targeting MASTL are induced together with RFP after 
doxycycline administration. These observations support the effectiveness of the system 
to stably inhibit MASTL expression in 8505C cells. 
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Figure 4.8 Stable MASTL silencing in TC cells 
A) Schematic representation of the pTRIPZ Inducible Lentiviral shRNA and relevant features (TRE: 
tetracycline-inducible promoter, RFP: red fluorescent protein, UBC: human ubiquitin C promoter 
for constitutive expression of rtTA3 and puromycin resistance genes; rtTA3: reverse tetracycline-
transactivator 3 for tetracycline-dependent induction of the TRE promoter, PuroR: Puromycin 
resistance to selectively propagate stable integrants). B) Representative images of 8505C cells 
stably transduced with either TRIPZ-shMASTL #1 or TRIPZ-shMASTL #2 lentiviral vectors; cells 
were treated with 1 µg/ml doxycycline, 2 µg/ml doxycycline or left untreated, and pictures were 
taken at the indicated time points to monitor RFP expression in the different populations. C) 
Western blot analysis of MASTL expression levels in 8505C-TRIPZ-shMASTL #1 and 8505C-TRIPZ-
shMASTL #2 cells represented in B); GAPDH and Actin represent loading controls. 
 
We performed a preliminary experiment to test the growth of 8505C-TRIPZ-shMASTL #2 
upon MASTL depletion. We induced the expression of RFP and shMASTL #2 by 
administration of 2 µg/ml doxycycline and monitored RFP expression, which was clearly 
detectable even 11 days later in treated cells, and absent in untreated ones (Figure 4.9A). 
We observed, by western blot analysis and CellTiter-Glo assay respectively, that 
doxycycline treatment decreased MASTL expression (Figure 4.9B) and inhibited 8505C cell 
growth (Figure 4.9C), in comparison with untreated cells. Together, these results further 
support the effectiveness of lentiviral system and suggest that long-term MASTL 
depletion impairs the growth of TC cells. 
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Figure 4.9 Effects of MASTL knockdown on long-term 8505C cell growth 
8505C cells transduced with TRIPZ-shMASTL #2 lentiviral vector were tested for RFP expression, 
MASTL silencing and proliferation ability. A) Representative images of treated and untreated cells 
cells at 11 days after doxycycline administration; both visible and RFP fluorescence images are 
reported. B) Western blot analysis of MASTL expression at the indicated time points after 
doxycycline treatment in cells represented in A); actin was used as loading control. C) Growth 
rates of cells, represented in A) and B), at the indicated time points; cell growth was evaluated by 
CellTiter-Glo assay at the indicated time points after plating, plotted as mean +/- sd and 
normalized on day 1 values; unpaired two-tailed Student’s t-test was used to compare untreated 
vs doxycycline-treated cells (*p<0.05; **p<0.01; ***p<0.001). 
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4.3.6. Set up of IHC analysis of MASTL expression  
 As preliminary for future studies aimed to assess MASTL expression in thyroid tissues, 
we purchased MASTL antibody (clone 4F9, Millipore) used for immunohistochemistry 
(IHC) analysis in the study presented by Wang and colleagues (136) and tested its working 
conditions on 8505C cells transfected with siNT and siMASTL as positive and negative 
controls, respectively. By western blot analysis, we first confirmed the reduction of 
MASTL expression in siMASTL-cells, in comparison with siNT (Figure 4.10A). Then, in 
collaboration with the immunohistochemistry facility of our institute, we embed 8505C 
siNT and siMASTL cells in paraffin, in order to mimic conditions of IHC tissue analysis, and 
performed IHC; nuclear MASTL staining was observed in the positive (siNT) but not 
negative (siMASTL) control (Figure 4.10B). These observations assert the effectiveness of 
the antibody for IHC applications and support the feasibility of future studies aimed to 
assess MASTL expression in thyroid tissues by IHC.  
 
 
Figure 4.10 IHC analysis of MASTL expression in paraffin embedded 8505C cells 
8505C cells were transfected with control and MASTL siRNAs and embedded in paraffin 48 hours 
later for IHC testing of MASTL antibody. A) Western blot analysis for MASTL expression in siNT 
and siMASTL 8505C cells; GAPDH represents loading control. B) Representative images of IHC 
analysis of MASTL expression in 8505C siNT and siMASTL cells; scale bar=50 µm. 
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4.4. Discussion 
 In this chapter, we dissected the effects of MASTL depletion on the regulation of 
thyroid tumor cell biology. We knocked down MASTL in two ATC-derived cell lines by 
using three different siRNAs and demonstrated a significant reduction of the growth of TC 
cells, compared to control. We found that MASTL-depleted TC cells displayed increased 
nuclear aberrations, such as multiple nuclei, micronuclei or lobular nuclei. MASTL 
depletion also led to increased expression of apoptotic markers, cell death and DNA 
damage, compared to control.  
 MASTL recently emerged as promising therapeutic target for cancer treatment: its 
inhibition was able to reduce the viability of head and neck tumor cells when combined 
with cisplatin treatment (136) and of non small cell lung cancer cells when combined to 
radiation therapy (135). Notably, these studies reported that MASTL inhibition alone had 
a partial (136) or null (135) growth inhibitory effect on tumor cells. To date, MASTL role in 
the regulation of thyroid tumor cell biology has been never explored. Our studies 
demonstrated that its inhibition hampered the growth of thyroid tumor cells, thus further 
pointing out its relevance as possible target for cancer treatment. Of note, we observed 
that the three different MASTL siRNAs produced different extents of growth inhibition on 
TC cells. We hypothesized that these differences may be related to the different 
sequences of siRNAs: as they target different MASTL exons, it may be possible that the 
secondary structure of the mRNA influences their stability and silencing efficacy during 
time. Moreover, we decided to set a lentiviral-mediated inducible system to stably silence 
MASTL expression, in order to obtain a more controlled inhibition of MASTL expression 
that would last during time; we already tested the system on 8505C cells and observed its 
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efficacy in depleting MASTL in cells together with inhibition of the growth. This system 
will be useful for future studies on the role exert by MASTL in thyroid tumor cell biology. 
 We described in the previous chapter the presence of aberrant mitotic figures in 
MASTL-depleted TC cells, which were in line with previous observations in other cell 
models (124,151). The outcome of such aberrant mitoses is indicated as “mitotic 
catastrophe”, that is an aberrant form of mitosis, whose ultimate step consists in the 
formation of cells with aberrant nuclear structures, as multiple nuclei, micronuclei and 
lobular nuclei (158). Mitotic catastrophe is considered as a process preceding cell death, 
which may occur through apoptotic or necrotic mechanisms either after or during 
deregulated mitosis. Here, we observed that MASTL silencing led to the increase of TC 
cells displaying such nuclear anomalies, thus suggesting that MASTL inhibition may cause 
mitotic catastrophe in TC cells. Moreover, we observed increased cell death upon MASTL 
depletion. Western blot analysis showed occurrence of apoptosis, but Annexin V assay 
suggested that also necrotic cell death may occur. Together, these findings agree with the 
current knowledge about the outcome of cells undergoing mitotic catastrophe (158). The 
stimulation of mitotic catastrophe emerged as a promising strategy for cancer treatment. 
As a matter of fact, tumor cells often displayed mitotic catastrophe features upon 
treatment with ionizing radiations (163) or with drugs that hinder proper cell division, 
such as agents targeting microtubules, mitotic checkpoint components (164), and mitotic 
regulators as Aurora kinases, PLK1 and MPS1 (164). The final result of these treatments 
was tumor cell death (165). With regards to thyroid tumors, the targeting of mitotic 
regulators has already been explored and promising results were provided: targeting of 
PLK1 (166) and Aurora kinases (167) through small-molecule inhibitors significantly 
reduced the growth and induced cell death in ATC-derived cell lines. Our study, by 
showing unequivocal reduction of cell viability and increase of cell death upon MASTL 
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depletion, identified a novel mitotic target and strengthened the evidence of mitotic 
regulators as promising targets for thyroid tumor treatment. 
 We also found that MASTL silencing led to the accumulation of DNA damage in TC cell; 
we hypothesized that this increase may be related to different mechanisms. Chromosome 
segregation errors during mitosis are known to generate structural damage to 
chromosomes (159) and it is known that mitotic catastrophe cells accumulate 
chromosomal breaks that eventually trigger DNA damage response and cell death (168). 
As we observed both aberrant mitotic figures and mitotic catastrophe features in TC cells 
upon MASTL depletion, we hypothesized that the inhibition of MASTL may lead to 
structural DNA damage in TC cells. On the other hand, it is known that tumor cells exhibit 
higher levels of endogenous DNA damage, compared to normal ones, as result of the 
activity of oncogenes that promote uncontrolled cell growth; therefore, tumor cells 
become dependent on the activity of pathways that promote damage repair in order to 
sustain tumorigenic processes (169). Since MASTL is involved in both the regulation of 
DNA damage response (153) and the maintenance of genome stability during DNA 
damage response (154), we hypothesized that its inhibition in TC cells may lead to further 
accumulation of damaged DNA. Whether MASTL-associated DNA damage accumulation is 
related to one or the other mechanisms, or even related to both, remains to be 
investigated. 
 On the whole, our studies supported the notion that MASTL represents a vulnerability 
for thyroid tumor cells: its inhibition hindered thyroid tumor cell growth and was 
associated with mitotic catastrophe, cell death and increased DNA damage. Our results, 
together with recent literature data, propose MASTL as valuable target for cancer 
therapy, putting the rationale for the development of small-molecule inhibitors to be 
tested for therapeutic purposes.  
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5. Results: COPZ1 studies 
 
 As previously reported, the aim of our studies was to identify thyroid tumor cell 
vulnerabilities; as described in chapter 3, among the putative non-oncogenes identified 
through the functional siRNA screening, we found COPZ1. Even though the majority of my 
studies were aimed to the dissection of MASTL role in TC cell biology, in our laboratory 
we also studied the role exerted by COPZ1 in the regulation of TC cell viability, to which I 
directly collaborated. 
 COPZ1 encodes the ζ-subunit of coatomer protein complex I (COPI), which is a 
heptameric vesicular-carrier protein complex (137). COPI most characterized function is 
the transport of proteins from the Golgi complex back to the endoplasmic reticulum and 
in between Golgi compartments. In addition to this function, COPI complex was also 
found to be involved in the maturation of endosomes and regulation of autophagy: 
depletion of COPI subunits impaired transport of autophagic vacuoles into early 
endosomes with the consequent accumulation of autophagic vacuoles and inhibition of 
the autophagic flux (138). Moreover, COPI was identified as regulator of lipid storage and 
subsequent maintenance lipid homeostasis (139).  
  COPZ1 recently emerged as target gene for tumor therapy (125). It was 
demonstrated that tumor cells become dependent on COPZ1 activity because of the 
downregulation of its isoform COPZ2. The suppression of COPZ1 activity was effective in 
inducing cell death in both proliferating and non-diving tumor cells, while leaving 
unaffected normal cells. Also other members of COPI complex were reported to be 
promising targets for cancer therapy. COPA, which encodes the α-subunit of the complex, 
emerged from a siRNA screening as vulnerability gene in mesothelioma cells, as its 
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silencing inhibited both in vitro and in vivo tumor cell growth (170). KRAS mutant tumors 
showed synthetic lethality with COPB2, that encodes the β’-subunit of COPI (171). The 
targeting of different members of the COPI complex was associated with abortive 
autophagy and induction of cell death in different types of tumor cell lines (172) and a 
recent work identified ARCN1, which encodes the δ-subunit of the complex, as valuable 
target to block cell growth in different tumors (173). Interestingly, COPZ1 crystal structure 
was produced, thus laying the foundation for future studies aimed to design specific 
COPZ1 inhibitors (174).  
 COPZ1 was among the top-ranked hit genes resulted from the functional screening 
described in chapter 3; the aim of the studies presented in this chapter was to dissect the 
mechanisms through which COPZ1 knockdown inhibited the growth of TC cells. The 
results of this study are hereafter summarized.  
 We demonstrated that COPZ1 depletion by transient siRNA transfection dramatically 
impaired the growth of TC cell lines, representative of the different histotypes and 
carrying different genetic lesions; we also found that its silencing did not affect the 
growth and viability of normal thyrocytes and human mammary epithelial HME-1 cells. 
We demonstrated in a PTC-derived (TPC-1) and an ATC-derived (8505C) cell lines that 
COPZ1 depletion impaired productive autophagy by causing the accumulation of 
autophagosomes and block of autophagic flux, thus producing an abortive autophagy 
process. We also observed endoplasmic reticulum stress and unfolded protein response 
activation upon COPZ1 depletion, that eventually caused apoptotic cell death. In vivo 
silencing of COPZ1 in 8505C mouse xenografts significantly reduced tumor growth and 
immunohistochemical analysis on explanted tumors showed decrease of proliferation 
markers and increase of necrosis. We analyzed the expression levels of COPZ2, that is 
COPZ1 isoform, in publicly available thyroid data sets, and found that is downregulated in 
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TC specimens, compared to normal thyroid, thus supporting the hypothesis that COPZ1 
vulnerability of TC cells may be related to the absence of its paralogous COPZ2.  
 Together, our findings demonstrated that COPZ1 represents a vulnerability for TC 
cells, thus providing a new potential target for the design of therapeutic strategies. 
 
Details and results of the study are presented in the attached reprint of the paper 
(Appendix B): 
 
 Anania MC, Cetti E, Lecis D, Todoerti K, Gulino A, Mauro G, Di Marco T, Cleris L, 
Pagliardini S, Manenti G, Belmonte B, Tripodo C, Neri A, and Greco A. Targeting 
COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells. 
Cancer Letters (2017) in press doi: 10.1016/j.canlet.2017.09.024. 
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6. General discussion and future perspectives 
 
6.1. Discussion and conclusions 
 The global aim of the thesis was to identify potential novel targets for thyroid cancer 
treatment. The entire project arose from the evidence that current therapies for thyroid 
tumors, which are the most common endocrine malignancy, are still not effective in 
treating the recurrent and advanced forms (84). Most of thyroid tumors are represented 
by well-differentiated forms, which generally have a good prognosis and standard therapy 
is generally effective (78). Nevertheless, some tumors relapse and progress to the 
undifferentiated forms, whose treatment is still a demanding challenge. Despite the 
recent improvement in both the diagnosis and the knowledge of molecular alterations 
that drive thyroid tumorigenesis, the lack of effective therapies, especially for the 
advanced forms, is still present (1). The use of novel therapies such as small-molecule 
kinase inhibitors improved the survival of patients not responding to conventional 
treatment, but also produced severe side verse effects that hampered quality of life of 
patients (84). To identify nodal points for therapeutic intervention, our laboratory faced 
the concept of non-oncogene addiction (NOA) in thyroid tumors. NOA concept states 
that, in response to activation of oncogenes, tumor cells undergo increased cellular 
stresses and therefore rely on the activity of genes involved in stress support pathways, in 
order to maintain their tumorigenic capacity (98). Normal cells are not dependent on 
these genes, as their stress levels are not increased. NOA genes, which are not oncogenes 
themselves, become therefore attractive targets for therapeutic intervention, as their 
targeting would ideally be detrimental for tumor cell growth while not affecting normal 
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cells. To identify potential NOA genes in thyroid tumors, our laboratory performed a loss-
of-function screening on tumor and normal thyroid cell lines using a siRNA library 
targeting about 9000 genes considered “druggable”. RNAi-based loss of function 
screenings, at variance with the current approaches of NGS technologies that allow the 
identification of genetic lesions at the basis of tumorigenic processes, demonstrated to be 
a successful strategy for the identification of “non-onogenes” essential for tumor growth 
(106-108,110). Our functional screening identified a list of 15 genes whose inhibition 
inhibited the growth of tumor but not normal thyroid cells. 
 The first part of the thesis aimed to validate the 15 hit genes in the original cell models 
used for the screening and to extend the analysis of the effects of their silencing on the 
viability of various thyroid cell lines, representative of the different TC histotypes. Thyroid 
TCGA dataset interrogation showed that hit genes had variable expression levels among 
PTC samples and the normal counterpart and, notably, were not mutated, thus 
uncovering their reliability as putative “non-oncogenes”. After selection of efficiently 
working antibodies and siRNAs, we selected 3 out of the 15 hit genes for validation 
studies: MASTL (encoding a mitotic kinase), CCND1 (encoding a regulator of CDK4/6 
activity) and COPZ1 (encoding a regulator of protein vesicular transport). Functional 
studies confirmed the growth inhibitory effect of MASTL, CCND1 and COPZ1 silencing in 
the tumor but not normal cell lines used for the screening and, interestingly, we 
demonstrated that the growth of other TC cell lines, derived from different tumor 
histotypes and carrying different genetic lesions, was sensitive to their inhibition. These 
results demonstrated that MASTL, Cyclin D1, and COPZ1 represent thyroid tumor cell 
vulnerabilities and are noteworthy for further studies, aimed to explore their targeting as 
possible strategy for therapeutic intervention. Moreover, this validation study highlighted 
the effectiveness of large-scale RNAi-based functional screening in identifying tumor cell 
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vulnerabilities, thus supporting the strength of RNAi-based approaches in the discovery of 
novel therapeutic targets (106-110). 
 The studies presented in the second and third part of the thesis aimed to identify the 
mechanisms through which the inhibition of MASTL and COPZ1, respectively, hindered TC 
cell growth. We observed that MASTL silencing in two ATC-derived cell lines reduced cell 
proliferation ability. In parallel, cells exhibited features of mitotic catastrophe, 
documented by the increase of aberrant nuclear morphologies as micronuclei or multiple 
nuclei. Moreover, MASTL depletion was associated with TC cell death that was possibly 
mediated by both apoptotic and necrotic mechanisms, as already discussed in section 4.4. 
We also found that MASTL silencing led to increased DNA damage levels in TC cells. With 
regards to COPZ1, we observed that its silencing inhibited the growth of various TC cell 
lines by inducing autophagosome accumulation and abortive autophagy, endoplasmic 
reticulum stress and unfolded protein response, which ultimately led to apoptotic cell 
death. Moreover, COPZ1 silencing inhibited in vivo tumor growth in mouse xenograft and 
was associated with decreased expression of proliferation markers and increase of 
necrosis; these findings further supported the reliability of COPZ1 targeting in vivo as 
potential therapeutic strategy.  
 Collectively, our studies suggest that MASTL and COPZ1 may effectively represent 
“non-oncogenes” in thyroid cancer. As previously discussed, thyroid TCGA dataset 
interrogation revealed that neither MASTL nor COPZ1 were overexpressed in PTC 
compared to normal counterpart, and, except for one silent mutation of COPZ1, no 
mutations were reported for both of them in about 500 PTC samples. Thus, both MASTL 
and COPZ1 properly comply with the concept of NOA (98).  
 We hypothesized that MASTL may act on mitotic stress support pathway and its 
depletion may impair stress support and cause tumor cell death (98). Tumor cells often 
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face with elevated mitotic stress, due to the high number of mutations that alter mitosis 
fidelity and cause chromosome missegregation; thus, in order to avoid excessive genomic 
instability, they become dependent on stress support pathways (175). Both sensitization 
and overload of mitotic stress were exploited as strategies to interfere with tumor cell 
growth, and are widely exemplified by the targeting of mitotic machinery elements, such 
as PLK1 and Aurora kinases, as well as by the use of microtubule-targeting agents like 
chemotherapy drugs (already discussed in section 4.4). Other regulators of mitotic 
process, such as the spindle assembly checkpoint (SAC) components Mad2 and BubR1, 
triggered cell death when genetically eliminated in mice and were therefore proposed as 
targets for inducing further chromosomal instability and consequent cell death in tumor 
cells (176). Our results suggest that MASTL may effectively represent an example of non-
oncogene acting on the mitotic stress support pathway, since we observed that its 
silencing interfered with TC cell mitosis and was associated with mitotic catastrophe and 
cell death. On the other hand, also DNA damage and replication stress is often present in 
tumor cells, as a result of the high degree of replication and the rate of spontaneous DNA 
damage formation. Targeting of elements that promote DNA repair, such as ATM, was 
successful in causing stress sensitization and tumor cell death (177). Also radiations and 
chemotherapy were effective in overloading DNA damage and replication stress and 
leading to tumor cell death. The increase of DNA damage and cell death observed upon 
MASTL depletion suggest that MASTL vulnerability of TC cells may be related also to 
impaired DNA damage stress support pathway. 
 Regarding COPZ1, our results suggest that its depletion may be associated with 
proteotoxic stress. COPZ1 depletion in thyroid tumor cells blocked autophagic flux and 
increased endoplasmic reticulum stress, ultimately leading to apoptosis. It was 
demonstrated that prolonged endoplasmic reticulum stress results in cell death (178) and 
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that tumor cells rely on autophagy as mechanism to clear damaged/unfolded proteins 
and to lower proteotoxic stress (179). We hypothesized that COPZ1 depletion may affect 
protein balance in cells, leading to an overload of proteotoxic stress that, together with 
block of productive autophagy, could ultimately drive tumor cell fate towards a 
programmed form of cell death.  
 Remarkably, we demonstrated that the growth inhibitory effect of MASTL and COPZ1 
targeting was restricted to thyroid tumor cells and did not affect viability of normal cells, 
as previously reported for other tumor types (125,135,136); these observations support 
the hypothesis that their targeting in vivo may produce limited side verse effects.  
 In conclusion, we identified putative non-oncogenes in thyroid cancer and validated 
MASTL and COPZ1 as “Achille’s heel” of thyroid tumors, thus providing evidence that they 
represent valuable elements for future studies, aimed to test their inhibition as strategy 
for thyroid cancer treatment.  
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6.2. Future perspectives 
 The studies presented in the thesis highlighted MASTL and COPZ1 as valuable 
candidates for future studies aimed to validate their targeting as potential therapeutic 
approach in thyroid cancer management. 
 MASTL represents an interesting mitotic element that recently emerged as potential 
target for cancer therapy (135,136) and our studies demonstrated its significance as 
thyroid tumor cell vulnerability.  
 To assess its reliability as target for thyroid tumor treatment, the effects of its 
inhibition in vivo will be investigated using a thyroid tumor mouse xenograft model, 
already used for COPZ1 studies. MASTL silencing will be performed by in vivo siRNA 
injection. The set up of the optimal conditions for treatment is in progress. 
 Deregulated mitoses can cause mitotic cell death and this mechanism often occurs 
upon mitotic catastrophe (158). Live imaging on TC cells expressing the fluorescent 
nuclear marker H2B-GFP will allow us to the assess the fate of MASTL-depleted TC cells at 
single cell level, by monitoring cell division and observing nuclear structural changes. 
 Analysis of the activation status of regulators of DNA damage response pathway will 
allow us to clarify the effects of MASTL silencing on DNA damage accumulation.  
 MASTL overexpression was found in head and neck, prostate and advanced breast 
carcinomas (136), while for other tumors, including thyroid cancer, its expression level 
has been never explored. MASTL expression at protein level will be assessed by IHC 
analysis of normal and tumor thyroid tissues, and correlated with gene expression data 
derived from analysis of publicly available thyroid dataset. Together, these results will 
allow the characterization of MASTL expression status in thyroid cancer.  
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ABSTRACT
The incidence of thyroid carcinoma is rapidly increasing. Although generally 
associated with good prognosis, a fraction of thyroid tumors are not cured by standard 
therapy and progress to aggressive forms for which no effective treatments are 
currently available. In order to identify novel therapeutic targets for thyroid carcinoma, 
we focused on the discovery of genes essential for sustaining the oncogenic phenotype 
of thyroid tumor cells, but not required to the same degree for the viability of normal 
cells (non-oncogene addiction paradigm). We screened a siRNA oligonucleotide library 
targeting the human druggable genome in thyroid cancer BCPAP cell line in comparison 
with immortalized normal human thyrocytes (Nthy-ori 3–1). We identified a panel of 
hit genes whose silencing interferes with the growth of tumor cells, while sparing that 
of normal ones. Further analysis of three selected hit genes, namely Cyclin D1, MASTL 
and COPZ1, showed that they represent common vulnerabilities for thyroid tumor cells, 
as their inhibition reduced the viability of several thyroid tumor cell lines, regardless 
the histotype or oncogenic lesion. This work identified non-oncogenes essential 
for sustaining the phenotype of thyroid tumor cells, but not of normal cells, thus 
suggesting that they might represent promising targets for new therapeutic strategies.
INTRODUCTION
The incidence of thyroid cancer (TC), the 
most common endocrine malignancy, has increased 
significantly over the last few decades [1]. All TCs, 
except medullary thyroid carcinoma, are derived from 
thyroid follicular cells. Differentiated tumors, namely 
papillary and follicular carcinoma (PTC and FTC, 80% 
and 10% of cases, respectively) are generally cured by 
current treatment involving surgery, thyroid hormone and 
radioactive iodine therapy; however, they occasionally 
progress into undifferentiated, more aggressive and lethal 
carcinomas. Poorly differentiated (PDTC) and anaplastic 
(ATC) carcinoma, although rare, are the most clinically 
aggressive TCs; for ATC patient the survival is reduced to 
few months [2].
Genetic studies performed in the last 25 years have 
dissected the molecular bases of TC. PTC is associated 
with a high frequency of deregulation of RTK/RAS/
RAF/MAPK pathway [3]. This includes oncogenic 
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rearrangements of the RET and NTRK1 receptors, and 
point mutations in the BRAF and RAS genes, with 
the BRAFV600E as the most frequent PTC alteration. 
The genetic landscape of PTC has been very recently 
expanded by integrated genomic characterization studies 
which identified several novel driver alterations [4]. 
FTC is associated with RAS mutations and PAX8/PPARγ 
rearrangements. RAS mutations are common in PDTC. 
ATC is associated with mutations of BRAF, RAS, TP53, 
PTEN, and PIK3CA. The identification and functional 
characterization of differentially expressed genes and 
miRNAs have also contributed to the understanding of 
thyroid tumor biology, and provided important diagnostic/
prognostic tools [5–8].
Molecular findings have been translated into the 
clinical setting, leading to clinical experimentation of 
agents targeting thyroid oncoproteins or downstream 
pathways [9]. Several kinase inhibitors, primarily targeting 
BRAF and angiogenic kinases, are under evaluation in 
clinical trials [10]. Nevertheless, no effective targeted 
therapies are currently available for aggressive TC that are 
not curable by the standard therapeutic approaches.
The traditional approach for cancer target discovery 
is based on the identification of driver oncogenes through 
the characterization of the molecular alterations of primary 
tumors. However, according to the concept of “non-
oncogene addiction” (NOA), the uncontrolled growth 
of cancer cells often relies on normal genes, that are 
not themselves oncogenes or otherwise mutated, whose 
activity is essential for tumor cells but not required to the 
same extent by normal cells [11]. NOA genes cannot be 
identified by genetic approaches aimed at identifying gene 
mutation/aberrancy, but rather by large-scale siRNA-based 
functional screening, a strategy which is nowadays widely 
used for the identification of tumor cell vulnerabilities to 
be explored for therapeutic purposes [12–15].
In order to identify novel, unforeseen molecular 
targets for thyroid carcinoma, in this study we have 
undertaken the screening of a siRNA oligonucleotide 
library in tumor (BCPAP) and normal (Nthy-ori 3–1) 
thyroid cell lines, and we have identified a set of genes 
whose silencing reduces the growth of tumor cells, 
while sparing growth of non-transformed cells of the 
same tissue origin. Among the top ranked genes, we 
selected Cyclin D1 (CCND1), MASTL and COPZ1. All 
of them passed a secondary confirmation study, which 
unequivocally demonstrated the dependency of BCPAP 
cells upon their activity. Interestingly, we found that 
silencing of Cyclin D1, MASTL and COPZ1 inhibits the 
growth of several further thyroid tumor cell lines.
RESULTS
Druggable genome siRNA screening
To identify genes affecting growth of thyroid tumor 
cells, we conducted an RNAi-based phenotypic screening, 
examining effects on cell growth. The papillary thyroid 
carcinoma BCPAP cell line, carrying the BRAFV600E 
mutation, and the immortalized normal human thyrocyte 
Nthy-ori 3–1 cell line were transfected with a siRNA 
library containing 25139 siRNA oligos targeting about 
9000 potentially “druggable” genes (3 duplexes/gene, 
on average), and with a non-targeting siRNA (siNT) and 
a siRNA targeting the proteasomal subunit PSMC3 as 
negative and positive controls, respectively. Cells were 
transfected at low density in 96-well plates and colony 
formation assay (CFA) was performed after 7 (Nthy-
ori 3–1) or 8 (BCPAP) days. Images of a representative 
plate for each of these lines are shown in Figure 1A. We 
preferred CFA to short-term (48–72 hours) proliferation 
assay, since it allows the detection of long-term 
consequences of “weak” phenotypes (our unpublished 
results). The screening results are shown in Figure 1B: 
scatter plots represent the fluorescence signal, derived 
from CFA acquisition, normalized with respect to siNT 
(% siNT) of Nthy-ori 3–1 and BCPAP cells transfected in 
duplicate with the library siRNA oligos (the complete list 
is reported in Table S1). Of note, the uneven distribution 
of data across graph diagonal denotes slightly higher 
transfection efficiency for Nthy-ori 3–1 than for BCPAP. 
Genes essential for cell viability of BCPAP, but not Nthy-
ori 3–1 cells, were identified through the “d parameter” 
(defined in Materials and Methods). d values close to 0 
denote preferential inhibition of BCPAP cell proliferation 
with respect to Nthy-ori 3–1. Based on data distribution, a 
threshold of -3σ (corresponding to d = 47.2) was applied 
to define differentially active hits: 398 siRNA oligos 
(1.58%), targeting 386 genes, were found to be below 
this threshold and thus were defined as “differential hits” 
(Figure 1C; hit list is reported in Table S2). A significant 
preferential activity towards BCPAP cells was observed 
for 12 genes with 2 oligos out of 3, and for the remaining 
374 genes with 1 oligo out of 3; the latter include BRAF, 
consistent with the notion that BCPAP cells are addicted 
to BRAFV600E oncogene [16]. No genes emerged with 
3/3 oligos among hits. Functional annotation clustering 
analysis was performed on the 386 gene list (382 
DAVID IDs), using Gene Ontology-Biological Process 
(GO-BP) and Gene Ontology–Molecular Function 
(GO-MF) annotation terms and medium classification 
stringency. A significant Enrichment score (>1.3) was 
found in 15 out of the 117 annotation clusters that 
were globally identified. The top ranked GO-terms, 
representative for the 15 significant clusters, have been 
reported in Figure S1A.
By setting an arbitrary threshold of 20% colony 
growth with respect to siNT controls, we identified 1695 
siRNA oligonucleotides (6.74%) capable of inhibiting cell 
growth both in BCPAP and Nthy-ori 3–1, therefore defined 
as “lethal hits” (Figure 1C). Two hundred and seventeen 
genes emerged as indiscriminately lethal hits with 
2/3 (163) or 3/3 (54) oligonucleotides (Table S3). Most of 
them encode proteins involved in fundamental processes, 
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and some, such as the kinases PLK1, WEE1, AURKB and 
several proteasome subunits, have previously been shown 
to be essential for cell survival, emerging as top-ranking 
lethal hits in RNAi-mediated phenotypic proliferation 
screens in different tumor cell lines [14, 17, 18].
Confirmation of differentially active hits
Eightyfour siRNA oligonucleotides, targeting 
28 genes, were selected for confirmatory studies. Hits 
were prioritized for technical confirmation based on d 
values of individual oligos and on specific interest of 
identifying candidate druggable target genes. siRNAs 
were picked from library plates and transfected manually 
in triplicate on Nthy-ori 3–1 and BCPAP cells using 
the same experimental conditions as employed in 
primary screening. In these experiments a threshold of 
-2σ (corresponding to d = 49.8) was applied to define 
oligos with significantly low d values, i.e. displaying 
differential activity. We considered equally confirmed 
any siRNA oligos that in confirmation experiments gave 
the same phenotype of the screening, including the ones 
inactive or lethal for both cell lines. Figure 2A shows the 
comparison between primary screening and confirmation 
results. Eighteen out of 35 siRNA oligos (targeting 15 
genes), which had shown differential activity (d < -3σ) 
in the primary screening were confirmed by manual 
transfection (d < -2σ). All of 49 oligos which were not 
found to be differentially active in the screening run 
(d > -3σ) were confirmed as such by manual transfections 
(d > -2σ). Overall, the phenotype of 67 out of 84 oligos 
was confirmed. Representative images of outgrown 
colonies from the confirmatory study are shown in Figure 
2B and the corresponding quantifications are reported 
in Figure 2C. The list of confirmed hits is shown in 
Table 1: 3 genes were confirmed with 2 oligos (MASTL, 
Figure 1: siRNA screening results. A. Representative colony plates generated by transfecting Nthy-ori 3–1 (left) and BCPAP (right) 
cell lines with the same siRNA oligo mother plate. a. siRNA oligo lethal for both cell lines (blue); b. siRNA oligo selectively lethal for 
BCPAP (green); c. controls (yellow). B. Scatter plot of Colony Formation (CF) values obtained from 25139 unique siRNA oligos transfected 
in Nthy-ori 3–1 and BCPAP, reported as % of growth respect to NT for inter-plate data normalization (dot are the averages of two technical 
replicates performed in both cell lines). The mean d value (μ) is represented by a red line (dashed red lines: +/− 3σ). C. Scatter plot of 
normalized CF values showing the negative controls (siNT, blue), the lethal hits (green) and the differential hits (red). Insert: distribution 
of normalized d values after sigma binning.
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PLA2G15 and COPE) and 12 genes were confirmed with 
1 oligo (RGS3, CCND1, RASD1, NUDT9, OXTR, BRAF, 
COPZ1, MAP4K5, EPHB4, DNM3, REM2, SRPK1). 
Functional annotation analysis indicates that these genes 
are involved in several biological processes, such as cell 
cycle control, DNA damage and cell death, vesicular 
transport and endocytosis, cellular metabolic processes 
and intracellular signal transduction (Table 1). Network 
analysis performed by Ingenuity Pathway Analysis (IPA) 
identified two major connection networks as reported in 
Figure S1B.
Molecular profiling of confirmed hit genes
The thyroid TCGA data set [4], including 496 PTC 
samples, 58 of which matched with normal thyroid, 
was interrogated for assessing the mutational status and 
the expression level of hit genes in PTC. As expected, 
oncogenic BRAF mutations were detected with high 
frequency, being present in 248 samples. No mutations 
affecting the other genes were detected, with the exception 
of a silent mutation in COPZ1 gene in one case (data not 
shown). Expression analysis of hit genes was investigated 
on the whole data set (data not shown), as well as on the 
58 matched tumor and normal samples (Figure 3); in 
both cases identical results were obtained. According to 
their expression levels, hit genes can be classified in three 
groups: 1) genes with significantly high overexpression 
in PTC vs normal thyroid: CCND1, RGS3, OXTR, 
RASD1, DNM3; 2) genes with equal or slightly different 
expression in PTC and normal thyroid: COPE, COPZ1, 
PLA2G15, SRPK1, REM2, EPHB4, BRAF; 3) genes that 
are significantly downregulated in PTC vs normal thyroid: 
MAP4K5, NUDT9, MASTL. No differences among 
different PTC variants (classical, follicular, tall cell) or 
tumor stage were observed (data not shown).
Data retrieved from the Cancer Cell Line 
Encyclopedia (http://www.broadinstitute.org/ccle/home) 
showed that all the hit genes are expressed in BCPAP cells, 
with levels ranging from “low” to “very high” (data not 
Figure 2: Confirmation of differentially active hits. A. Comparison between d values obtained from the screening (bottom) and 
from confirmation experiments (top) performed with 84 siRNA oligos targeting 28 genes selected among the top ranked hits (A, B and 
C: three oligos per gene). Non-targeting Oligo (siNT) and siRNA oligos against PSMC3 were respectively used as negative and positive 
controls of transfection. Values represent the means of two technical replicates. The thresholds used to define differentially active oligos 
are shown in red (d = 47.2 for screening and d = 49.8 for confirmations). B. Representative pictures of individual wells showing colony 
formation in confirmation experiments after transfection of Nthy-ori 3–1 and BCPAP cells with the indicated siRNA oligos. C. Colony 
Formation (% siNT) values from image acquisition in B. All 84 oligos used for confirmation are shown; among these, oligos corresponding 
to the 15 genes are reported in B and are highlighted in color with standard deviation bars.
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Table 1. List of the confirmed hits after the primary screening.
Gene 
Symbol
Full Gene Name Accession GO-BP Term Confirmed 
active 
oligos
d (active oligos)
MASTL
microtubule 
associated serine/
threonine kinase-like
NM_032844
GO:0006468 protein 
amino acid phosphorylation 
GO:0006793 phosphorus 
metabolic process
2/2 33.75 (B) - 47.36 (A)
PLA2G15 phospholipase A2, 
group XV
NM_012320
GO:0006575 cellular amino 
acid derivative metabolic 
process  
GO:0006643 membrane lipid 
metabolic process
2/2 40.56 (B) - 47.71 (A)
COPE
coatomer protein 
complex, subunit 
epsilon
NM_007263
GO:0006890 retrograde 
vesicle-mediated transport, 
Golgi to ER transport 
GO:0051640 organelle 
localization
2/2 47.40 (C) - 48.45 (B)
RGS3 regulator of 
G-protein signaling 3
NM_017790
GO:0000165 MAPKKK 
cascade 
GO:0008277 regulation of 
G-protein coupled receptor 
proteinsignaling pathway
1/1 28.04 (A)
CCND1 Cyclin D1 NM_053056
GO:0000075 cell cycle 
checkpoint 
GO:0000077 DNA damage 
checkpoint
1/2 35.57 (C)
RASD1
RAS, 
dexamethasone-
induced 1
NM_016084
GO:0007264 small GTPase 
mediated signal transduction 
GO:0016481 negative 
regulation of transcription
1/1 36.74 (C)
NUDT9
nudix (nucleoside 
diphosphate linked 
moiety X)-type motif 
9
NM_024047
GO:0006163 purine nucleotide 
metabolic process 
GO:0006811 ion transport
1/1 45.6 (B)
OXTR oxytocin receptor NM_000916
GO:0000165 MAPKKK 
cascade 
GO:0003012 muscle system 
process
1/1 46.59 (C)
BRAF
v-raf murine sarcoma 
viral oncogene 
homolog B1
NM_004333
GO:0000165 MAPKKK 
cascade 
GO:0010941 regulation of cell 
death
1/1 47.45 (C)
COPZ1
coatomer protein 
complex, subunit 
zeta 1
NM_016057
GO:0006886 intracellular 
protein transport 
GO:0006890 retrograde 
vesicle-mediated transport, 
Golgi to ER
1/1 47.46 (A)
(Continued )
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Gene 
Symbol
Full Gene Name Accession GO-BP Term Confirmed 
active 
oligos
d (active oligos)
MAP4K5
mitogen-activated 
protein kinase kinase 
kinase kinase 5
NM_006575
GO:0000165 MAPKKK 
cascade 
GO:0001932 regulation 
of protein amino acid 
phosphorylation
1/1 47.88 (C)
EPHB4 EPH receptor B4 NM_004444
GO:0007169 transmembrane 
receptor protein tyrosine 
kinase signaling pathway 
GO:0045765 regulation of 
angiogenesis
1/1 48.98 (A)
DNM3 dynamin 3 NM_015569
GO:0006897 endocytosis 
GO:0010324 membrane 
invagination
1/1 49.29 (A)
REM2
RAS (RAD and 
GEM)-like GTP 
binding 2
NM_173527
GO:0006355 regulation of 
transcription, DNA-dependent 
GO:0007264 small GTPase 
mediated signal transduction
1/2 49.33 (B)
SRPK1 SFRS protein kinase 
1
NM_003137
GO:0006396 RNA processing 
GO:0007243 protein kinase 
cascade
1/2 49.80 (B)
PARP15
poly (ADP-ribose) 
polymerase family, 
member 15
NM_152615 0/1 −
RPS6KC1
ribosomal protein 
S6 kinase, 52kDa, 
polypeptide 1
NM_012424 0/1 −
RIPK3
receptor-interacting 
serine-threonine 
kinase 3
NM_006871 0/1 −
CAPN13 calpain 13 NM_144575 0/1 −
GNG7
guanine nucleotide 
binding protein (G 
protein), gamma 7
NM_052847 0/1 −
TAOK2 TAO kinase 2 NM_004783 0/2 −
UBE2E2
ubiquitin-conjugating 
enzyme E2E 2 
(UBC4/5 homolog, 
yeast)
NM_152653 0/1 −
TUFM
Tu translation 
elongation factor, 
mitochondrial
NM_003321 0/1 −
MMAA
methylmalonic 
aciduria (cobalamin 
deficiency) cblA type
NM_172250 0/1 −
GRPR gastrin-releasing peptide receptor NM_005314 0/1 −
(Continued )
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shown). Mutation analysis data indicated a low number 
(50/1651) of mutated genes in BCPAP cells. Cyclin D1, 
MASTL, MAP4K5, SRPK1 and EPHB4 genes were found 
to be of wild-type status, whereas no information was 
available for the remaining hit genes. These findings 
suggest that the addiction of BCPAP cells to the activity 
of the hit genes is unlikely related to alterations of the 
cognate proteins caused by mutations.
Hit gene expression in thyroid cell lines
We investigated the expression of 10 genes (the top 
11 hits except BRAF, see Table 1), in the normal (Nthy-ori 
3–1) and tumor (BCPAP) cell lines used for the siRNA 
library screening, as well as in a panel of thyroid tumor 
cell lines, representative of different tumor histotypes, 
and/or carrying different oncogenes: PTC-derived 
(TPC-1, carrying the RET/PTC1 oncogene); FTC-derived 
(WRO82–1); ATC-derived (8505C and HTC/C3, carrying 
the BRAFV600E oncogene; KAT-18). The expression 
of MASTL, PLA2G15, COPE, Cyclin D1, COPZ1 and 
MAP4K5 was investigated by western blot analysis 
(Figure 4A). Cyclin D1 was found to be 1.3 to 2.7 fold 
overexpressed in 6 out of 7 tumor cell lines with respect 
to Nthy-ori 3–1, with the exception of KAT-18, in which 
it was found less expressed. For COPE a slight increase in 
the protein expression levels in tumor cells, except KAT-
18, with respect to Nthy-ori 3–1 was observed. MASTL 
was found frequently less expressed in tumor cells, in 
keeping with what was observed by gene expression 
analysis in tumor samples (Figure 3). COPZ1 protein 
expression was slightly increased in all the tumor cell 
lines, and greater in 8505C. PLA2G15 expression was 
slightly reduced in all the tumor cell lines, except BCPAP, 
and strongly reduced in KAT-18. For MAP4K5, a slight 
increase in BCPAP, WRO82–1 and 8505C, and a decrease 
in the remaining cell lines were observed.
The expression of RASD1, NUDT9, RGS3 and 
OXTR genes was investigated by RT-PCR, as we failed 
to unequivocally detect the specific protein by western 
blot analysis (data not shown). As shown in Figure 4B, 
the genes are expressed in all the cell lines analyzed, and 
no differences can be appreciated.
Hit validation in BCPAP cell line
Among the candidate BCPAP vulnerability genes 
identified by the screening we selected CCND1, MASTL 
and COPZ1 for a validation study using commercially 
available siRNAs, different from those of the library 
screening. Four different oligos for MASTL, and a smart 
pool of oligos for CCND1 and COPZ1 were used (details 
are reported in Table S4). Firstly, the efficiency of gene 
knock-down was evaluated by investigating the expression 
of corresponding proteins in Nthy-ori 3–1 cells transiently 
transfected with specific siRNAs and with non-targeting 
oligos (siNT) as control (Figure 5A). For MASTL the 
highest silencing efficiency was obtained with oligos 1 
and 4 (89 and 95% of inhibition at 72 hours, respectively). 
siRNA targeting COPZ1 and CCND1 completely 
abrogated protein expression. Of note, in keeping with the 
siRNA library screening results, no macroscopic effects 
on Nthy-ori 3–1 cell growth/survival were observed (data 
not shown).
To investigate the effect of MASTL, CCND1 and 
COPZ1 gene silencing on BCPAP and Nthy-ori 3–1 cell 
viability, cells were transfected in 96 well plates with the 
different oligos above described, or with NT and PSMC3 
siRNAs as controls, and analyzed by CellTiter-Glo 
assay 10 days later. Scatter plots in Figure 5B represent 
the luminescence signal (average of two replicates, 
normalized with respect to siNT) of cells transfected with 
each siRNA oligo. siMASTL#1, siMASTL#4, siCCND1 
and siCOPZ1 reduced cell viability by 60%, 93%, 94% 
and 86%, respectively, an efficiency comparable to 
that of the control siRNA PMSC3 (93%). No effects 
were observed for siMASTL#2 and siMASTL#3, in 
keeping with their low silencing efficiency (Figure 5A). 
Gene 
Symbol
Full Gene Name Accession GO-BP Term Confirmed 
active 
oligos
d (active oligos)
CPT1C
carnitine 
palmitoyltransferase 
1C
NM_152359 0/1 −
GPX7 glutathione 
peroxidase 7
NM_015696 0/1 −
CCRK cell cycle related 
kinase
NM_012119 0/1 −
Genes are listed according to the number of active oligos; A, B and C represent three different oligos targeting the same gene. 
d values (<49.8) for each oligo, from the confirmation experiment, are also reported. NM: RefSeq Accession Number (http://
www.ncbi.nlm.nih.gov/refseq/about/). Representative Gene Ontology-Biological Process (GO-BP) terms are selected for each 
of the 15 validated genes, by means of DAVID6.7 functional annotation analysis.
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The effect of MASTL, CCND1, COPZ1 gene silencing 
in BCPAP cells was further confirmed by a different 
experimental approach. Cells were transfected in 6-well 
plates with the oligos which showed efficient silencing in 
the previous experiment (siCCND1 and siCOPZ1 smart 
pools, siMASTL #1 and #4 oligos), and the newly in 
house synthesized MASTL oligo #5 (see Figure S2 for 
silencing efficiency). Six days later the effect of MASTL, 
COPZ1 and CCND1 silencing on both cell growth and cell 
viability was evident by microscope observation: silenced 
BCPAP cultures were less confluent than control (siNT); 
in addition, they presented numerous floating (most likely 
dead) cells (Figure 5C). Trypan blue exclusion assay 
showed a reduction of cell growth by 69.5%, 59.7% and 
71% for siMASTL#1, #4 and #5, respectively; by 99.6% 
for siCOPZ1, by 91.5% for siCCND1 in comparison with 
the control (siNT). Western blot analysis performed at 
the end point of the experiment (Figure 5E) showed the 
complete abrogation of MASTL and Cyclin D1 protein 
expression. The same analysis was not feasible for COPZ1: 
due to the massive lethal effect of siCOPZ1, an insufficient 
amount of protein extract was recovered (data not shown).
Overall these results confirmed the growth inhibitory 
effect of Cyclin D1, MASTL, and COPZ1 gene silencing, 
thus providing evidence that BCPAP cells are addicted to 
the activity of these genes.
Effect of Cyclin D1, MASTL and COPZ1 gene 
silencing on different thyroid tumor cell lines
Irrespective of the specific oncogenic driving lesion 
and histotypes, thyroid tumors may share common effector 
Figure 3: Hit gene expression levels in PTC. Box plot distribution of RNAseq normalized expression values from the thyroid 
TCGA dataset of 15 selected genes in 58 matched normal (N) and PTC samples; A, B and C. represent genes overexpressed, equally or 
downregulated in PTC vs normal samples, respectively. The statistical significance of differences among the groups was assessed using 
Wilcoxon test.
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pathways for sustaining their transformed phenotype. To 
assess whether the survival genes confirmed in BCPAP 
cells are involved in such common pathways, we 
investigated the effect of CCND1, MASTL and COPZ1 
gene silencing in a panel of thyroid tumor-derived cell 
lines representative of different tumor histotypes.
Cell lines were transfected in 96 well plates with 
oligos targeting MASTL, CCND1 and COPZ1 genes and 
analyzed by CellTiter-Glo assay 10 days later. As reported 
in Figure 6A, gene silencing induced variable extents 
(15–95%) of cell growth inhibition in the majority of cell 
lines tested; no effect of CCND1 silencing in 8505C and 
KAT-18 cells, and of MASTL silencing in KAT-18 was 
observed. We also assessed viability of cells transfected 
in 6-well plates by trypan blue exclusion assay performed 
four-seven days after siRNAs transfection. As reported 
in Figure 6B, in all the cell lines analyzed (except KAT-
18), MASTL, COPZ1 and CCND1 gene silencing led to 
a significant decrease of cell viability: by 30–63% for 
siMASTL#1, by 35–75% for siMASTL#4, by 40–75% for 
siMASTL#5, by 75–99% for COPZ1 and by 70–94% for 
siCCND1. KAT-18 cells were found to be less sensitive to 
all the siRNA oligos: we found a decrease of cell growth 
by 31% for siMASTL#1, by 53% for si siCOPZ1 and by 
43% for CCND1, and by 52.3% for the siPSMC3 control, 
and no effect for siMASTL#4 and #5. The reduction of 
cell growth in all the cell lines was also documented by 
images taken before cell count: silenced cells appeared less 
confluent in comparison with the control, and presented 
variable fractions of detached and floating cells (Figure 
S3). Concomitantly, western blot in Figure 6C shows the 
high efficiency of MASTL, CCND1 and COPZ1 silencing 
in the same samples. The same analysis was not feasible 
for TPC1 cells transfected with siCOPZ1, due to massive 
lethal effect (data not shown). Importantly, this experiment 
revealed a growth inhibitory effect of CCND1 silencing 
in 8505C and KAT18, and of MASTL silencing in KAT18 
cells, which was not previously observed. This could be 
ascribed to variability in the experimental conditions and/
or silencing efficiency.
Figure 4: Hit gene expression in different thyroid tumor cells. A. Western blot analysis of MASTL, Cyclin D1, COPZ1, 
MAP4K5, PLA2G15 and COPE protein expression in a panel of thyroid cell lines; values represent band intensity, assessed by densitometry 
analysis, reported as the ratio to actin (loading control) and normalized for the Nthy-ori 3–1 value. B. RGS3, RASD1, NUDT9 and OXTR 
mRNA expression by RT-PCR in a panel of thyroid cell lines; GAPDH was used as housekeeping control. One out of three representative 
experiments is shown.
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We next performed some experiments to further 
corroborate the dependency of thyroid cancer cells upon 
Cyclin D1, MASTL and COPZ1 activity.
We tested thyroid tumor cell lines for susceptibility 
to palbociclib (PD-0332991), a specific inhibitor of 
Cyclin D1 associated kinases CDK4/6 [19]. Treatment 
with increasing doses of palbociclib showed a consistent 
antiproliferative effect in thyroid cancer cells, with an IC
50
 
value ranging from <0.003 μM for BCPAP cells to 0.20 
μM for HTC/C3 cells (Figure 7A and 7B). Representative 
images of thyroid cancer cell lines untreated or treated 
with 2.2 μM palbociclib for 72 h are reported in Figure 7C.
It has been reported that inhibition of MASTL induces 
multiple mitotic defects [20]. To investigate this issue in 
MASTL-depleted thyroid tumor cells, we performed the 
analysis reported in Figure 8. Asynchronous 8505C cells 
Figure 5: Effect of MASTL, CCND1 and COPZ1 silencing on BCPAP cells. A. Western blot analysis of MASTL, Cyclin D1 
and COPZ1 protein expression in Nthy-ori 3–1 cells, transiently transfected with siRNAs; actin was used as loading control. B. Scatter plot 
graph representing the percentage of cell growth (luminescence signal by CellTiter-Glo assay), normalized to that of Non Targeting oligo 
(siNT) 100%, 10 days after siRNA transfection in Nthy-ori 3–1 and BCPAP cells; siPSMC3 was used as positive control; one out of three 
representative experiments is shown. C. Representative pictures at 10X magnification of BCPAP cells 6 days after siRNA transfection. 
D. Cell proliferation assay of BCPAP cells 6 days after siRNAs transfection; the growth rate was determined by the trypan blue exclusion 
assay. Cell count of viable cells was normalized to that of siNT (100%); data represent the mean +/− sd of two independent experiments; 
the asterisks indicate differences significant by the unpaired Student’s t-test (**P < 0.01, ***p < 0.001). E. Western blot analysis of MASTL 
and Cyclin D1 expression performed in the same samples of panel D; actin was used as loading control for cell extracts.
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were transfected with the siMASTL or NT siRNA oligos 
and, 48 hours later, analyzed by immunofluorescence for 
β-tubulin, phospho-histone H3, and DNA for the presence 
of mitosis and nuclei aberrations. Several abnormalities 
associated with MASTL knockdown [20] were observed 
in MASTL-depleted 8505C cells. These include: 
Figure 6: Effect of CCND1, MASTL and COPZ1 silencing on different thyroid tumor cell lines. A. Scatter plot graph 
representing the percentage of cell growth (luminescence signal by CellTiter-Glo assay), normalized to that of Non Targeting oligo (siNT) 
100%, 10 days after siRNA transfection in a panel of thyroid cell lines; siPSMC3 was used as positive control. One out of three representative 
experiment is shown. B. Cell proliferation assay 4 days (for TPC1, 8505C and HTC/C3 cells), 5 days (for KAT-18 cells), 6 days (for BCPAP 
cells), 7 days (for WRO82–1 cells) after siRNAs transfection; the growth rate was determined by the trypan blue exclusion assay. Cell 
count of viable cells was normalized to that of siNT (100%); data represent the mean +/− sd of two independent experiments; the asterisks 
indicate differences significant by the unpaired Student’s t-test (*P < 0.05, **P < 0.01, ***p < 0.001). C. Western blot analysis of MASTL, 
Cyclin D1 and COPZ1 expression performed in the same samples of panel B; actin was used as loading control for cell extracts.
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multinuclear cells (panel B); abnormal mitotic figures, 
documented by the presence of condensed chromosomes 
that did not correctly align to metaphase plate (panel 
C); and chromatin bridges connecting daughter cells 
during anaphase (panel D). None of these abnormalities 
was observed in the control siNT cells (panel A). These 
results suggest that the growth inhibitory effect of MASTL 
silencing in thyroid tumor cells may be the consequence of 
failure of correct cell division process.
Shtutman et al [21] have recently reported that tumor 
cell COPZ1 vulnerability is related to downregulation of 
the paralogous COPZ2 gene. To assess whether this occurs 
also in thyroid tumor cells we investigated the expression 
of COPZ2 by Real Time PCR (Figure 9). With respect to 
control Nthy-ori 3–1 all the tumor cell lines analyzed, but 
WRO 82–1, showed downregulation of COPZ2 mRNA. 
This result indicates that for the majority of thyroid 
tumor cell lines the COPZ1 dependence may result from 
downregulation of COPZ2.
Collectively, our study identified Cyclin D1, 
MASTL and COPZ1 as thyroid cancer cell specific 
vulnerabilities, suggesting that they could provide a 
common therapeutic target in thyroid cancer treatment.
DISCUSSION
Despite much progress having been made in 
the genetic and molecular characterization of thyroid 
carcinoma, few or no therapeutic options are currently 
available for patients with aggressive and iodine-refractory 
thyroid tumors. Kinase inhibitors (KIs) in particular 
are being intensively studied in clinical trials in thyroid 
cancer: of note, various BRAF inhibitors for tumors that 
bear mutation of this gene [22–24], as well as a series 
of multi-kinase inhibitors, are emerging as potentially 
effective options in the treatment of advanced TC that 
are not responsive to traditional therapies [10]. However, 
the efficacy of KIs in patients with differentiated thyroid 
Figure 7: Thyroid cancer cell line sensitivity to palbociclib. A. Proliferation dose response curves of thyroid cancer cell lines 
treated with palbociclib for 72 hours. Nuclei were stained with Hoechst and counted in each well by means of an ArrayScan high-content 
screening reader. The cell count per field, derived from nuclear staining, was reported as proliferative parameter and normalized with respect 
to untreated controls (100%). Each value represents the mean and standard deviation of two replicates. B. IC50 values (μM) obtained using 
a sigmoid function for nonlinear interpolation of experimental points; for KAT-18, the IC50 value was derived from graphical analysis. 
C. Representative ArrayScan fields of the thyroid cancer cell lines untreated (CTRL) or treated with 2.2 μM palbociclib for 72 h and stained 
with Hoechst (bar = 50 μm).
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carcinoma has given contrasting evidence in the clinical 
trials, probably due to the drug resistance (as in other 
tumor types). Furthermore, KIs might cause significant 
side effects. This underlines the need for further efforts 
aimed at the identification of novel therapeutic approaches 
for thyroid tumors [10].
Large-scale siRNA-based functional screening 
on cancer cell lines are nowadays widely used for 
the identification of tumor cells vulnerabilities to be 
explored for therapeutic purposes [12]. Interestingly, 
such approaches allow the discovery of target genes 
that are required by tumor cells in specific contexts, 
thus providing the premise for the identification of 
therapeutic approaches with no or limited effect on 
normal cells.
In this paper, we described, for the first time, 
a high-throughput siRNA phenotypic screening 
campaign for the identification of thyroid tumor cell 
vulnerabilities. By screening a “druggable genome” 
siRNA library, we identified 398 siRNA oligos (targeting 
386 genes) which preferentially inhibited the growth 
of the BCPAP papillary thyroid cancer cell line as 
compared to that of non-transformed thyrocytes (Nthy-
ori 3–1). Fifteen out of 28 hit genes were technically 
confirmed. The relevance of this screening study and 
its ability to identify bona fide cell vulnerabilities is 
supported by two lines of evidence. First, BRAF was 
detected among the top BCPAP vulnerability genes. This 
was expected, as the dependency of BCPAP cells upon 
BRAFV600E oncogene has been previously documented 
[16]. Second, the screen efficiently detected genes that 
were indiscriminately lethal for both the Nthy-ori 3–1 
and BCPAP cell lines: in many cases, these were found 
to be genes that encode proteins of essential function 
and have been identified as survival genes in previous 
functional screenings [14, 18, 25].
Figure 8: MASTL silencing causes abnormal mitotic figures. 8505C cells transfected with the indicated siRNAs were analyzed 
by immunofluorescence for β-tubulin (green), phospho-histone H3 (red) and DAPI (DNA, blue). Arrows indicate normal mitosis 
(A), multinuclear cell (B), condensed chromosomes not correctly congressed to metaphase plate (C), DNA bridge (D) (Magnification 40x).
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Analyzing the thyroid TCGA data set, we found 
no mutations affecting the confirmed hit genes, besides 
BRAF, suggesting that functional alterations in PTC may 
be excluded. With respect to gene expression the hit genes 
were found to be either equally or differentially (both 
upregulated and downregulated) expressed in PTC in 
comparison with normal samples.
Three hit genes, namely Cyclin D1, MASTL and 
COPZ1, were selected for further confirmation. Their 
vulnerability for BCPAP cells was confirmed by using 
siRNA oligos different from the screening. Interestingly, 
we showed that the silencing of Cyclin D1, MASTL 
and COPZ1 reduces the growth and survival of several 
different TC cell lines, regardless the histotype and the 
oncogenic lesion.
Cyclin D1 is an important cell cycle regulator 
that promotes G1/S phase transition by activation of 
CDK4 and CDK6 kinases [26]. Cyclin D1 is frequently 
overexpressed in human cancer, and it has been proposed 
as a therapeutic target. Several approaches aimed at its 
inhibition are presently ongoing. As for all cyclins, while 
the lack of enzymatic activity makes direct targeting of 
Cyclin D1 difficult, a much more amenable approach is 
to target cyclin functions by inhibition of their associated 
kinases. Indeed, several CDK4/6 inhibitors have shown 
promising antitumor activity in experimental systems, and 
are presently under clinical evaluation for different tumor 
types [26]. Alternative approaches are also currently under 
investigation, including the targeting of factors which 
regulate Cyclin D1 protein turnover, such as the USP2 
deubiquitinase [27]. In thyroid carcinoma overexpression 
of Cyclin D1 at mRNA and protein level has been 
documented, and has been suggested to contribute to 
tumor progression [28–30]. However, no functional data 
dissecting the role of Cyclin D1 in thyroid tumorigenesis 
are available. We found that Cyclin D1 inhibition led to a 
consistent reduction of cell growth in all the thyroid tumor 
cell lines analyzed. This was not associated with Cyclin D1 
expression level, suggesting that the dependency of 
thyroid tumor cells upon Cyclin D1 activity may not 
require aberrant protein expression. We also found that 
all the thyroid tumor cell lines are sensitive to palbociclib 
(PD-0332991), a selective CDK4/6 inbititor approved for 
the treatment of ER+/HER2- breast cancer in combination 
with letrozole [31]. Whether the antiproliferative effect 
after Cyclin D1 silencing or palbociclib treatment in 
thyroid tumor cells, but not in normal ones, is related 
to the presence of functional pRB, as reported for other 
tumor types [19], remains to be investigated. Our studies 
identified Cyclin D1 as a therapeutic target for thyroid 
tumors, and provide a rationale for preclinical and clinical 
studies aimed to assess the efficacy of inhibitors of 
Cyclin D1 function in thyroid cancer.
MASTL (Microtubule associated serine/threonine 
kinase-like) regulates mitosis progression by inhibiting 
PP2A/B55δ, the principal protein phosphatase complex 
that dephosphorylates CDK1 substrates. MASTL activity 
is essential for prevention of defects in chromosome 
condensation and segregation, prometaphase arrest and 
mitotic collapse during cell division [32]. Furthermore, 
it modulates DNA damage response by promoting 
checkpoint recovery and cell cycle progression [33]. 
Little is known about MASTL in cancer. Nagel et al. 
[34] reported that the knockdown of MASTL, through 
promoting defects in in cytokinesis and a shortened G2/M 
phase arrest, is capable of sensitizing lung cancer cells 
to radiations. Notably, MASTL inhibition affects tumor 
cell but not normal primary fibroblast radiosensitivity, 
thus suggesting that MASTL could represent a druggable 
target to combine with radiotherapy. In head and neck 
carcinoma MASTL was found involved in progression and 
recurrence and proposed as therapeutic target [35]. We 
Figure 9: Expression of COPZ2 in thyroid tumor cell lines. Real-time PCR analysis of COPZ2 gene expression; results are 
presented as log10-transformed relative quantity (RQ) of COPZ2 mRNA normalized for HPRT1 housekeeping gene expression. Data 
represent the mean +/− sd of three independent experiments.
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have identified MASTL as vulnerability gene for thyroid 
carcinoma. In fact, MASTL silencing interfered with the 
growth of all thyroid cell lines, although with variable 
extents. Moreover, evidence of failure of correct cell 
division process was found in MASTL-depleted cells. 
Of note, our study identified MASTL as a novel mitotic 
machinery target in thyroid tumor, in addition to PLK1 and 
AURKs, both overexpressed and proposed as therapeutic 
targets in ATC [36, 37]. Remarkably, we found that 
MASTL vulnerability in thyroid tumor cell lines is not 
associated with overexpression; on the contrary, MASTL 
is slightly downregulated in PTC samples and in thyroid 
tumor cells. Overall these findings highlights the need of 
further investigation in order to assess whether MASTL 
may represent a useful target in different tumor types, as 
well as the search/design of strategies to block the activity 
of MASTL, for which no specific inhibitors have been so 
far identified.
COPZ1 (coatomer protein complex ζ1) is a subunit 
of coatomer protein complex I (COPI), a secretory vesicle 
coat protein complex involved in Golgi apparatus and 
endoplasmic reticulum traffic, endosome maturation, 
autophagy [38, 39] and lipid homeostasis [40]. COPZ1 has 
been proposed as a tumor-specific gene target. It has been 
shown that tumor cells become dependent on COPZ1, as 
a result of a tumor-specific downregulation of its isoform 
COPZ2 [21]. Interestingly, COPZ1 knockdown kills both 
proliferating and non-dividing tumor cells, but does not 
affect normal cells, thus suggesting that COPZ1-targeting 
therapies have the potential for eradicating cancer cells, 
independently of whether they are actively proliferating. 
Our screening and validation identified COPZ1 as a 
thyroid tumor cell specific survival gene. Interestingly, 
we also found a significant downregulation of COPZ2 
mRNA expression in the majority of thyroid tumor cell 
lines. An exception is represented by WRO82–1 which, 
despite expressing COPZ2 mRNA levels higher than 
control, is sensitive to COPZ1 silencing. This raises the 
possibility that other mechanisms, in addition to COPZ2 
downregulation, may be involved in determining tumor 
cell COPZ1 dependency. Whether the thyroid tumor cell 
dependency upon COPZ1 is related to downregulation 
of COPZ2 isoform, or to deregulation of other COPI 
components, as well as the modalities through which 
COPZ1 inhibition leads to growth suppression of thyroid 
tumor cells, remains to be investigated.
In conclusion, by a siRNA-based functional 
screening we have identified a signature of vulnerability 
for thyroid carcinoma cells, thus identifying novel 
potential therapeutic targets in this setting. Further 
characterization of three hit genes, namely Cyclin D1, 
MASTL and COPZ1, demonstrates that their abrogation 
selectively impairs the growth of several thyroid tumor 
cell lines, irrespective of the histotype or driving genetic 
lesion, thus indicating that they represent common 
examples of “non-oncogene addiction” in thyroid 
cancer. Variable extents of cell growth inhibition among 
the cell lines upon silencing of these target genes were 
observed. Whether these differences are related to 
genetic background and/or intrinsic sensitivity to cell 
death remains to be investigated. The dependency upon 
Cyclin D1, MASTL and COPZ1 activity is restricted to 
tumor cells and not normal thyroid cells, as previously 
reported for other tumor types [21, 27, 34, 35]. Thus 
we envisage that Cyclin D1, MASTL and COPZ1 are 
attractive targets for new therapeutic approaches for 
thyroid cancer which spare normal cells and which would 
thus have limited side effects.
MATERIALS AND METHODS
Cell lines
Nthy-ori 3–1 cell line (SV-40 immortalized 
normal human thyroid follicular cells) was purchased 
from European Collection of Cell Cultures (ECACC) 
(Salisbury, UK); BCPAP, TPC-1, WRO82–1, 8505C, 
KAT-18 were obtained from Prof. A. Fusco (University 
Federico II, Naples, IT); HTC/C3 was purchased from 
Riken Cell Bank (Tsukuba, Japan).
Nthy-ori 3–1 and the PTC-derived BCPAP cell 
lines were cultured in RPMI 1640 medium (Gibco Life 
Technologies, Carlsbad, CA, USA) supplemented with 
10% (v/v) heat-inactivated fetal bovine serum (FBS) 
(EuroClone, Pero, Italy), penicillin (100 U/ml) and 
streptomycin (100 mg/ml). The other cell lines PTC-
derived TPC1; FTC-derived WRO82-1; ATC-derived 
8505C, KAT18 and HTC/C3 were maintained in DMEM 
(Gibco, Life Technologies, Carlsbad, CA, USA) medium 
containing 10% FBS and 2 mM glutamine. All cell 
lines were cultured as monolayer at 37°C in a 5% CO
2
 
humidified atmosphere.
Cell lines were genotyped at the Fragment 
Analysis Facility of Fondazione IRCCS Istituto 
Nazionale dei Tumori, using Stem Elite ID System 
(Promega Corporation, Madison, USA) according to 
the manufacturer’s instructions and ATCC guidelines. 
The profiles obtained matched to their original profiles 
[41, 42]. WRO82–1 profile matched to that reported by 
Xu et al. [43] and HTC/C3 to that reported by JCRB 
Cell Bank (http://cellbank.nibio.go.jp/legacy/celldata/
jcrb0164.htm).
Mycoplasma contamination was tested periodically 
and found negative in all cell lines (PCR Mycoplasma 
Detection Set, TAKARA Bio Inc).
siRNA transfection optimization
Optimal conditions for reverse siRNA transfection 
of Nthy-ori 3–1 and BCPAP cells were determined by 
comparing cell viability after transfecting a positive 
control siRNA targeting the proteasome subunit PSMC3, 
and a negative control non-targeting oligo (siNT), in the 
presence of different cell densities and Lipofectamine 
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RNAiMAX reagent (Invitrogen Life Technologies 
Carlsbad, CA, USA) concentrations. The best reagent and 
transfection conditions were those that produced the least 
(<10%) cell loss with siNT, and the greatest (>90%) cells 
decrease with the lethal PMSC3 oligo.
High throughput siRNA screening
The human Silencer Select Druggable Genome 
siRNA Library V4 (Ambion Life Technologies, Carlsbad, 
CA, USA) is composed by 309 96-well plates containing 
25139 unique lyophilized siRNA oligos targeting 9031 
human genes (three oligos per gene, on average). Stock 
plates were obtained by dissolving oligonucleotides with 
100 μl of DEPC-treated water (Ambion Life Technologies, 
Carlsbad, CA, USA) (final concentration 2.5 μM) and 
by adding NT and PSMC3 siRNA oligos (2.5 μM) in 
alternate position in the empty column 12 of each plate 
(see Figure 1A). Library oligonucleotides were further 
diluted to 800 nM with DEPC-treated water (mother 
plates). Daughter plates were prepared by transferring 
17 μl/well of mother plate oligonucleotide solution in 
plates prefilled with 119 μl of Opti-MEM® I medium 
(Gibco Life Technologies, Carlsbad, CA, USA) containing 
4 μl/ml of lipofectamine® RNAiMAX. The solution was 
gently mixed by pipetting and incubated for 20 minutes 
room temperature, and then 30 μl/well were split into four 
transfection plates, to which 120 μl/well of cell suspension 
(1250 cells /ml) were added. Two plates for each cell line 
(Nthy-ori 3–1 and BCPAP) were used. Each well contained 
150 cells, 20 nM oligo, RNAiMAX 0.1% vol/vol. 
After transfection, plates were kept at room temperature 
for 15–20 minutes to minimize uneven distribution of 
the cells in each well [44], and then incubated at 37°C 
for 7–8 days by stacking in alternate orientations to limit 
uneven medium evaporation and to facilitate gas exchange. 
As a result of this procedure, no edge effects or evidences 
of asymmetric cell growth emerged from screening data 
analysis, and visual inspection of plate scans confirmed 
homogeneous cell distribution in all plates. The following 
custom-barcoded 96-well microplates purchased from 
Greiner Bio-One (Frickenhausen, Germany) were used: 
U-bottom microplate for mother and daughter plates; 
CELLSTAR®, Black /μClear® plate for transfection plates. 
All liquid handling and plate tracking were performed with 
a Freedom EVO® robotic platform (Tecan, Männedorf, 
Switzerland); disposable MCA384 Tips and reservoirs 
were purchased from Tecan.
siRNAs
Information on siRNAs used in the transfection 
setup, as control in the screening, or in confirmation 
and validation studies is summarized in the Table S4. 
Oligos produced in house were designed and synthesized 
with stabilizing modifications (i.e.: phosphorylation in 
5′ position of the antisense strand and 2′-O-methyl ribosyl 
substitution at position 2 of the sense strand) known to 
reduce off-target effect [45].
Colony formation assay (CFA)
Seven-eight days after transfection, cells were fixed 
with formaldehyde 3.7% v/v solution at room temperature 
for 30 minutes, washed with PBS and stained for 20 minutes 
with a PBS solution containing 0.05% v/v Triton® X-100 
(Sigma-Aldrich, St. Louis, MO, USA) and TO-PRO®-3 
iodide (Invitrogen Life Technologies (Carlsbad, CA, USA) 
diluted 1:1000. After a second wash, 50 μl PBS were left 
in each well. Plates were sealed and analyzed with an 
Odyssey® infrared scanner (LI-COR Biosciences, Lincoln, 
NE, USA) which provides whole-well fluorescence 
quantification of cells stained with TO-PRO®-3 dye. The 
fluorescence intensity (FI) was considered as readout, which 
is proportional to both colony number and size.
Screening data analysis
FI values were registered in a proprietary Oracle 
database through Symyx Assay Explorer® and matched with 
the library information. The FI of each sample was divided 
by the average FI of the three non-targeting oligos within 
the same plate (set as 100%) for interplate normalization. 
TIBCO SpotFire (Boston, MA, USA) and Microsoft Excel 
(Redmond, WA, USA) were used for statistical analysis and 
visualization of screening data distributions. The means and 
standard deviations of FI (% siNT) values and z*-scores [46] 
were calculated from the two technical replicates for each 
cell line and reported in  Table S1 (Excel file with screening 
results).
To identify genes whose RNAi-mediated inhibition 
affects the growth of BCPAP but not Nthy-ori 3–1 cells, a 
distance factor (d) expressed as:
 
d = "1100 − % NTONthy−ori 3−1 2 2 + 1% NTOBCPAP 2 2
was introduced. “d” represents the distance 
between the %NT value of any given siRNA oligo and 
the point of maximal lethality towards BCPAP without 
effects on Nthy-ori 3–1 (coordinate %NT
Nthy-ori 3–1
 = 100, 
%NT
BCPAP
 = 0). Screening hits were selected among 
siRNA oligos with significantly low d values, whereas 
oligos either equally inactive on both cell lines, or equally 
lethal on both cell lines, or preferentially lethal on Nthy-
ori 3–1, are excluded. Based on the distribution analysis 
of d scores, a -3σ threshold (corresponding to d = 47.2) in 
the primary screening, and a -2σ threshold (corresponding 
to d = 49.8) in the confirmation study, were applied to 
define hits.
Cell proliferation assay
Cells (500 cells/well) were reverse transfected 
in 96-well plate with 20 nM specific siRNAs using 
Oncotarget34645www.impactjournals.com/oncotarget
the Lipofectamine RNAiMAX reagent, according to 
manufacturer’s instruction. Ten days later, cell viability 
was assessed by CellTiter-Glo Luminescent Cell Viability 
Assay (Promega Corporation, Madison, USA), performed 
as recommended by the supplier. Luminescence signals 
were acquired using a microplate reader (TecanUltra, 
Tecan Trading AG, Switzerland).
For the trypan blue exclusion assay, BCPAP and 
8505C (1 × 105), TPC-1 (6 × 104), WRO82–1, HTC/C3 
and KAT-18 (8 × 104) cells were transfected the day later 
in 6-well plate with 20 nM of specific siRNAs using 
Lipofectamine RNAiMAX, according to manifacturer’s 
instruction. At different days after transfection (4 days 
for TPC1, 8505C and HTC/C3 cells; 5 days for KAT-18 
cells, 6 days for BCPAP cells, 7 days for WRO82–1 cells) 
the fraction of viable and dead cells was analyzed. For 
palbociclib experiments, cells (8000 cells/well) were seeded 
in black/clear bottom 96-well plates and, the following 
day, treated with increasing doses of the palbociclib 
(PD 0332991) inhibitor (Selleck Chemicals, Houston, 
TX, USA, cat. S2768). After 72 hours, cells were fixed 
with 3.7% paraformaldehyde solution for 30 minutes at 
RT, washed and stained with 1 mg/ml Hoechst 33342. The 
plates were analyzed with an ArrayScan VTI high-content 
screening reader (Thermo-Fisher Scientific, Pittsburgh, 
PA): at least 800 cells were acquired in each well with a 
10X objective in one fluorescence channel (XF93 optical 
filter set). Cell nuclei were automatically recognized and 
counted in ten fields to estimate the cell number per well 
as proliferation readout. IC50 values were calculated by 
sigmoid curve fitting of experimental points.
Gene Ontology and gene expression analyses
The functional annotation analysis on the identified 
gene lists was performed by means of the Database for 
Annotation, Visualization and Integrated Discovery 
(DAVID) tool v6.7 (https://david.ncifcrf.gov/). Gene 
Ontology (GO) Biological Process (BP) and Molecular 
Function (MF) terms were used as annotation categories 
and medium classification stringency was set for the 
functional annotation clustering analysis. The annotation 
clusters with an Enrichment score (ES) >1.3 were selected 
and representative GO-terms were indicated for each 
significant cluster. To assess the interactions between the 
validated fifteen genes, network analysis was carried out 
using the Ingenuity Pathway Analysis Tool (Ingenuity® 
Systems, http://www.ingenuity.com). The Core Analysis 
function was used to compare genes pooled from literature 
and other molecules in IPA’s database.
The thyroid TCGA data set, containing the molecu-
lar data on nearly 500 PTC, is the largest data collection so 
far available (https://tcgadata.nci.nih.gov/tcga/tcgaCancer-
Details.jsp?diseaseType=THCA&diseaseName=Thyroid). 
Illumina HiSeq Level 3 data were downloaded from TCGA 
Data Portal and RSEM [47] gene normalized expression 
values of selected genes were derived for 58 PTC patients, 
in tumor and adjacent normal samples, respectively. The 
statistical significance of gene expression difference 
between PTC and normal groups was assessed using Wil-
coxon test.
RNA extraction, RT-PCR and Real time PCR
RNA extraction and RT-PCR were performed 
as previously described [48], using the follow-
ing primer: 5′-ATGAGAGGCCTGTGGAGCACT-3′ 
(forward), 5′-TCATGTGTCGACTTGCAGGAG-
3′(reverse) for RGS3 fragment amplification; 
5′-GCAGATCCTCAGATCAGTGAA-3′(forward), 
5′-TATAATGGGATCTGCAGCGTG-3′ (reverse) for 
NUDT9; 5′-CGAGGTCTACCAGCTCGACAT-3′ (for-
ward), reverse 5′-CACGTCCACGTTCTCCTTGGT-3′ 
(reverse) for RASD1; 5′-ATGTGGAGCGTCTGGGAT-
GC-3′ (forward), 5′-GCTCAGGACAAAGGAGGACG-3′ 
(reverse) for OXTR [49].
For Real Time PCR analysis 20 ng of retrotranscribed 
RNA were amplified in PCR reactions carried out in 
triplicate on an ABI PRISM 7900 using TaqMan gene 
expression assays (Applied Biosystem, Foster City, 
CA). Hs00212698_m1 was used for COPZ2 expression; 
human HPRT1 (HPRT-Hs99999909_A1) was used as 
housekeeping gene for the normalization among samples. 
Data analysis was performed using the SDS (Sequence 
Detection System) 2.4 software.
Western blot analysis
Western blot analysis was performed as previously 
described [48], using the following antibodies: anti-
Cyclin D1 (DCS-6: sc-20044, 1:500), anti-COPE, 
(E-20: sc-12104, 1:500), anti-PLA2G15 (LYPLA3, 
H-167: sc-135297, 1:500), anti-MAP4K5 (KHS, N-19: 
sc-6429, 1:1000), anti-COPZ1 (D-20: sc-13349, 1:750), 
anti-GAPDH (6C5, sc-3223: 1:2000) purchased from 
Santa Cruz, CA, USA; anti-MASTL (ab86387, 1:7000) 
from Abcam, Cambridge, UK; anti-β-actin (A2066, 
1:5000) and anti-vinculin (V9131, 1:1000) from Sigma-
Aldrich, St Louis, Mo, USA.
Immunofluorescence analysis
Cells growing on glass coverslips were transfected 
with 20 nM NT or MASTL siRNAs and, 48 hours later, 
fixed for 10 minutes with 4% paraformaldehyde (Sigma 
Aldrich, St Louis, Mo, USA). After permeabilization 
for 10 minutes with 1% BSA and 0.1% Triton X-100 in 
PBS, and incubation for 30 minutes with 1X blocking 
solution (2% BSA in PBS), cells were incubated with 
anti-β-tubulin (clone TUB 2.1: T4026, 1:400, Sigma 
Aldrich, St. Louis, MO, USA) or anti-histone H3 (phospho 
S10) (E173: ab32107, 1:1000, Abcam, Cambridge, 
UK) primary antibodies for 1 hour. After washing with 
PBS, cells were incubated with Alexa Fluor® 546 rabbit 
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(1:500, Invitrogen/Molecular Probes®) and Alexa Fluor 
488® mouse (1:500, Invitrogen/Molecular Probes®) 
secondary antibodies for 1 hour. Slides were then 
prepared using ProLong Diamond Antifade mountant 
with DAPI (P36966, Molecular Probes®) and imaged with 
immunofluorescence microscopy (Eclipse E1000; Nikon 
Instruments, Inc. NY, USA).
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SUPPLEMENTARY FIGURES AND TABLES 
Supplementary Figure S1: A. Pie chart of functional annotation clustering analysis on 386 genes by DAVID 6.7 tool. Only 15 
annotation clusters with an Enrichment Score (ES) > 1.3 are reported. A representative Biological Process (BP) or Molecular Function (MF) 
GO-term and the percentage of the genes on the 382 DAVID IDs globally identified are indicated for each significant annotation cluster; 
for each selected cluster the ES is also indicated. B. Visual representation of the two principal networks generated by Ingenuity Pathway 
Analysis (IPA) including the fifteen validated hits. Solid lines represent a direct interaction between the two gene products and dotted lines 
mean an indirect interaction.
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Supplementary Figure S2: western blot analysis of MASTL protein expression in Nthy-ori 3–1 cells, transiently transfected with 
MASTL#5 siRNA; actin was used as loading control.
www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2015
Supplementary Figure S3: representative pictures at 10X magnification of TPC-1, WRO82–1, 8505C, HTC/C3 and KAT-18 cells, 
taken before the trypan blue exclusion assay
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Supplementary Table S1: List of 25139 siRNA oligonucleotides of the human Silencer Select 
Druggable Genome siRNA Library V4 (Ambion Life Technologies, Carlsbad, CA, USA) and screening 
results. Average and standard deviation (StDev) of the fluorescence intensity (FI) normalized on siNT 
(%NT), and average and standard deviation (StDev) of z* scores for BCPAP and Nthy-ori 3–1, distance 
factor (d) and binned d (based on σ distribution) are shown. The gene symbols, full gene names, Refseq 
(http://www.ncbi.nlm.nih.gov/refseq/about/) accession numbers, siRNA batches and their corresponding 
plate blocks were provided by Ambion.
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Supplementary Table S2: List of 398 siRNA oligonucleotides resulted to preferentially inhibit the 
proliferation of BCPAP cells with respect to Nthy-ori 3–1 (d < -3σ) and thus defined as “differential hits”. 
www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2015
Supplementary Table S3: List of 1695 siRNA oligonucleotides resulted to inhibit the proliferation of 
both BCPAP and Nthy-ori 3–1 (signal intensity < 20% siNT), therefore defined as “lethal hits”. 
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Supplementary Table S4: siRNA oligos.
siRNA Sequence/catalog number Source Used in
siNT 5′-UGGUUUACAUGUCGACUAAtt-3′ in house
transfection 
setup, screening, 
confirmation
siPSMC3 5′-CGGCUGAAGUGCGCAAUAAtt-3′ in house
transfection 
setup screening, 
confirmation
siNT ON-TARGET plus Non-targeting Pool siRNA D-0018–10–05
ThermoScientific, Dharmacon Inc., 
Chicago, IL, USA
validation
siPSMC3 MISSION esiRNA EHU107331 Sigma-Aldrich, St. Louis, MO, USA validation
siMASTL #1 ON-TARGET plus set of 4 siRNAs J-004020–12
ThermoScientific, Dharmacon Inc., 
Chicago, IL, USA
validation
siMASTL #2 ON-TARGET plus set of 4 siRNAs J-004020–11
ThermoScientific, Dharmacon Inc., 
Chicago, IL, USA
validation
siMASTL #3 ON-TARGET plus set of 4 siRNAs J-004020–10
ThermoScientific, Dharmacon Inc., 
Chicago, IL, USA
validation
siMASTL #4 ON-TARGET plus set of 4 siRNAs J-004020–09
ThermoScientific, Dharmacon Inc., 
Chicago, IL, USA
validation
siMASTL#5 5′-UGUGGAUUCUGGUGGGAUAdTdT 3′ in house validation
siCCND1 MISSION esiRNA EHU153321 Sigma-Aldrich, St. Louis, MO, USA validation
siCOPZ1 MISSION esiRNA EHU1040461 Sigma-Aldrich, St. Louis, MO, USA validation
List of siRNA oligos used in the transfection setup, as control in the screening, or in confirmation and validation studies
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Abstract  
Thyroid carcinoma is generally associated with good prognosis, but no effective treatments are 
currently available for aggressive forms not cured by standard therapy. To find novel therapeutic 
targets for this tumor type, we had previously performed a siRNA-based functional screening to 
identify genes essential for sustaining the oncogenic phenotype of thyroid tumor cells, but not 
required to the same extent for the viability of normal cells (non-oncogene addiction paradigm). 
Among those, we found the coatomer protein complex ζ1 (COPZ1) gene, which is involved in 
intracellular traffic, autophagy and lipid homeostasis. In this paper, we investigated the mechanisms 
through which COPZ1 depletion leads to thyroid tumor cell death. We showed that siRNA-
mediated COPZ1 depletion causes abortive autophagy, endoplasmic reticulum stress, unfolded 
protein response and apoptosis. Interestingly, we observed that mouse tumor xenografts, locally 
treated with siRNA targeting COPZ1, showed a significant reduction of tumor growth. 
On the whole, we demonstrated for the first time the crucial role of COPZ1 in the viability of 
thyroid tumor cells, suggesting that it may be considered an attractive target for novel therapeutic 
approaches for thyroid cancer.  
 
Keywords: thyroid carcinoma, COPZ1, non-oncogene addiction, cell death  
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1. Introduction  
Cancer cells often depend on non mutated genes and pathways to support their unchecked growth. 
The activity of these genes is essential for tumor cells, but not required to the same extent by 
normal cells; this concept is known as "non-oncogene addiction" (NOA) paradigm [1]. NOA genes 
represent tumor vulnerabilities and their inhibition results in the failure of the oncogenic phenotype. 
Nowadays, large-scale siRNA-based functional screening of cancer cell lines represent a powerful 
strategy for the identification of NOA genes that can be investigated as therapeutic targets for many 
types of tumors [2].We used this approach to unveil nodal points for therapeutic intervention for 
thyroid carcinoma (TC), which represents the most frequent endocrine cancer, with a rapidly 
increasing incidence [3]. 
The majority of TC originates from epithelial cells and includes well-differentiated papillary (PTC) 
and follicular (FTC) carcinomas, poorly differentiated (PDTC) and undifferentiated anaplastic 
carcinomas (ATC). Most TC are effectively treated by standard therapy, involving surgery, thyroid 
stimulating hormone and radioiodine. Nevertheless, a fraction of patients cannot be cured due to 
local recurrence (in up to 20% of patients), distant metastasis (in approximately 10% at 10 years 
[4]) and/or radioresistant disease. Furthermore, patients with PDTC and ATC have a very poor 
prognosis, with survival of few months in the case of ATC [5;6]. Even though recent molecular 
findings allowed the development of several therapies designed to specifically target thyroid 
oncoproteins or their downstream pathways, this strategy showed modest results and only partial 
response [7;8]. Few or no therapeutic options are currently available for patients with aggressive 
and iodine-refractory thyroid tumors. Thus, there is a need to better understand the mechanisms of 
thyroid carcinogenesis and to improve the treatment of the most aggressive tumor forms not curable 
by standard therapy. 
We have recently discovered several thyroid tumor cell vulnerabilities. By screening a siRNA 
library, we identified a set of genes whose silencing inhibited the growth of a panel of thyroid tumor 
cells, but not of normal immortalized thyrocytes. The COPZ1 gene was found among the top ranked 
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genes [9]. COPZ1 (coatomer protein complex ζ1) belongs to the coatomer protein complex I 
(COPI), an heptameric complex which is involved in: assembly of coated vesicles on Golgi 
membranes, retrograde transport of luminal and membrane proteins in the ER-Golgi secretory 
pathway, endosome maturation, autophagy [10;11] and lipid homeostasis [12]. It has been 
demonstrated that COPZ1 knockdown causes cell death in both proliferating and nondividing tumor 
cells. Unlike tumor cells, normal cells are not sensitive to COPZ1 inhibition [13]. We identified 
COPZ1 as a thyroid tumor cell specific survival gene, as its inhibition induced cell death in tumor 
cell lines but not in immortalized thyrocytes. This evidence, together with a not significant variation 
of expression and absence of mutations in PTC, allowed us to classify OPZ1 as an example of 
"non-oncogene addiction” for thyroid cancer cells [9]. 
Here we investigated the mechanisms through which COPZ1 depletion leads to thyroid tumor cell 
death and explored its potential use as therapeutic target for thyroid carcinoma. We found that cell 
death induced by COPZ1 depletion is associated with abortive autophagy, ER stress, UPR and 
apoptosis. Interestingly, local treatment with siCOPZ1 oligos reduced tumor growth in an in vivo 
model of thyroid carcinogenesis. 
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2. Materials and Methods  
2.1 Cell lines  
Thyroid tumor cell lines, primary thyrocytes and mammary epithelial h-TERT-HME1 cells were 
cultured as previously described [9;14;15]. Source and culture conditions are reported in 
Supplementary. GFP-LC3 stable cell lines were generated by transfecting 2µg of pEGFP-LC3 
plasmid (from Tamotsu Yoshimori’s laboratory [16], using the Lipofectamine 3000 reagent 
(Invitrogen Life Technologies, Carlsbad, CA, USA) for TPC-1, and Lipofectamine LTX (Invitrogen 
Life Technologies) for 8505C cells, according to manufacturer’s instruction. Transfected cells were 
selected and propagated in medium containing G418 (500µg/ml, Invitrogen Life Technologies).  
 
2.2 Detection of LC3 puncta 
Cells growing on glass coverslips were transfected as described below and 24h, 48h, 72h later fixed 
for 20 minutes with 4% paraformaldehyde. After washing with PBS, cells were treated with the 
ProLong Diamond Antifade mountant with DAPI (P36966, Molecular Probes, Invitrogen Life 
Technologies) and imaged with immunofluorescence microscopy (Eclipse E1000; Nikon 
Instruments, Inc. NY, USA). The percentage was calculated as the ratio between cells displaying 
LC3 puncta and total cells (at least 150), considering six randomly selected 60X fields. 
 
2.3 siRNA reagents and transfection 
siRNA transfection was performed using 20 nM of siRNA oligos (see list in Supplementary) and 
the Lipofectamine RNAiMAX reagent (Invitrogen Life Technologies), according to manufacturer’s 
instruction.  
 
2.4 Colony formation assay  
Cells were plated in 100 mm  dishes and transfected the following day with 20 nM of siRNAs. One 
day later, cells were collected and plated as follows: 2x104 cells in 24 well-plates for colony 
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formation assay; 1.5x105 cells in 60 mm dishes for western blot analysis. For the colony formation  
assay, cells were fixed five days later with formaldehyde 3.7% v/v solution for 30 minutes, washed 
with PBS and stained for 20 minutes with 0.1% crystal violet (w/v). Pictures were taken using an 
Epson image scanner.  
 
2.5 Western blot analysis 
WB analysis was performed as previously described [17]. The list of antibodies is provided in 
Supplementary.  
 
2.6 RNA extraction and Real time PCR 
RNA extraction and Real time PCR were performed as previously described [17]. The following 
TaqMan gene expression assays (Applied Biosystem, Foster City, CA) were used: Hs01023197_m1 
for COPZ1 and Hs00358796_g1  for CHOP expression; Hs02800695_m1 for HPRT1, used as 
housekeeping gene for normalization among samples.  
 
2.7 Apoptosis assay 
Cells were transfected with 20 nM of siRNA oligos in the presence of 2 µM of the fluorogenic 
substrate for activated caspase-3/7 (CellEvent™ Caspase-3/7 Green Detection Reagent, Invitrogen 
Life Technologies). Live-cell fluorescence images were taken 72h later with microscope (Eclipse 
TE2000-S; Nikon Instruments). 
 
2.8 In vivo studies 
Female CD-1 nu/nu mice (5-weeks old) (Charles River, Calco, Italy) were injected subcutaneously 
into the left flank with 8505C cells (10x106). When xenograft tumors reached the mean volume of 
0.085 mm3 (range 0.040-0.144), they were randomly divided into three groups and then locally 
treated with 20 µg of siCOPZ1 oligos (4457308, Ambion® ID s22427) or non-targeting oligos 
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(4457289, Ambion® In Vivo Negative Control #1 siRNA) mixed in 50 µl of MaxSuppressor™ In 
Vivo RNA-LANCEr II reagent (Bioo Scientific, Austin, TX, USA), or with MaxSuppressor™ only. 
Treatments were carried out at day 17, 20, 23, 27, 30 after cell injections. Tumor growth was 
followed for 34 days and assessed by monitoring tumour weight (TW), as previously described 
[18]. Animal studies were reviewed and approved by the Ethics Committee for Animal 
Experimentation of the hosting institution and are in accordance with the guidelines of the UK 
Coordinating Committee for Cancer Research [19].  
 
2.9 Immunohistochemistry 
Serial sections from paraffin-embedded tumor xenografts (2-µm thick) were stained with 
hematoxylin and eosin and evaluated under a light microscope to assess the pattern of tumor 
growth. Antigen retrieval was performed using 1 mM citrate buffer (pH 6), then sections were 
immunostained with a primary rat polyclonal antibody anti-human COPZ1 (1:400 SAB4500896 
Sigma-Aldrich St Louis, Mo, USA), anti-human Ki-67 (Mib1) (1:200 M7240 Dako, Agilent 
Technologies, CA, USA). Immunostains were performed using standard immunoperoxidase 
protocol followed by diaminobenzidine chromogen reaction (Dako REAL™ EnVision™ Detection 
System, K5007 Dako). The intensity of staining for COPZ1 was scored as low (1+), medium (2+) 
or high (3+). The percentage of cells immunostained for Ki67 and necrotic cells was estimated 
counting one 10X field, randomly selected. One sample of each group of tumor explants was 
excluded from the IHC analysis due to technical problems. 
 
2.10 Gene/miRNA expression analysis 
Gene expression data of COPZ2 gene (log scale) from 58 normal-thyroid tissue samples compared 
to 31 ATC, 72 PTC and 17 PDTC samples, were obtained combining GSE3467 [20], GSE6004 
[21], GSE33630 [22;23] and GSE76039 [24] publicly available datasets. Raw intensity expression 
values on U133 Plus 2.0 array (Affymetrix, Santa Clara, CA) were processed by Robust Multi-array 
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Average procedure [25], with the re-annotated Chip Definition Files from BrainArray libraries 
version 20.0.0 [26], available at http://brainarray.mbni.med.umich.edu. Batch effects were removed 
by using sva R/Bioconductor package [27]. The analysis of the thyroid TCGA dataset from 58 
paired normal/PTC samples was performed as previously described [9]. Normalized reads per 
million miRNA mapped (RPM) data were obtained for the same 58 tumor samples from Illumina 
HiSeq Level 3 isoform quantification files (TCGA Data Portal website), by summing up the reads 
aligned to each 3p or 5p miRBase v16 mature strands [28;29]. Pearson’s correlation method was 
applied to evaluate the correlation between RNAseq normalized gene and miRNA read counts (log 
scale) in 58 tumor samples. 
3. Results 
3.1 COPZ1 depletion affects thyroid tumor cell viability 
The issue that COPZ1 represents vulnerability for thyroid tumor cell lines but not for normal 
thyrocytes [9] is further documented by the colony forming assay in Figure 1A. Upon transfection 
of siRNA oligos targeting COPZ1 (siCOPZ1), a drastic growth inhibition was observed in thyroid 
tumor cell lines (PTC-derived: BCPAP and TPC-1; FTC-derived: WRO82-1; ATC-derived: 8505C, 
KAT-18, and HTC/C3) in comparison to non-targeting (siNT) transfected cells, and to COPZ1-
depleted Nthy-ori 3-1 cells, normal immortalized thyrocytes. Western blot (WB) analysis performed 
in parallel documented the efficient COPZ1 silencing in all the cell lines (bottom panel). SiRNA 
transfected TPC-1, 8505C, HTC/C3, and Nthy-ori 3-1 cell lines were also analyzed by time-lapse 
phase-contrast video microscopy (Supplementary Videos). Unlike siNT-transfected cells, COPZ1-
depleted tumor cells showed morphological changes, such as shrinking and rounding up 30 hours 
(h) (for TPC-1 cells) and 48h (for 8505C and HTC/C3 cells) after silencing Then, cells detached 
from dishes and reached massive cell death at the end of the experiment (68h for TPC-1 cells, 89h 
for 8505C and HTC/C3 cells). None of these effects was observed in COPZ1-depleted NThy-ori 3-
1 cells, which proliferated as the control (siNT) and reached confluence at the end of the experiment 
(68h). In Figure 1B, representative images of each cell lines at the end of experiment are reported. 
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Further images documenting cell morphological changes after COPZ1 depletion are shown in 
Supplementary Figure S1. We also showed the lack of effect of COPZ1 silencing on primary human 
thyrocytes and human mammary epithelial HME-1 (Figure 1C): COPZ1 depletion leaves unaffected 
the growth of these non malignant cells, similarly to the negative control siNT; on the contrary, a 
massive cell death was observed in cells transfected with siRNA oligos targeting Ubiquitin B 
(siUBB), used as control. WB analysis 72h after siRNA transfection documented the complete 
abrogation of COPZ1 protein expression. 
 
3.2 COPZ1 depletion affects autophagy  
COPI complex members are involved in autophagy [11] and are required for completion of the 
autophagic process. Moreover, the depletion of COPI members impairs productive autophagy, as 
demonstrated in prostate, breast and ovarian carcinoma cells [13;30]. TPC-1 and 8505C cell lines, 
stably expressing the autophagosome marker GFP-LC3 (hereafter referred as TPC1-GL3 and 8505-
GL3) were transfected with siCOPZ1 and siNT oligos, and analyzed at different time points by 
fluorescence microscopy for the presence of the typical autophagy-associated LC3 puncta (Figure 
2A). The number of siNT-transfected cells displaying LC3 puncta remained low over the time. On 
the contrary, the number of COPZ1-depleted cells presenting puncta significantly increased over the 
time.  In TPC1-GL3 cells puncta were detected in 5.7% and 38% at 24h and 48h, respectively; the 
analysis at 72h was not feasible, as cells detached from glass coverslip due to the lethal effect of 
COPZ1 silencing. In 8505-GL3 cells, puncta were present in 6%, 14% and 34%, at 24h, 48h and 
72h, respectively. In Figure 2B, representative images of COPZ1-depleted cells displaying LC3 
puncta and relative controls are shown. Autophagosome formation upon COPZ1 silencing was also 
demonstrated by assessing the conversion of the endogenous LC3-I to LC3-II by WB. 
Accumulation of LC3-II protein was observed in COPZ1-depleted naive TPC-1 and 8505C cells. In 
both cell lines, the endogenous LC3-II was barely detectable at 48 h and progressively increased at 
the latest time points (Figure 2C). Since an increased steady-state expression of LC3-II could 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
 
suggest persistent accumulation of autophagosomes, impaired recycling and consequently block of 
the autophagic flux, we investigated whether COPZ1 depletion causes abortive autophagy. We 
monitored by WB whether LC3-II accumulation was associated with increased expression of 
SQSTM1/p62, an LC3-binding protein mainly degraded through autophagy catabolism and whose 
increase is a marker of abortive autophagy [31]. We observed an increase of SQSTM1/p62 in both 
COPZ1-depleted cell lines in comparison to controls (Figure 2D). Such increase was 1.4 and 1.6 
fold in TPC-1 cells at 72h and 96h, and 2.9 and 2.5 fold in 8505C cells. The persistent 
accumulation, rather than turnover/degradation of autophagosomes, and the concomitant increase of 
SQSTM1/p62 protein expression suggest that COPZ1 depletion is associated with abortive 
autophagy. 
 
3.3 COPZ1 depletion induces endoplasmic reticulum stress and unfolded protein response 
As COPZ1 regulates vesicular transport, its depletion could be associated with protein accumulation 
in the endoplasmic reticulum (ER) and with a deficit in proteins coming back from the Golgi. Since 
these effects could be linked to the activation of ER stress and of unfolded protein response (UPR), 
we investigated the expression of some components of these pathways. COPZ1-depleted TPC-1 and 
8505C cells showed an increased expression of the chaperone GRP78/BiP, which, upon ER stress, 
is the major responsible for the activation of downstream UPR signals [32;33]. In TPC-1 cells, the 
level of GRP78/BiP increases by 1.5, 2.8 and 11 fold at 48h, 72h and 96h after siRNA transfection, 
respectively, in comparison to the control; whereas, in 8505C cells the increase was by 1.8, 3.9 and 
3.2 fold (Figure 3A). Concomitantly, we observed an increase of another marker of ER stress, the 
ER lumen chaperone calnexin (1.2 at 48h and 1.6 from 72h fold increase in TPC-1; 1.4 and 2.8 fold 
increase in 8505C cells) (Figure 3A). CHOP, also known as GADD153, is transcriptionally 
upregulated during ER stress and UPR [34;35]. We analyzed the expression of CHOP and COPZ1 
by Real Time PCR in TPC-1 and 8505C cells at different time points after COPZ1 silencing. As 
shown in Figure 3B, COPZ1 depletion led to a drastic increase of CHOP expression in comparison 
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to the control. In conclusion, our data indicate that COPZ1 depletion causes the onset of ER stress 
and UPR. 
 
3.4 COPZ1 depletion induces apoptotic cell death   
Prolonged ER stress or failure of adaptive response can result in cell death [36]. Moreover, CHOP 
activation triggers apoptotic death [34;35]. TPC-1 and 8505C cells were transfected with siCOPZ1 
or siNT oligos in the presence of the fluorescent substrate for activated caspase-3/7. Live-cell 
fluorescence microscopy performed 72h after transfection showed a significant increase of Caspase-
3/7 activity in COPZ1-depleted cells in comparison to the siNT control (Figure 4A). The induction 
of apoptosis by siCOPZ1 is also documented by the WB analysis in Figure 4B: COPZ1 depletion 
increases cleaved PARP and cleaved caspase-3 levels, which were detectable at 48h and 72h after 
siRNA transfection in TPC-1 and 8505C cells, respectively. Overall, these results suggest that the 
depletion of COPZ1 induces caspase-dependent apoptosis in thyroid tumor cells.  
 
3.5 In vivo effects of COPZ1 depletion 
We used 8505C cell mouse xenografts as in vivo model of thyroid carcinogenesis and, in a 
preliminary experiment, we tested the in vivo efficacy of siRNA targeting COPZ1. Nude mice were 
xenografted with 8505C cells and then locally treated with siCOPZ1, explanted and analyzed by 
WB three days later. As shown in Figure 5A, a consistent reduction (by 40%) of COPZ1 protein in 
siCOPZ1-treated tumor in comparison to vehicle- or siNT- treated control was observed. The 
expression of COPZ1 protein in tumor explants was also analyzed by immunohistochemistry (IHC). 
The intensity of staining for COPZ1 in siCOPZ1 explant was reduced in comparison to siNT 
explant: score 1+ vs 3+. This was associated with a reduction of the rate of proliferating cells, 
determined by Ki67 staining: 15% in siCOPZ1 explant vs 50% in siNT explant (Figure 5B). After 
proving the efficacy of siCOPZ1 in an in vivo setting, we evaluated the effect of COPZ1 silencing 
on in vivo tumor growth. Nude mice were xenografted with 8505C cells and, at day 17 after, they 
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were locally treated twice a week with siCOPZ1, or with siNT, or with the vehicle only. At day 34, 
tumors were excised and weighted. As shown in Figure 5C, treatment with siCOPZ1 significantly 
reduced tumor growth compared to siNT or vehicle treatments (controls). Then, tumor explants 
were analyzed by IHC for the expression of COPZ1 protein. COPZ1 immunostaining was high in 
two siNT samples and ranged from medium to high in two other samples. Conversely, in COPZ1-
depleted explants it was very low (two samples), low with medium areas (two samples) or medium 
(one sample). In line with this, the mean rate of proliferating cells (Ki67) was 53.7% for siNT  and 
31% for siCOPZ1 explants. Concomitantly, when we evaluated the neoplastic cellularity, we 
observed an increase of necrosis (20%) in siCOPZ1 explants in comparison with the controls 
(11.2%) (Figure 5D). Representative pictures of selected explants are shown in Figure 5E: the siNT-
9 sample showed high COPZ1 and Ki67 (50%) expression and low necrotic cells (5%), whereas the 
siCOPZ1-19 sample displayed an opposite state, being the COPZ1 staining low, Ki67 20% and 
necrotic cells 25%. Overall, our results demonstrated that the local treatment with siCOPZ1 
productively reduced tumor growth in our model of thyroid carcinoma in nude mice. 
 
3.6 COPZ2 is downregulated in thyroid cancers  
COPZ1 vulnerability is related to downregulation of the paralogous COPZ2 gene in tumor cells. 
While normal cells tolerate COPZ1 inhibition because COPZ2 can replaces its activity in the COPI 
complex, the absence of COPZ2 in tumor cells confers sensitivity to COPZ1 depletion. 
Interestingly, COPZ2 was found downregulated in several primary tumors compared to their normal 
counterparts [13]. We have previously provided evidence that dependence of thyroid tumor cell 
lines on COPZ1 may result from downregulation of COPZ2, since COPZ2 mRNA expression is 
downregulated in the majority of analyzed thyroid tumor cell lines [9]. In order to assess whether 
also thyroid tumors belonging to different histotypes may be sensitive to COPZ1 targeting, we 
interrogated several publicly available datasets for the expression status of COPZ2. The first 
analysis combined data from different datasets, including 58 normal thyroid, 72 PTC, 17 PDTC and 
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31 ATC samples [20-24]: COPZ2 was found downregulated in all the tumor histotypes (Figure 6A). 
Furthermore, COPZ2 gene was significantly downregulated in the 58 PTC samples from the thyroid 
TCGA dataset [28], compared to the paired normal counterpart (Figure 6B, left). Therefore, the 
frequent downregulation of COPZ2 in thyroid tumors allow predicting their sensitivity to COPZ1 
inhibition.  
The first intron of the COPZ2 gene encodes the precursor of miR-152 [37], which exerts a tumor 
suppressor role and is frequently downregulated in several tumors. miR-152 and its hosting gene 
COPZ2 are transcribed from the same promoter and are concurrently silenced in tumor cells [13]. 
To assess mirR-152 expression in thyroid tumors, data were retrieved from TCGA and correlated 
with COPZ2 expression. The analysis shows a notable positive correlation between COPZ2 and 
hsa-miR-152 RNAseq expression levels (Figure 6B, right). This result indicates that miR-152, 
concurrently to COPZ2, is downregulated in thyroid cancer, and it may exert an oncosuppressor 
role also in this tumor type.  
4. Discussion 
By performing a siRNA-based functional screening, we have recently discovered several thyroid 
tumor cell vulnerabilities, consisting in a set of genes, defined non-oncogenes, whose silencing 
inhibited the growth of a panel of thyroid tumor cells, but not that of normal immortalized 
thyrocytes. The COPZ1 gene was found among the top significant genes, exerting a role in 
sustaining the phenotype of thyroid tumor cells. In this study, we dissected the mechanisms leading 
to cell lethality upon COPZ1 depletion, and explored its employability as therapeutic target for 
thyroid carcinoma. 
First, we confirmed that COPZ1 represents vulnerability for several thyroid tumor cell lines since 
its silencing drastically impairs their viability, and demonstrated the lack of effect also in normal 
primary thyrocytes, and mammary epithelial cells.  
Our study, aimed at better characterizing the mechanisms leading to cell death upon COPZ1 
depletion, showed that, similarly to other members of the coatomer complex [11;30], COPZ1 was a 
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critical player of autophagy. Indeed, COPZ1 silencing initiated autophagy, which became abortive 
due to an increase rather than a turnover of autophagosomes. Concomitantly, COPZ1-depleted cells 
displayed the activation of markers of ER stress and UPR. Whether the impairment of autophagy is 
the cause or the consequence of ER stress remains to be investigated. We then demonstrated that the 
onset of a prolonged ER stress exacerbates cell death, since COPZ1-depleted cells rapidly 
underwent caspase-dependent apoptosis.  
Interestingly, in support to what observed by functional studies, a preliminary gene expression 
profiling of COPZ1-depleted 8505C cells indicated that the main upregulated canonical pathways 
consist of the unfolded protein and ER stress response, lipid metabolism and cell death (apoptosis). 
In parallel, proteomic profiling of COPZ1-depleted 8505C cells by nano-scale liquid 
chromatographic tandem mass spectrometry, indicated that the main involved pathways deal with 
vesicle trafficking, autophagy and caspase cascade in apoptosis (our unpublished results), in 
keeping with what observed by gene expression analysis.  
Our results suggest that thyroid tumor cells dependence upon the activity of COPZ1 may be related 
to its pivotal involvement on the regulation of autophagy, UPR and ER stress, processes generally 
known as cytoprotective and adaptive mechanisms for cancer cell survival. Thus, COPZ1 inhibition 
may represent a strategy to target these processes, and convert their effect into a lethal mechanism. 
Interestingly, normal cells, which are probably not strictly dependent on these mechanisms, are 
preserved from cell death. However, apart from the well known role of COPZ1 in vesicle 
trafficking, the possible direct involvement of COPZ1 in cancer cell survival is still unclear. How 
COPZ1 depletion modulates the activation of intracellular multiple signalling pathways, executors 
of the final lethal effect,  remains to be better investigated. This will allow identifying other critical 
nodes in the oncogenic network whose inhibition will result in cell collapse. 
In our study, the most striking effect of COPZ1 silencing was observed in mouse tumor 8505C 
xenografts: in fact, siCOPZ1-treated tumors showed a consistent reduction of tumor growth.  
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Moreover, IHC analysis of tumor explants showed that COPZ1 silencing was associated with the 
decrease of the proliferative marker Ki67 and with an increase of necrosis. Further studies are 
needed to identify the mediators mainly involved in this process. An attractive hypothesis is that 
COPZ1 depletion could establish an inflammatory microenvironment through the release of 
cytokines/chemokines; this is supported by gene expression profile of COPZ1-depleted cells, 
showing upregulation of genes coding for cytokines involved in mediating communication between 
immune cells. More information on mediators released after cell death will be provided by the 
characterization of the cellular secretome content after COPZ1 depletion. 
Tumor cell sensitivity to COPZ1 depletion is related to downregulation of its paralogous COPZ2 
gene. COPZ1 inhibition is tolerated by normal cells because COPZ2 substitutes for it in the COPI 
complex, whereas tumor cells, characterized by the absence of COPZ2, display sensitivity. This 
“synthetic lethality” renders COPZ1 depletion an attractive strategy to kill tumor cells. By 
interrogating publicly available data sets including a large collection of thyroid tumors we found 
that COPZ2 was frequently downregulated in PTC, PDTC and ATC samples, thus indicating that 
the majority of thyroid tumors may be eligible for COPZ1 targeting. As reported in other tumor 
types [13], we observed a concomitant low expression of miR-152, encoded within the COPZ2 
gene, which exerts a tumor suppressor role and is donwnregulated in different tumors, including 
thyroid ones [38]. Whether the downregulation of COPZ2 and miR-152 in thyroid tumors is due to 
promoter hypermethylation, as reported for other tumor types [39], remains to be investigated. 
Moreover, we cannot exclude that COPZ1 dependency of thyroid tumors may also rely on other 
mechanisms or on other components of the COPI complex. Indeed, we had previously observed that 
the FTC-derived WRO82-1 cell line is sensitive to COPZ1 depletion, even though it expresses high 
level of COPZ2 mRNA [9].  
Recent reports indicate that, as for COPZ1, targeting other COPI complex members may represent a 
therapeutic approach for cancer. A siRNA-based functional screening proposed COPA gene, 
encoding the α subunit of COPI complex, as a potential therapeutic target for mesothelioma [40]. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
 
Claerhout et al have shown that targeting the COPI complex members is a potent approach to block 
productive autophagy and stimulate cell death in cancer cells [30]. Recently, ARCN1, the δ-subunit 
of the COPI complex, has been proposed as a new therapeutic target [41]. COPB2 was found as 
synthetic lethal partner of mutated KRAS [42]. The co-occurrence of mutations in KRAS and LKB1, 
present in a small fraction of lung adenocarcinomas, drives addiction to the COPI complex 
members [43]. Of note, COPE gene, encoding the ε subunit of COPI complex, emerged from our 
screening in the list of genes specifically inhibiting thyroid tumor cell growth [9]. All this evidence 
suggests that targeting the coatomer complex, and consequently causing abortive autophagy and ER 
stress, may represent an optimal strategy to kill cancer cells, especially those resistant to 
conventional therapy. 
In conclusion, we demonstrated that COPZ1 represents vulnerability for thyroid tumor cells, thus 
providing the first evidence of non-oncogene addiction for this tumor type. This adds a new element 
to the list of potential therapeutic targets, which includes, in addition to the driver oncogenic 
proteins and downstream pathways, several genes and miRNAs differentially expressed in thyroid 
tumors, some of which identified by our group [17;18;44-47], and whose role in promoting or 
suppressing the transformation process has been functionally demonstrated. On the whole, our 
results pave the way for designing novel therapeutic approaches based on COPZ1 inhibition useful 
for thyroid tumor patients who do not respond to standard therapies and rapidly progress to 
malignant forms. Notably, being effective on tumor but not on normal cells, these novel therapeutic 
approaches may have limited side effects. 
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9. Figure legends 
Figure 1.  Effect of COPZ1 silencing on cell viability. (A) Colony forming assay of thyroid cell 
lines, 5 days after siRNA transfection; (B-C) Representative pictures at 10X magnification of Nthy-
ori 3-1, TPC-1, 8505C, HTC/C3 cells, primary normal thyrocytes and human mammary epithelial 
cells (HME-1) at the indicated time points after siRNA transfection.  In (A) and (C),  cells were 
assessed by WB for protein levels of COPZ1 72h after siRNA transfection;  β-actin was used for 
normalization of gel loading. siNT: Non-Targeting siRNAs; siCOPZ1: siRNAs targeting COPZ1; 
siUBB: siRNA targeting Ubiquitin B.  
 
Figure 2. Effect of COPZ1 silencing on autophagy. (A) Percentage of  TPC1- and 8505C-GL3 cells 
displaying LC3 puncta at different time points after siCOPZ1 and siNT oligos transfection; the 
asterisks indicate differences significant by the unpaired Student’s t-test (*P<0.05, **P<0.01). (B) 
Representative pictures of TPC1- 8505C-GL3 cells, 48h and 72h after siRNA transfection,  
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respectively; cells were analyzed by fluorescence microscopy for the presence of LC3 puncta 
(green; arrows); nuclear DNA was stained with DAPI. (C-D) TPC-1 and 8505C cells were analyzed  
by WB for the expression of LC3-I/II, SQSTM1/p62 and COPZ1 proteins, at the indicated time 
points after siRNA transfection;  β-actin was used for normalization of gel loading. In 8505C cells 
(D), p62 and COPZ1 expression in the same cell extracts was assessed in two separate gels.  
 
Figure 3. Effect of COPZ1 silencing on ER stress and UPR. (A) WB analysis of calnexin and BiP 
protein expression in TPC-1 and 8505C cells, at the indicated time points after siRNA transfection; 
β-actin was used for normalization of gel loading. In TPC-1 cells, calnexin, COPZ1 and BiP 
expression in the same cell extracts was assessed in two separate gels; in 8505C cells, calnexin and 
BiP expression was assessed in the same gel of Figure 2D. (B) Real-time PCR analysis of COPZ1 
and CHOP gene expression in TPC-1 and 8505C cells at the indicated time points after siRNA 
transfection; results are presented as log10-transformed relative quantity (RQ) of COPZ1/CHOP 
mRNA normalized for HPRT1 housekeeping gene expression. Data represent the mean +/- sd of 
two independent experiments.  
 
Figure 4. Effect of COPZ1 silencing on cell death. (A) TPC-1 and 8505C cells were transfected 
with siCOPZ1 or siNT oligos in the presence of 2 µM of the fluorogenic substrate for activated 
caspase-3/7; live-cell fluorescence images (10X magnification) were taken 72h later with 
microscope. (B) WB analysis of cleaved PARP (arrowhead), cleaved caspase 3 and COPZ1 protein 
expression, at the indicated time points after siRNA transfection; β-actin was used for normalization 
of gel loading. Cleaved PARP expression in the same cell extracts was assessed in two separate 
gels. 
 
Figure 5. Effect of COPZ1 silencing on 8505C in vivo tumor growth. (A) WB analysis of COPZ1 
expression in tumour xenografts, excised three days after siRNA treatment; actin was used as 
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loading control for cell extracts. The graph represents the densitometric analysis of the bands; data 
are reported as ratio of COPZ1 to actin and normalized for the siNT sample value. (B) IHC analysis 
of COPZ1 and Ki67 expression in siNT and siCOPZ1 tumor explants. (C) In vivo tumorigenicity 
assay: the line within each box represents the median tumor weight (g) value of 10 controls (five 
vehicle and five siNT) and six siCOPZ1 treated explants at the end of the experiment (34 days); 
upper and lower edges of each box represent the 75th and 25th percentile, respectively; upper and 
lower bars indicate the highest and lowest values less than one interquartile range from the extremes 
of the box. *P= 0.026, controls vs. siCOPZ1-treated mice, Kruskal-Wallis Test. (D) Mean 
percentage of Ki67 positive and necrotic cells in tumor explants (four siNT and five siCOPZ1 
samples); the asterisk indicates differences significant by the unpaired Student’s t-test (*P< 0.05). 
(E) IHC analysis of COPZ1 and Ki67 expression and H&E staining of two representative tumor 
explants (siNT-9, siCOPZ1-19); black arrow indicates areas of necrosis. 
 
Figure 6. Expression of COPZ2 and mir-152 in thyroid carcinomas. (A) Scatter plot distribution of 
COPZ2 gene expression levels (log2 scale) in 58 normal thyroid-tissues, 72 PTC, 17 PDTC and 31 
ATC primary tumor samples; in the graph the median is recorded. Nonparametric pairwise multiple 
comparisons between all analyzed groups were performed by Dunn’s test and Benjamini-Hochberg 
correction, following a significant Kruskal-Wallis test (p= 5.733 e-11). (B) (left) Scatter plot 
distribution of RNAseq normalized expression values (natural scale) from the thyroid TCGA 
dataset of COPZ2 in 58 matched normal (N) and PTC samples. Illumina HiSeq Level 3 data were 
downloaded from TCGA Data Portal website and RSEM gene normalized expression values were 
derived for 58 PTC patients, in tumor and adjacent normal samples, respectively; in the graph the 
median is recorded. Differential gene expression levels between tumor and normal groups were 
evaluated by Wilcoxon test (p-value= 2.442x10-10); (right) dispersion plot of COPZ2 (x-axis) and 
hsa-miR-152 (y-axis) RNAseq normalized expression levels (log2 scale) in the 58 PTC samples. 
Normalized reads per million miRNA mapped (RPM) data were obtained for the same 58 tumor 
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samples from Illumina HiSeq Level 3 isoform quantification files (TCGA Data Portal website), by 
summing up the reads aligned to each 3p or 5p miRBase v16 mature strands. Pearson’s correlation 
method was applied to evaluate the correlation between RNAseq normalized gene and miRNA read 
counts in 58 tumor samples (r= 0.67, p-value= 8.41x 10-9 ).  
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Highlights 
• COPZ1 represents an example of non-oncogene addiction in thyroid tumor cells 
• COPZ1 depletion affects thyroid tumor cell viability 
• Cell death is associated with abortive autophagy, ER stress, UPR and apoptosis 
• In vivo COPZ1 depletion reduces the growth of  thyroid tumor mouse xenografts 
• COPZ1 represents an attractive therapeutic target for thyroid cancer 
 
 
 
